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ABSTRACT: 
 
 
Background: 
This thesis presents a study of the safety of medicines with respect to drug counterfeiting in 
developing countries (East Africa and the Middle East). Counterfeit medicines are also present in 
industrialised countries, but not on the same scale as in developing countries. The aim of the 
study was to establish the responsiveness of health care professionals at the practice level 
concerning the counterfeiting of medicinal products in developing countries focusing on six 
countries in the East African region and seven countries located in the Middle East. 
 
Method: 
The method of data acquisition used was by survey questionnaires issued in 13 developing 
countries (6 in East Africa and 7 in the Middle East).  The questionnaires were delivered to the 
respondents either personally or by e-mail and the questionnaire, responses were returned by the 
same means. Respondents returned their questionnaire forms direct to the author either on the 
same day or later by e-mail. The data were analysed with regard to the specific questions. 
Results: 
The study findings suggested that the poorer the country, the higher the degree of counterfeiting. 
All the respondents (n: 2180) agreed that there was a fake or counterfeit medicine problem in 
their own country (71% of respondents in Africa and 63% of respondents in the Middle East 
considered this a major problem).  Both branded and generic drugs were counterfeited and the 
extent of the problem and several other factors concerning counterfeited drugs differed 
significantly between industrialised and developing countries. The difference depended on drug 
regulation control and enforcement and also on the quality and the prices in the legal supply 
chain. In most industrialised countries like the USA, Japan or the members of the EU, the level 
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of drug counterfeiting is <1% of the total medicines market value. An exception is the former 
Soviet Union where up to 20% of the market is occupied by counterfeit drugs. In contrast, within 
regions of Africa, Asia and parts of Latin America, between 10-30% of the available medicines 
are fakes (WHO 2006) 
 
Conclusions: 
  
The study showed that healthcare workers were aware of the prevalence of counterfeit medicines 
and quite a number of them had encountered them in their supply role. There is an indication that 
the respondents tried to assure themselves of the quality of the drugs they purchased by using 
several methods. However, no rigorous effort was taken to confirm as well as report suspected 
counterfeit drugs to regulatory authorities. 
 
In the industrialised world, medicines regulatory authorities have developed strict standards and 
controls to ensure the safety and effectiveness of drugs. However, as this study has found, in less 
developed countries a lack of human and financial resources within the health sector as a whole 
restricted the activity of  regulatory agencies, resulting in a sub-optimally regulated environment 
in which substandard drug production persisted without detection. 
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GLOSSARY OF TERMS 
 
A non-governmental organization NGO: is a legally constituted organisation created 
by natural or legal persons that operates independently from any government. The term 
originated from the United Nations (UN), and is normally used to refer to organisations that do 
not form part of the government and are not conventional for-profit business 
 
Counterfeit Medicine: a counterfeit drug is a medication or pharmaceutical product, which is 
produced and sold with the intent to deceptively represent its origin, authenticity or effectiveness. 
A counterfeit drug may contain inappropriate quantities of active ingredients, or none, may be 
improperly processed within the body (e.g. absorption by the body), may contain ingredients that 
are not on the label (which may or may not be harmful), or may be supplied with inaccurate or 
fake packaging and labeling.   
 
Developing countries: Also known as, a less-developed country is a nation with a low level of 
material well-being. 
 
Developed countries: is a country has a high level of development according to some criteria. 
Which criteria, and which countries are classified as being developed, are a contentious issue. 
According to the International Monetary Fund, advanced economies comprise 65.8% of global 
nominal GDP and 52.1% of global GDP (PPP) in 2010 
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Drug Product: A finished formulation, for example a tablet or capsule that contains the active 
substance, generally in association with one or more other ingredients. 
 
Good Manufacturing Practice (GMP): Are guidance that outline the aspects of production and 
testing that can impact the quality of a product. Many countries have legislated that 
pharmaceutical and medical device companies must follow GMP procedures, and have created 
their own GMP guidelines that correspond with their legislation. Basic concepts of all of these 
guidelines remain more or less similar to the ultimate goals of safeguarding the health of the 
patient as well as producing good quality medicine, medical devices or active pharmaceutical 
products. In the USA, a drug may be deemed adulterated if it passes all of the specifications tests 
but is found to be manufactured in a condition, which violates current good manufacturing 
guidelines. Therefore, complying with GMP is a mandatory aspect in pharmaceutical 
manufacturing 
 
Gross domestic product (GDP): refers to the market value of all final goods and services 
produced within a country in a given period. GDP per capita is often considered an indicator of a 
country's standard of living. 
 
HIV: is a lentivirus (slowly replicating retrovirus) that causes acquired immunodeficiency 
syndrome (AIDS) a condition in humans in which progressive failure of the immune system 
allows life-threatening opportunistic infections and cancers to thrive. 
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Khat: is a flowering plant native to the Horn of Africa and the Arabian Peninsula. Amongst 
communities from these areas, khat chewing has a long history as social custom dating back 
thousands of years. Khat contains the alkaloid called cathinone, an amphetamine-like stimulant, 
which is said to cause excitement, loss of appetite and euphoria. 
 
International Criminal Police Organization – INTERPOL: is an organization facilitating 
international police cooperation. INTERPOL was established as the International Criminal 
Police Commission in 1923 and adopted its telegraphic address as its common name in 1956. 
 
International Chamber of Commerce (ICC): is the largest, most representative business 
organisation in the world.  ICC’s hundreds of thousands of member companies in over 130 
countries have interests spanning every sector of private enterprise 
 
Radio-frequency identification (RFID): is the use of a wireless non-contact radio system to 
transfer data from a tag attached to an object, for the purposes of automatic identification and 
tracking. Some tags require no battery and are powered by the radio waves used to read them. 
 
Pearson Product Moment Correlation model: In statistics, the Pearson product-moment 
correlation coefficient is a measure of the correlation (linear dependence) between two variables 
X and Y, giving a value between +1 and −1 inclusive 
 
 
 
 
 xviii 
Substandard medicines: medicines that are genuine medicines produced by legitimate 
manufacturers that do not meet the quality specifications that the producer says they meet. For 
example, they may contain less (or more) active ingredient than written on the package. 
 
Viagra: Sildenafil citrate, sold as Viagra, Revatio and under various other trade names, is a drug 
used to treat erectile dysfunction and pulmonary arterial hypertension 
 
World Intellectual Property Organization (WIPO): is one of the 17 specialised agencies of 
the United Nations. WIPO was created in 1967 "to encourage creative activity, to promote the 
protection of intellectual property throughout the world. 
 
World Health Organization: is a specialised agency of the United Nations (UN) that is 
concerned with international public health. WHO was established on 7 April 1948, with 
headquarters in Geneva, Switzerland and is a member of the United Nations Development Group. 
Its predecessor, the Health Organisation, was an agency of the League of Nations.  
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1 CHAPTER ONE 
 
 
 
 
 
 
 
 
1.1 General Introduction: 
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1.1.1 Introduction:  
 
This thesis presents findings on quality performance at the practice level concerning the 
safety and use of medicines and counterfeit drugs in developing countries. The study covers 6 
East African countries and 7 Middle East countries (see Figure 1.9) and the findings focus on 
counterfeit medicines. 
 
At the end of 2010, a global effort to combat the distribution and sale of counterfeit and 
illegal medicines online culminated in “Operation Pangea III,” resulting in the seizure of 
approximately one million illicit and counterfeit medicines valued at approximately 
$2.6 million. (Mackey and Liang, 2011) 
 
Counterfeit medicines are not confined to specific drug classes, and instead span a broad 
spectrum ranging from lifestyle to life-saving medicines, as well as generic drug forms. This 
includes counterfeits in therapeutic classes that extend to antimalarials, antibiotics, birth 
control, cancer, diabetes, erectile dysfunction, heart disease, schizophrenia, and transplant 
drugs (WHO. 2010). Surveillance by the Pharmaceutical Security Institute, a non-profit 
organisation dedicated to the development of anticounterfeiting resources, have shown that 
close to 1000 counterfeit incidents occurred in 2005 involving some 100 countries, with 687 
different pharmaceutical products in a wide array of therapeutic and organ system categories. 
(Kubic and Mollo, 2006) 
 
Represented by a number of international organisations, approximately 45 countries, and 
other private and public sectors in a multipronged effort, this operation is the largest 
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enforcement action in size and scope against criminal internet-based activities involving 
illegal sales of dangerous counterfeit medicines. (Mackey and Liang, 2011) 
 
Substandard and counterfeit drugs are prevalent throughout the world but developing 
countries are worst affected.  Counterfeiting is generally perceived by society as a victimless 
crime, with fakes simply constituting a cheap alternative option, and seen by criminals as 
having a low risk of prosecution with light penalties relative to the large profits to be made. 
The reality is that the international trade in counterfeit products is estimated to exceed 6% of 
global trade (Patil et al., 2012).  
 
In today’s global environment, it does not matter if you live in the United States of America, 
Europe, Asia, or Africa—everyone is at risk from unsafe drugs. Counterfeit drugs defraud 
consumers and deny patients therapies that may alleviate suffering and save lives. 
Unfortunately, in some cases, these drugs have caused great harm and fatalities especially in 
developing countries. (Cockburn, 2002) 
 
According to World Health Organization (WHO) estimates, up to 1% of medicines available 
in the developed world are likely to be counterfeit (WHO 2006 b). This figure rises to 10% 
globally, although in some developing countries it is estimated that one third of medicines are 
counterfeit. 36.5 per cent of antibiotics and anti-malarials on WHO essential drug list in 
Thailand and Nigeria are substandard (Shakoor et al., 1997) 
 
In several developing countries (especial East African Countries like Somalia and Ethiopia) 
drug quality is a source of concern. There is a general feeling that there is a high incidence of 
drug preparation, which is not of acceptable quality. Instances, which are quoted, are often 
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linked with terms such as counterfeit and fake, which carry economic and perhaps political 
implication. Poor quality drug preparation may lead to adverse clinical results both in terms 
of low efficacy and encouraging drug resistance (Ten Ham, 1992). 
 
 Researchers found that substandard drugs are available in markets across the developed 
world but the problem is more severe in developing countries. (Charatan, 2001) 
 
Counterfeit medicines are invariably unsafe and ineffective. They result in wasted resources 
spent on purchasing, inventory, and transport and dispensing, with little or no beneficial 
effect and they may even cause actual harm to the patient. Counterfeited medicinal products 
threaten patient safety by at best, producing no improvement or worse, causing an added 
burden of disease and even death. They endanger public health for instance, by increasing the 
risk of antimicrobial resistance and by eroding patient trust in health professionals and 
healthcare systems, which are perceived as providing inadequate treatment. Consequently, 
public health and patient safety are being put at risk and it is timely to act now. (Cockburn, 
2002) 
 
The problem of counterfeiting is difficult to detect, investigate, and quantify. It simply means 
that it is hard to comprehend or even estimate the true extent of the problem. It is estimated 
that counterfeit drugs account for nearly 1 % to 50 % of the worldwide trade in 
pharmaceutical industry (See figure 1.1) (Newton et al: 2006). 
 
The majority of wholesalers are not properly informed on the issue of counterfeit medicines 
and how to handle such cases. To protect the pharmaceutical product supply chain from 
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counterfeit medicine intrusion, distributers and wholesalers should be aware and sensitised to 
countermeasures against counterfeit medicines. (Khan et al., 2011). 
 
1.1.2 Background:  
This thesis considers the extent of the counterfeit medicines problem especially in developing 
countries and provides several examples of drugs which have been counterfeited. 
Additionally, the effects of counterfeit products on consumers, health care providers, drug 
manufacturers and the government developing countries are discussed. Counterfeiting is 
deceptive and immoral in any field but in healthcare, it is criminal and simply unacceptable. 
(Cockburn, 2002) 
 It is important to make a distinction between counterfeit medicines and other kinds of 
substandard medicines. All counterfeit medicines are substandard because they are 
manufactured and distributed outside of regulatory control and their composition is 
unpredictable. On the other hand, not substandard medicines are counterfeit because not all of 
them have been deliberately and fraudulently mislabeled (Cockburn, 2002).  
 
Many cases of counterfeiting have been uncovered while investigating therapeutic failure or 
adverse events observed in patients. Such cases lead to a serious consequence i.e. the erosion 
of confidence in health-care systems and counterfeit drugs particularly affect the most 
disadvantaged people in poor countries.  
 
One of the most worrying implications of counterfeit medicines is the emergence of drug 
resistant pathogens, bacteria, viruses, and parasites (Newton et al., 2002). Such a situation 
will often lead to therapeutic failure and a need for the discovery and development of new 
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drugs. Counterfeit medicines may also cause adverse effects through excessive doses or due 
to the presence of potentially toxic active ingredients or pathogenic contaminants (Saywell et 
al., 2002). Loss of confidence and faith in medicines and in the health care system is also 
another very serious damaging consequence of counterfeit medicines. Not only the patient, 
but also healthcare professionals, pharmaceutical manufacturers, distributors, suppliers, 
retailers for example lose confidence in the medicines upon which they rely. In addition, 
pharmaceutical companies may lose the incentive to invest in research and development as 
well as future innovation because the counterfeit product may result in a significant loss of 
revenue.   
It is estimated that as many as 20% of the annual deaths from malaria worldwide may be the 
result of taking ineffective drugs. A study in the Lancet concluded that up to 40% of 
artusenate products (an effective medicine to combat resistant malaria) contained no active 
ingredients (Cockburn et al., 2005). Counterfeit Viagra is a worldwide problem and the 
University of London reported in 2004 that half the men buying Viagra received a counterfeit 
drug. (Rudolf, 2004) 
 
Fig 1.1: Pharmaceutical production and Counterfeit Drug Distribution Flowchart 
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Sources:   Harper and Gellie, Counterfeit medicines – Survey report, Council of Europe 
Publishing, 2006, 242 p. 
 
1.1.3 What is Counterfeit Medicine? 
A counterfeit medication or drug is a medication or pharmaceutical product, which is 
produced and sold with the intent to deceptively represent its origin, authenticity or 
effectiveness. Generic drug products or drug products whose only violation is that of patent 
laws, are not counterfeit drug products (Cockburn, 2002). A counterfeit drug may contain 
inappropriate quantities of active ingredients, may be improperly processed within the body 
(e.g., absorption by the body), or may contain ingredients that are not on the label (which 
may or may not be harmful), and is often sold with inaccurate, incorrect, or fake packaging 
and labeling. Medicines, which are deliberately mislabeled in order to deceive consumers, are 
therefore counterfeit. A drug, which has not received regulatory approval, is not necessarily a 
counterfeit. Some tested counterfeit medications contain excessive amounts of active 
ingredients the effect of which may be harmful (Jackson et al., 2010) 
 
Table 1.1: Risk from a patient safety perspective from 
Public Risk Manufacturer Risk 
Contraindications and other drug, related 
problems Compliance issues 
Administration errors Dispensing errors 
Recalls Expired medical products 
The cost of a recall due to counterfeiting can be 
US$100 million (Euros 64 million) and as high 
as few billion US$ for future earnings loss and 
several billions US$ for liability. 
(Source: IMS, 2007) 
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1.1.4 What encourages counterfeiting of medicines? 
Table 1.2 provides a breakdown of some of the main reasons for counterfeiting. 
Table 1.2. What encourages counterfeiting of medicines? 
Medicines attractive for counterfeiting 
• Lack of political will and commitment to establish a strong national medicines 
authority 
• Lack of appropriate medicine legislation 
• Absence of, or weak national medicines regulatory agency 
• Weak enforcement including corruption and conflict of interest 
• Shortage or erratic supply of medicines 
• Inappropriate use of medicines 
• Price differentials 
• Inefficient co-operation between stake holders 
• Lack of control over export medicines 
• Trade through several intermediaries 
• Trade through free-trade zones/free ports 
 
 
(Source: 3 June 2010: World Health Organisation. Counterfeit medicines) 
1.1.5 Global (developed and less developed countries) Perspective of 
counterfeit medicine:  
 
Countries with advanced regulatory systems are seriously challenged by this deceptive 
practice. An analysis conducted by International Medical Product Anti-Counterfeiting 
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Taskforce (IMPACT, 2006) showed that counterfeiting is greater in those areas where 
regulatory and legal oversight is weaker particularly in developing countries.  The extent of 
the problem and several other factors concerning counterfeited drugs however differ 
significantly between industrialised and developing countries (Dahiya, 2008).  
 
The most important sources for data on medicine counterfeiting are the WHO and 
International Medical Products Anti-Counterfeiting Taskforce (IMPACT, 2006) as the 
WHO’s organisation for the fight against counterfeit drugs. For some years the estimation of 
the global prevalence of counterfeit drugs has been 10 % overall (IMPACT, 2006).  
 
The new estimates differentiate between developed countries, including the EU with the 
exemption of some of its most eastern parts, the USA, Canada, Australia, New Zealand and 
Japan, where less than 1 % of the drugs sold are counterfeit and a proportion of over 10 % for 
some less well developed countries. Indeed, for some countries in parts of Asia and Latin 
America, the estimations exceed 30 % whilst in several countries of the former Soviet Union, 
counterfeits reach a prevalence of over 20 % according to the WHO figures (IMPACT / 
WHO; 2008). 
 
A much higher incidence can be found in drugs bought from illegal Internet pharmacies, 
where up to 50 % of the medicines sold are found to be fakes even in developed countries. 
However, occurrence differs between developed and less developed countries or between 
different world regions, and can also vary significantly within a single country between 
different cities or cities and rural areas. (IMPACT/WHO, 2008). 
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Other sources yield similar alarming numbers and between 2000 and 2006 the prevalence of 
counterfeits are estimated to have grown by 800% expected to grow at an annual rate of 13% 
up to 2010. This resulted in an estimated market of over $75 billion, an increase of over 90 % 
in comparison with 2005 figures. This would represent a market share of around 15 % of the 
legal pharmaceuticals market. (Cheng et al., 2009) 
 
The evidence tends to show that where regulation is less effective, counterfeit products have 
become more prevalent and less sophisticated. It is clear that the populations of developing 
countries are at greatest risk. The International Pharmaceutical Federation (IPF) is seriously 
concerned about the risk to public health represented by counterfeiting, particularly in 
countries where legislation governing the manufacture and distribution of medicines, or the 
enforcement of legislation, is ineffective or nonexistent (Alan 2003). 
 
Although more insulated from the dangers of counterfeit medicines introduced into the 
domestic drug supply chain, reports have emerged from the USA indicating patient safety 
issues and deaths related to counterfeit medicines. As the world's largest market for 
pharmaceutical sales, it is natural that counterfeit manufacturers and sellers have targeted the 
USA as its most lucrative market. (Liang, 2006). In the US, the value of seized fake drugs in 
2003 was $200 million while the value of the counterfeits market in the USA was estimated 
to be $39 billion in total in 2008 (Bate, 2008). 
 
The counterfeit drug cases opened by the US FDA were stable at between 5 to 11 cases per 
year at the end of the 1990s but this number showed a clearly increasing trend starting in 
2000. A maximum was reached in 2010 where 72 cases were reported (See Figure1.2).  
 (FDA 2011). 
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 Figure 1.2 showing an ooverview of USA FDA opened counterfeit drug cases from 1997 
to 2011. Data obtained from the FDA. FDA Initiative to Combat Counterfeit Drugs 
(accessed on 02-01-2012) http://www.fda.gov/Drugs/DrugSafety/ucm180899.htm 
 
The European Union (EU) is particularly threatened by an influx of counterfeit medicines, 
especially those sold on the Internet. Counterfeits have become a serious public health 
problem in this region with estimates reflecting annual increases in counterfeit sales of 15% 
per annum and one in five Europeans admitting that they have purchased a prescription drug 
without a prescription. This increase has also been evidenced by the seizure of 11.4 million 
counterfeit drugs at EU borders in 2009, representing a 422% increase since 2006 (Tim et al., 
2011). 
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In addition, high-profile discoveries of counterfeiting operations within the EU, such as a 
counterfeiting operation in the United Kingdom (UK) producing 500,000 counterfeit tablets 
daily, continue to highlight the risk of both counterfeit production and consumption in middle 
to high-income countries in Europe (Liang 2006). Similar instances involving counterfeit 
production and distribution have been discovered in countries such as the Netherlands, Italy, 
Spain, and France, sold both through EU parallel trade and on the Internet 
Of particular concern, is also the rapid spread of counterfeit medicines in resource-poor 
countries of the developing world, which have low levels of gross national product per capita. 
These countries are especially vulnerable because they lack sufficient infrastructure and 
technical expertise to regulate and police criminal activity (Newton et al., 2010).  
1.1.6 Dangers of counterfeit medicine: 
In this respect, a debate is raging as to whether "counterfeit products are first and foremost a 
threat to human health and safety or whether provoking anxiety is just a clever way for 
wealthy nations to create sympathy for increased protection of their intellectual property 
rights. 
Counterfeiting of drugs is a huge industry in Africa; the situation is extremely serious since 
half of the malaria medications sold may well be ineffective or even harmful. There is 
currently no good way to identify counterfeit drugs. However, researchers from Lund in 
Sweden and the UK have now developed a technique that could resolve the situation 
(Jakobsson, 2010)  
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1.1.7 Types of Fake Drugs:  
Counterfeiters specialising in fake pharmaceuticals invariably try to manufacture a product to 
resemble any type of drug. Widely used medicines such as atorvastatin and paracetamol are 
more frequently counterfeited, but so are other, less commonly used products. The most 
frequently counterfeited medicines are expensive life style medicines such as hormones, 
steroids and antihistamines (Newton et al., 2001). However, life-saving drugs including 
antimalarials, anti-HIV/AIDS, anticancer and anti-infectives (antibacterials, antibiotics, 
antifungals, antiprotozoans and antivirals) are among the most counterfeited drugs found in 
developing countries (Newton et al., 2001). Other than drugs, the problem extends to medical 
devices and consumables such as syringes, gauzes and other medical equipment (WHO, 
2003). It is clear therefore that counterfeit medicines are not limited to a particular category 
of pharmaceuticals but can be found amongst many therapeutic categories (See Figs 1.3 and 
1.6). 
 
 
Figure 1.3:  A typical collection of counterfeit pharmaceutical drugs seized by the East African Authority. 
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Figure 1.4: An example of a drug store in Ethiopia taken by one of the agent 
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Figure 1.5: Location of a typical clinic in Ethiopia taken by one of the agent  
 
1.1.8 The presence of counterfeit medicines globally: 
The problem is truly global. Counterfeit medicines are increasingly detected not only in 
developing countries but also in European and North-American countries (Cockburn, 2002).  
 
 
Figure 1.6: Source: PSI - Pharmaceutical Security Institute http://www.psi-inc.org/index.cfm. 
 
One case reflects at least one production lot, e.g. thousands of tablets, capsules, or other 
forms. Several cases included multiple therapeutic categories (See figure 1.6) (PSI). 
Available data underestimate reality, especially in poorer areas where detection and reporting 
are extremely weak.   
 
Counterfeit medicines are detected increasingly not only in developing countries but also in 
Europe and North America. This suggests that even countries with advanced regulatory 
systems are seriously challenged by this menace (Cockburn, 2002). 
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In the Mekong countries (Cambodia, Lao People’s Democratic Republic, Myanmar, Thailand 
and Viet Nam), a study undertaken in 2001 indicated that more than one third of products 
supposedly containing the antimalarial artesunate actually contained no active ingredients at 
all. A follow-up study in 2004 showed that the situation had worsened, with 99 out of 188 
artesunate samples found to be counterfeit (Reggi., 2007). Moreover, in Africa (Gabon, 
Ghana, Kenya, Mali, Mozambique, Sudan and Zimbabwe), a recent survey of quality of 
antimalarials concluded that between 20% and 90% of products failed quality testing (Mara, 
2010).  
 
In Niger, during the meningitis epidemic of 1995, more than 50, 000 people were vaccinated 
with fake vaccines, received as a gift from a country, which thought they were safe. The 
incident resulted in deaths of 2500 people (Newton et al., 2001). 
 
 In Haiti the consumption of paracetamol syrup prepared with diethylene glycol (a toxic 
chemical used in antifreeze) resulted in the deaths of 89 people in 1995 and also 30 infants 
died in the India in 1998 from an identical adulteration  (Newton et al., 2001). 
 
Counterfeit medicines have also been found in Latin American countries with instances in 
Argentina, Brazil, Colombia, Venezuela, Mexico, Peru, and Guatemala. Mexico is a major 
source of counterfeit medicines with trade of US $ 650 million per year equal to 10% of total 
drug sales in Mexico (Bate and Boateng 2007). 
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1.1.9 The size of the problem: 
The extent of counterfeiting is impossible to quantify. Currently, the sources of information 
available include reports from nongovernmental organizations, pharmaceutical companies, 
national medicine regulatory and enforcement authorities, ad hoc studies on specific 
geographical areas or therapeutic groups, and occasional surveys (WHO). These sources of 
information emphasize the complexity of estimating the problem.  
 
According to the UK’s Daily Telegraph report (August 2005), as many as 100,000 people die 
each year in China as a result of taking counterfeit or fake drugs. These figures indicate that 
the counterfeit drugs are found in high ratio in china as compared to other neighboring 
countries (Anon, 2008 c) 
 
Reports from developing countries, especially in East and sub-Saharan Africa, are extremely 
rare and do not permit a realistic picture of the situation to be drawn. This is generally 
considered to be highly unsatisfactory because of the weakness of regulatory and 
enforcement systems and the widespread presence of unregulated distribution and retail 
facilities.  
 
Counterfeiting is greatest in those regions where the regulatory and legal control is weakest. 
This situation puts rural and the poorer segments of the population at a particular 
disadvantage (See figure 1.7).  
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Fig 1.7: Medicines, including antibiotics and antimalarials on open sale on a market 
stall in Africa (Caudreon et al 2008). 
1.1.10   The limited awareness of the problem: 
In general, medical staff tend to be somewhat lacking in awareness of the extent of patient 
risk posed by substandard products and there is significant underreporting 
(Moride et al., 1997). Poor reporting in turn reinforces a limited understanding of the 
problems (usually the concentration of active ingredient). 
Up to half of medicines tested in prevalence surveys were substandard (Table1. 3), but these 
surveys are rare, often limited to a few drug classes and test for a narrow set of  
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Table 1.3: 
 
Country Drugs (n = number 
of different 
products tested) 
% 
Substandar
d 
Origin of 
production 
Stated issues References 
Kenya 41 different drugs 
(n = 277) 
46% Kenya Failure to 
comply with 
quality tests 
Kibwage et al., (1992) 
37 different drugs 
(n = 102) 
31% Imported Failure to 
comply with 
quality tests 
Roy (1994) 
Antimalarials 
(sulphadoxine-
pyrimethamine and 
amodiaquine) 
(n = 116) 
41% Not stated Under 
concentration 
of active 
ingredient; 
dissolution 
failure 
Amin et al., (2005) 
Antimalarials 42% India, China Over/under 
concentration 
of active 
ingredient 
Atemnkeng et al., (200
7) 
DRC 
Democratic 
Republic of the 
Congo 
Antimalarials 
(artemisinin 
derivatives) (n = 7) 
14% Belgium Over/under 
concentration 
of active 
ingredient 
Atemnkeng et al., (200
7) 
Bangladesh Paracetamol, 
ampicillin, 
cotrimoxazole, 
vitamin B 
tablets/injectables 
(n = 137) 
27% Not stated Under 
concentration 
of active 
ingredient 
Roy (1994) 
 
Myanmar 
Amoxicillin, 
chloroquine, 
metronidazole, 
paracetamol, 
tetracycline, 
ampicillin, 
chloramphenicol, 
rifampicin, co-
trimoxazole and 
ranitidine (n = 212) 
16% 21 countries 
(Asia, 
Europe, US 
and 
Australia) 
Under 
concentration 
of active 
ingredient; 
wrong active 
ingredient 
Wondemagegnehu 
(1999) 
Vietnam Amoxicillin, 
chloroquine, 
metronidazole, 
paracetamol, 
tetracycline, 
ampicillin, 
chloramphenicol. 
rifampicin. 
Diazepam, 
salbutamol (n = 288) 
8% 16 countries 
(Asia, 
Europe, 
Canada and 
Australia) 
Over/under 
concentration 
of active 
ingredient 
Wondemagegnehu 
(1999) 
Nigeria 21 antimalarials, 
antibacterials, 
antihelmitics and 
antifungals (n = 581) 
48% 12 countries, 
(including 
Europe, 
Nigeria, 
Egypt, Asia) 
Over/under 
concentration 
of active 
ingredient 
Taylor et al., (2001) 
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Chloroquine, 
amoxicillin, 
cotrimoxazole, 
tetracycline, 
ampiclox (n = 81) 
36% Not stated Over/under 
concentration 
of active 
ingredient 
Shakoor et al., (1997) 
Colombia, 
Estonia, India, 
Latvia, Russia, 
Vietnam 
Anti-TB drugs 
(n = 40) 
10% Not stated Under 
concentration 
of active 
ingredient 
Laserson et al., (2001) 
Laos Ampicillin tetracycline, 
chloroquine, ASA 
(n = 366) 
46% Laos, 
Thailand 
Over/under 
concentration 
of active 
ingredient 
Stenson et al., (1998) 
Ampicillin tetracycline, 
chloroquine, ASA 
(n = 300) 
22% Idem (repeat 
study) 
Over/under 
concentration 
of active 
ingredient; 
over 
concentration 
of non-active 
ingredient; 
disintegration 
Syhakhang et al., (2004
) 
Thailand Chloroquine, 
amoxicillin, 
cotrimoxazole, 
tetracycline, ampiclox 
(n = 15) 
40% Not stated Over/under 
concentration 
of active 
ingredient 
Shakoor et al., (1997) 
Tanzania Antimalarials (n = 33) 36% Cyprus, 
Tanzania, 
India, Kenya 
Under 
concentration 
of active 
ingredient; 
dissolution 
failure 
Minzi et al., (2003) 
Cambodia Antimalarials (n = 451) 27% 16 countries 
cited 
Under 
concentration 
of active 
ingredient; 
dissolution 
failure 
Lon et al., (2006) 
Cameroon, 
Madagascar, 
Chad 
Antibiotics, analgesics, 
antiparasitics (n = 429) 
18% Not stated Over/under 
concentration 
of active 
ingredient; no 
active 
ingredient 
(20%); 
contamination 
ReMeD (1995)      
 
“Cited in Caudreon et 
al 2008”        
Gabon, 
Ghana, 
Kenya, Mali, 
Mozambique
, Sudan, 
Zimbabwe 
Antimalarials 
chloroquine and 
sulphadoxine-
pyrimethamine 
(n = 278) 
23% Range: 
9% Sudan 
41% Mali 
Local and 
Imported 
Under 
concentration 
Maponga and Ondari 
(2003) 
Vietnam Amoxicillin, 
chloroquine, 
metronidazole, 
paracetamol, 
tetracycline, ampicillin, 
chloramphenicol. 
8% 16 countries 
(Asia, 
Europe, 
Canada and 
Australia) 
Over/under 
concentration 
of active 
ingredient 
Wondemagegnehu 
(1999) 
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rifampicin. Diazepam, 
salbutamol (n = 288) 
Nigeria 21 antimalarials, 
antibacterials, 
antihelmitics and 
antifungals (n = 581) 
48% 12 countries, 
(including 
Europe, 
Nigeria, 
Egypt, Asia) 
Over/under 
concentration 
of active 
ingredient 
Taylor et al., (2001) 
Chloroquine, 
amoxicillin, 
cotrimoxazole, 
tetracycline, ampiclox 
(n = 81) 
36% Not stated Over/under 
concentration 
of active 
ingredient 
Shakoor et al., (1997) 
Colombia, 
Estonia, 
India, Latvia, 
Russia, 
Vietnam 
Anti-TB drugs (n = 40) 10% Not stated Under 
concentration 
of active 
ingredient 
Laserson et al., (2001) 
Laos Ampicillin tetracycline, 
chloroquine, ASA 
(n = 366) 
46% Laos, 
Thailand 
Over/under 
concentration 
of active 
ingredient 
Stenson et al., (1998) 
Ampicillin tetracycline, 
chloroquine, ASA 
(n = 300) 
22% Idem (repeat 
study) 
Over/under 
concentration 
of active 
ingredient; 
over 
concentration 
of non-active 
ingredient; 
disintegration 
Syhakhang et al., (2004
) 
Thailand Chloroquine, 
amoxicillin, 
cotrimoxazole, 
tetracycline, ampiclox 
(n = 15) 
40% Not stated Over/under 
concentration 
of active 
ingredient 
Shakoor et al., (1997) 
Tanzania Antimalarials (n = 33) 36% Cyprus, 
Tanzania, 
India, Kenya 
Under 
concentration 
of active 
ingredient; 
dissolution 
failure 
Minzi et al., (2003) 
Cambodia Antimalarials (n = 451) 27% 16 countries 
cited 
Under 
concentration 
of active 
ingredient; 
dissolution 
failure 
Lon et al., (2006) 
Cameroon, 
Madagascar, 
Chad 
Antibiotics, analgesics, 
antiparasitics (n = 429) 
18% Not stated Over/under 
concentration 
of active 
ingredient; no 
active 
ingredient 
(20%); 
contamination 
ReMeD (1995) 
Gabon, 
Ghana, 
Kenya, Mali, 
Mozambique
Antimalarials 
chloroquine and 
sulphadoxine-
pyrimethamine 
23% Range: 
9% Sudan 
41% Mali 
Local and 
Imported 
Under 
concentration 
Maponga and Ondari 
(2003) 
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, Sudan, 
Zimbabwe 
(n = 278) 
 
 
Common problems associated with substandard medicines include under or over 
concentration, contamination, poor quality ingredients, poor stability and packaging 
problems.   
 
Table 1.4 provides a summary of these problems together with some recent examples. 
 
Issue Example Country Origin of product Reported 
Over 
concentration 
TB drugs Chad Europe (6 
countries), Kenya, 
India 
ReMeD 
Antimalarials Kenya, DRC  Atemnkeng et al.,(2007) 
Under 
concentration 
TB drugs Colombia, 
Estonia, India, 
Latvia, Russia 
and Vietnam 
Not stated Laserson et al.(2001) 
Paracetamol, 
ampicilin, co-
trimoxazole 
Bangladesh Not stated Stenson et al. (1998) 
Irregular filling 
of vials 
Over or subdosed 
Thiopental 
Sodium vials 
Belgium (MSF 
procurement 
centre 
warehouse) 
Cyprus Company alert (1998) “Cited 
in Caudreon et al 2008” 
Contamination Microbial 
contamination of 
distilled water 
MFS 
procurement in 
Europe 
Hungary MSF (1999). “Cited in 
Caudreon et al 2008” 
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Detergent 
contamination of 
i.v. fluids 
MSF 
procurement 
centres in 
Europe 
UK AFSSAPS (French DRA) 
and company alert (2003).  
“Cited in Caudreon et al 
2008” 
Fungal 
contamination of 
i.v. fluid bags 
MSF 
procurement 
centres in 
Europe) 
India MSF (2004). “Cited in 
Caudreon et al 2008” 
Black particles in 
SSG (Pentostam) 
vials 
Sudan UK Switzerland MHRA (UK DRA) and 
company alert (2006, 2007). 
“Cited in Caudreon et al 
2008” 
Ethyl methane 
sulphonate (EMS) 
contamination of 
Nelfinavir API 
and formulations 
EU and Africa  EMEA (2007). “Cited in 
Caudreon et al 2008” 
Mislabelling (not 
counterfeit) 
Paracetamol 
tablets labelled as 
co-trimoxazole 
Democratic 
Republic of 
Congo 
India MSF (2007). “Cited in 
Caudreon et al 2008” 
Problems with 
active ingredient 
Variable 
solubility and 
bioavailability of 
active ingredients 
of Rifampicin 
 Not stated MSF (2006). “Cited in 
Caudreon et al 2008” 
Morphology of 
the active 
ingredient 
(furosemide) 
affecting the 
France France, Kyghizstan, 
Kenya 
Cavenaghi  
s(1989),Bauer et al. (2002) 
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dissolution 
Problems with 
excipient 
Glycerin 
contaminated 
with diethylene 
glycol used in 
15 000 bottles of 
paracetamol 
liquid caused 
death of 88 
children 
Haiti Glycerin imported 
from 
China viaEurope 
O’Brien et al. (1998) 
Diethylene glycol 
used instead of 
propylene glycol 
in a cough syrup 
killed more than 
30 children in 
India 
India India Singh et al. (2001) 
Diethylene glycol 
used in a cough 
syrup killed 21 
persons in 
Panama 
Panama Panama FDA (2006). “Cited in 
Caudreon et al 2008” 
Poor stability Changes in color: 
amoxicillin and 
clavulanic acid 
tablets 
Georgia Cyprus MSF (2006). “Cited in 
Caudreon et al 2008” 
Change in smell: 
erythromycin 
tablets (two 
sources) 
Armenia Malta, India MSF (2004). “Cited in 
Caudreon et al 2008” 
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Change in 
consistency: 
crystalization in 
SSG vials 
Sudan India MSF (2004). “Cited in 
Caudreon et al 2008” 
Loss of potency 
(measles vaccine) 
Nigeria UNICEF Onoja et al. (1992) 
Loss of active 
ingredient: 
ergometrine 
injections 
Zimbabwe Not stated Nazerali and Hogerzeil 
(1998) 
Packaging 
problems 
I.v.fluid bottles 
contaminated 
Kenya India MSF (2002, 2003) 
Microcracks 
caused by wrong 
bottle shape, poor 
quality plastic or 
rough 
transportation 
Sudan India MSF (2004) 
Packaging 
problems 
TB drugs 
moisture-
damaged due to 
water-permeable 
blister packs 
India India Singh and Mohan (2003) 
Unsatisfactory 
dissolution 
profiles 
Higher 
dissolution rate of 
active ingredient 
in antidiabetic 
drugs (resulting in 
higher and 
quicker peak in 
France Cyprus, UK, Kenya Ba et al. (2005) 
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blood and 
toxicity) 
Poor dissolution 
of antimalarials 
Kenya Cyprus, Tanzania, 
India, Kenya 
Amin et al. (2005) 
 Tanzania  Minzi et al. (2003) 
 
 
(Table 1.3 and 1.4 source taken from Caudron,  J.-M. Ford, N. Henkens, M. Mace C, 
Kiddle-Monroe  R. and Pinel J. Substandard medicines in resource-poor settings: a 
problem that can no longer be ignored Tropical Medicine and International Health 
volume 13 no 8 pp 1062–1072 august 2008) 
 
1.1.11 Counterfeit drug impacts on health and economies: 
 
According to INTERPOL, malaria, tuberculosis, and HIV/AIDS are responsible for the 
deaths of more than 6 million people each year (Ly et al., 2007). Overall, P. falciparum 
malaria kills more than 900,000 Africans annually, mostly children under 5 years old 
(Centers for Disease Control, 2009). It is also estimated that 200,000 children die each year 
after taking counterfeit anti-malarial medications (INTERPOL 2008b). When the total deaths 
from malaria and tuberculosis are combined, the estimated number of deaths attributed to 
counterfeit drugs rises to 700,000 annually (Harris et al., 2009). Although this is an alarming 
number in itself, some researchers claim it is actually a conservative estimate (Harris et al., 
2009). Empirical studies in bacteria and parasite drug resistance and tests of active ingredient 
levels in counterfeit drugs have been conducted.  
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The danger of receiving drugs with inadequate levels of active ingredient is two-fold. First, 
the individuals receive no therapeutic value from the drug, which increases their risk of death, 
and secondly, the low levels of active ingredient assist the microorganisms in adapting to the 
drugs making them less effective.  
 
Regarding the drug resistance of the malaria parasite (Plasmodium), malaria expert Dr. Nick 
White of Oxford University said the following, “Counterfeit medicine is a major reason why 
malaria has become, over the past 30 years Africa’s biggest child killer, from an illness that 
used to be easily treated with medicines and there is now just one family of drugs left that 
malaria has not built up resistance to, artemisinins – which are being faked….Resistance to 
the Artemisinins would be an absolute catastrophe for our current attempts to try to control 
malaria (Shah, 2007). 
 
Patients are often unaware that they are buying a counterfeit product or of the risks to which 
they are exposed by purchasing such a medicine. Consumers may bypass the healthcare 
system to obtain treatment because they do not believe that their condition is serious enough 
to warrant medical attention (Shabsigh et al., 2004).   
 
Therefore, measuring the true amount of counterfeit product in the market place is 
notoriously difficult.  Popular brands attract brand parasites  lookalikes that do not exactly 
copy the original but trade-off its expensively generated brand recognition and kudos, Pfizer  
heavily targeted Viagra is a classic example of this (Davison, 2011).  
 
Sustained political will and financial support for coordinated action from the police, customs 
officials and MRAs is crucial. A recent forensic investigation into the trade in fake artesunate 
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demonstrated that police, scientists, the pharmaceutical industry, governments and the WHO 
can work together to combat these problems (Newton  et al., 2008).  
1.1.12  Challenges: 
Because of a lack of regulation and enforcement, the quality, safety and efficacy of both 
imported and locally manufactured medicines in many developing countries cannot be 
guaranteed. Subsequently, smuggling and illegal importation of drugs are often common. 
Substandard and counterfeit drugs are then not only sold in these countries but also exported 
or re-exported (Bagozzi, 2006). 
The situation is worsened by the fact that medicines exported from many industrialized 
countries are not regulated to the same level as those domestically consumed, while export of 
drugs to developing countries via free trade zones (i.e. Dubai Free Port) is increasing. 
Relabeling of products to mask details of their origin is also known to occur (Schofield, 
2001).  
Pharmaceuticals, however, cannot be considered a standard commodity since consumers and 
prescribers are unable to assess their quality, safety and efficacy and the results can be 
harmful to patient health. Growing international and national trade in alternative medicines, 
including herbal products, is also becoming more complex following rapid increases in 
demand (WHO 2006 Fact sheet  2003). Significant quantities of herbal products are now 
imported by countries in Europe, North America and Asia. However, the use and production 
of herbal products remains largely unregulated and their safety and therapeutic value cannot 
always be guaranteed (Morris and Stevens, 2006) 
In many countries, the official supply chain fails to reach rural areas. Poverty and the lack of 
an official supply chain are major factors in creating markets for counterfeit products. Also 
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international shipments are not searched or verified in free trade zones (WHO, 2006 b) 
making infiltration in the supply chain easier.  
Counterfeiting medicines is not properly defined and is dealt with in the same way as all 
other types of counterfeiting. The absence of deterrent legislation in many countries also 
encourages counterfeiters since there is no fear of being apprehended and prosecuted. 
Currently, the penalties do not match the crime and are therefore not acting as a sufficient 
deterrent. There is also a lack of a dedicated work force to handle the problem, no uniform 
international obligations and no specific treaty to tackle the problem (Latin America Battles 
Counterfeit Drug Threat: Daily International Pharmacy Alert: Washington Business 
Information: 2006: 292). 
The conclusion of a conference on counterfeit drugs held in Geneva in 2002, was that there is 
a glaring lack of political will to tackle the seriously underestimated problem of counterfeit 
drugs (Pincock, 2003).  Combating counterfeit medicines requires collaboration, at national, 
regional and international levels involving all stakeholders of the public sector and the civil 
society including health professionals, patients, manufacturers, distributors, as well as 
communication professionals and the media (WHO, 2006 b). 
Players in this important battle are the health professionals. This includes nurses and 
pharmacists who should be vigilant in detecting and reporting suspicious products. Similarly, 
physicians should rule out counterfeits as a possible cause of adverse reactions or therapeutic 
failure. Patients must report to their pharmacists and doctors if they sense any irregularity 
with their medication, if they experience a side effect or a decrease in beneficial effect.  
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1.1.13  Factors encouraging counterfeiting of drugs: 
The production of counterfeit drugs need not occur in large infrastructures or facilities. The 
majority of the counterfeiters apprehended so far carried out their activities in ordinary 
households, small cottage industries, in backyards or under the shade of a tree. 
1.1.14  Internet and Counterfeit medicine: 
Internet pharmacy is also known as online pharmacy, cyber-pharmacy, e-pharmacy, and 
virtual pharmacy/drugstores. The Internet is a global distribution channel for these fake 
medicines, but little is known about the extent to which consumers are able to buy medicines 
online safely. Hundreds of online pharmacies advertise themselves as cheap, fast alternatives 
to typical drugstores in developed countries compared to developing countries (Bate et al., 
2008).  These websites can be an enormous temptation for Americans facing the highest 
pharmaceutical prices in the world. In some ways, the internet has improved the 
pharmaceutical market with increased patient access and economic efficiency, but it is also a 
major source of counterfeit distribution. 
 
The pharmacy internet industry continues to grow as the result of consumer interest in more 
competitive prices and greater convenience.  Estimates of the number of internet pharmacy 
sites range between 500 and 600 (Newton et al., 2002).The proliferation of online pharmacies 
has generated considerable controversy, largely due to the variability of sites and professional 
concerns. Significant variation exists with respect to the quality and level of service provided 
by internet pharmacies and requires prior approval of a third-party (Crawford, 2003).  
 
Consequently, there has been a significant increase in internet use for the provision of direct 
patient care services, and these uses range from informal e-mail communications between 
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physicians and patients, to more formal services involving fees for storing medical records 
online, physical consultations with diagnoses and formulating treatment plans.  
 
 Additionally, the Web hosts countless online forums for support groups, in which patients 
can become involved in global exchanges of clinical and non-clinical discussions of medical 
topics.  Thus, the benefits and conveniences of cybermedicine are quite apparent.  However, 
there is also the perspective that these new capacities compromise the quality of medical care, 
as well as the stability and importance of the physician-patient relationship.  In industrialised 
countries and to some extent in poorer countries, internet-based sales of pharmaceuticals are a 
major source of counterfeit medicines, threatening those who seek cheaper, stigmatised or 
unauthorised treatments.   
 
Some internet pharmacies are completely legal operations, set up to offer clients convenience 
and savings.  They require patient prescriptions and deliver medications from government 
licensed facilities.  Illegal internet pharmacies on the other hand sell medications without 
prescriptions and may use unapproved or counterfeit products.  In some cases, internet 
pharmacies are operated internationally and sell products that have an unknown or vague 
origin (WHO, 2006 b). 
 
1.1.15  What is the nature of the Counterfeit medicine market? 
The massive growth of Chinese manufacturing has been one of the key drivers of the twenty-
first century global economy (UN report 2009). Much of this growth is the result of 
outsourcing by overseas companies, attempting to take advantage of China’s high 
productivity and low costs. Most of the retail value of these products accrues to the 
  
 Page 
32   
companies doing the outsourcing, while the Chinese manufacturing firms retain a relatively 
small share (UN report 2009).  
 
This mutually beneficial arrangement is only possible because most Chinese firms respect the 
intellectual property rights of the outsourcing companies. Unfortunately, this situation – in 
which the designers and manufacturers of a product often live on different continents – has 
fostered the growth of counterfeiting. Counterfeiting is an attractive alternative to licit 
commerce because costs are reduced to manufacturing, transport and distribution (Counterfeit 
product: Case studies of transnational threats: 173. 8: 176-177 WHO, 2003).  
 
The costs involved in research, design and marketing are all avoided. Because counterfeiters 
are essentially unaccountable and have no interest in building a brand reputation, costs can be 
additionally reduced by cutting corners in the production phase, such as employing 
sweatshop labour, engaging in environmentally unsound manufacturing processes and using 
inferior-grade materials. Profits can be further maximised by avoiding taxes. Thus, import 
duties are evaded through customs fraud or outright smuggling, and sales taxes are avoided 
via informal retailing, which itself often makes use of illegal migrants working for little 
compensation. The end result is a product that can look very much like the original, but 
which can be sold for much less while generating a larger profit (Counterfeit product: Case 
studies of transnational threats: 173. 8: 176-177 WHO, 2003).  
 
Mass-scale counterfeiting for export in China seems to be mainly a product of the last decade 
– in 2000, (See Figure  1.8) China ranked fourth among national sources of counterfeits to the 
EU, responsible for only 8% of the cases (Saywell,  2002).  
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The problem of counterfeiting is, of course, not limited to China, and the Chinese 
Government has taken extensive measures to address it. In 2009, the General Administration 
of Quality Supervision, Inspection and Quarantine dealt with some 200,000 cases of 
counterfeit or substandard products, dispatching nearly two million quality inspectors and 
seizing an estimated US$490 million worth of goods  (United nation report: 2012).   
 
The State Administration for Industry and Commerce announced seizing US$221 million in 
counterfeits in 2008 (Mara, 2010). In addition, Chinese Customs annually seize tens of 
millions of dollars worth of counterfeits bound for export. Those who were convicted faced 
stiff sentences and the ringleader of one software piracy operation was sentenced to seven 
years imprisonment in 2009 (WHO Substandard and counterfeit medicines, 2003). 
 
 
Figure 1.8: The value of exports from China 1999 - 2008: Source- Chinese Customs 
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1.1.16   What Does the Future Hold for Counterfeit Drugs in Africa? 
Presently, there is no agreement on how to define a counterfeit drug, let alone a scheme in 
international law to make counterfeiting a crime and pursue its perpetrators around the globe. 
(Bate and Attaran, 2010).   
 
  Drug counterfeiting is not an issue that is unique to these countries but an issue that affects 
most of Sub-Saharan Africa. These countries may have made strides to combat the issue 
within their own borders, and they may even have made vast improvements, but there is only 
so much that one country can do to tackle a regional problem. The porous borders between 
many African nations means that even if one country, for example, Nigeria, manages to 
resolve the issue of counterfeit drugs within its own borders, counterfeit drugs will still be 
prevalent, albeit to a lesser extent, unless it is neighbouring countries do the same.  
Eradicating counterfeit drugs from the continent will entail the effort of all affected countries. 
To start, perhaps, the African Union can plan a definition of what a counterfeit drug is, within 
the context of the African continent.  
 
Once all the countries have a clear idea of what they are looking to eradicate, they can then 
form a legal collective, such as the Africa and the East African Society, and create laws that 
impose more deterrent punishments on the drug counterfeiters. Many African officials see 
tougher penalties as the next logical step towards the eradication of this lethal trade (Ahmed 
and Dillard, 2011).  
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 There are no estimates on when Africa will be free of counterfeit drugs; however, even 
without an end in sight, many African countries are taking the necessary steps to safeguard 
the welfare of their people (Ahmed and Dillard, 2011). 
 
Controlling the entry of fake drugs into a country can be done, but it is a technological and 
human resource challenge. Renewed international understanding and cooperation is essential 
if we aim to control the fake drug problem. This will not be accomplished with just another 
international conference to discuss the issues. (Shepherd, 2010) 
1.1.17   Geographic Back Ground of the13 Countries that Studies Were 
Done: 
 
 
Figure 1.9: Show the map of 13 countries (Middle East and East Africa countries) 
Source: Perry-Castañeda Library Map Collection 
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1.1.18  Saudi Arabia 
Saudi Arabia is the largest Arab country of the Middle East and bordered by Jordan and Iraq 
on the north and northeast, Kuwait, Qatar, Bahrain and the (UAE) United Arab Emirates on 
the east, Oman on the southeast, and Yemen on the south ( See Figure 1.9). The Persian Gulf 
lies to the northeast and the Red Sea to its west.  
 
The Saudi Food and Drug Authority (SFDA) were established under the Council of Ministers 
resolution no (1) dated 2003 and Islamic calendar 07/01/1424 H, as an independent body 
corporate that directly reports to The President of Council of Ministers. The Authority 
objective is to ensure safety of food and drug for man and animal, and safety of biological 
and chemical substance as well as electronic products. 
1.1.19  Emirates (UAE): 
The United Arab Emirates (UAE) is a federation situated in the southeast of the Arabian 
Peninsula in Southwest Asia on the Persian Gulf, bordering Oman and Saudi Arabia and 
sharing sea borders with Iraq, Kuwait, Bahrain, Qatar and Iran (See Figure 1.9). The UAE 
consists of seven states, termed emirates, (because they are ruled by Emirs) which are Abu 
Dhabi, Dubai, Sharjah, Ajman, Umm al-Quwain, Ras al-Khaimah and Fujairah. The capital 
and second largest city of the United Arab Emirates is Abu Dhabi. It is also the country's 
center of political, industrial, and cultural activities. In 1974 the first law relating to the sale 
of medicine and pharmaceutical practice was passed, superseded by the second and current 
law in 1983 (Abu-Dhabi-Gov, 1995) 
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1.1.20  Qatar:  
Qatar is an Arab country, known officially as an Qatar, in the Middle East, occupying the 
small Qatar Peninsula on the northeasterly coast of the much larger Arabian Peninsula. It is 
bordered by Saudi Arabia to the south (See Figure 1.9); otherwise, the Persian Gulf surrounds 
the state. A strait of the Persian Gulf separates Qatar from the nearby island nation of Bahrain. 
Qatar is an oil- and gas-rich nation, with the third largest gas reserves, and the first or second 
in the world. An absolute monarchy, Qatar has been ruled by the al-Thani family since the 
mid-1800s and has since transformed itself from a British protectorate noted mainly for 
pearling into an independent state with significant oil and natural gas revenues. 
1.1.21  Yemen: 
Yemen is a country located on the Arabian Peninsula in Southwest Asia. It is bordered by 
Saudi Arabia to the north, the Red Sea to the west, the Arabian Sea and Gulf of Aden to the 
south, and Oman to the east (see Figure 1.9). 
Yemen has population approx. 19.7 Million inhabitants, 71% of whom live in rural areas. The 
illiteracy rate is high and reaches about 55.7%. Yemen is a low-income country with per 
capita GDP of US 659. Ministry of Public Health and population is responsible of regulating, 
registering and controlling medicine that is used in Yemen (Anon, 2008 a).  
1.1.22   Bahrain: 
Bahrain is a small island country in the Persian Gulf ruled by the Al Khalifa Royal family. 
While Bahrain is an archipelago of thirty-three islands, the largest (Bahrain Island) is 55 km 
(34 mi) long by 18 km (11 miles) wide. Saudi Arabia lies to the west and is connected to 
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Bahrain via the King Fahd Cause way, which was officially opened on 25 November 1986. 
Qatar is to the southeast across the Gulf of Bahrain (See Figure 1.9). 
In Bahrain, petroleum production and processing account for about 60% of export receipts, 
60% of government revenues, and 30% of GDP (Word Fact Book). Ministry Health (MOH) 
is responsible of regulating, registering and controlling medicine that is used in Bahrain. 
There is no independent regulatory agency, like Saudi Arabia and Yemen. 
In 1978 a Registration Committee was established to regulate medical practice and service in 
pharmaceutical area (Anon, 2012) 
1.1.23   Oman: 
Oman is an Arab country in southwest Asia on the southeast coast of the Arabian Peninsula. 
It borders the United Arab Emirates on the northwest, Saudi Arabia on the west and Yemen 
on the southwest. The coast is formed by the Arabian Sea on the southeast and the Gulf of 
Oman on the northeast. The country also contains Madha and Musandam, two exclaves on 
the Gulf of Oman, south of the Strait of Hormuz and surrounded by the United Arab Emirates 
on the land side (See Figure 1.9).  Ministry of Health (MOH) is responsible of regulating, 
registering and controlling medicine that is used in Oman. There is no independent regulatory 
agency, like Saudi Arabia and Jordan.   
1.1.24  Egypt: 
Egypt is a country mainly in North Africa, with the Sinai Peninsula forming a land bridge in 
Southwest Asia. Egypt is thus a transcontinental country, and a major power in Africa, the 
Mediterranean region and the Islamic world. Covering an area of about 1,010,000 square 
kilometers (390,000 sq mi), Egypt is bordered by the Mediterranean Sea to the north, the 
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Gaza Strip and Israel to the northeast, the Red Sea to the east, Sudan to the south and Libya 
to the west (See Figure 1.9). The Egyptian Drug Authority (EDA) is the pharmaceutical 
regulatory body of the Egyptian Ministry of Health (MOH) and it is responsible for 
cooperation with relevant international organizations (such as the WHO) in order to improve 
standards of pharmaceutical products and practices. 
1.1.25   Ethiopia: 
Ethiopia is the second-most populous nation in Africa with over 85.2 million people and the 
tenth-largest by area with its 1,100,000 km2. The capital is Addis Ababa. Ethiopia is bordered 
by Eritrea to the north, Sudan to the west, Djibouti and Somalia to the east, and Kenya to the 
south (See Figure 1.9). Ethiopia has shown a fast-growing annual GDP and it was the fastest-
growing non-oil-dependent African nation in 2007 and 2008. (Anon, 2008 b) retrieved on 16-
04-2010).  
Ethiopia has agency call Drug Administration and Control Authority of Ethiopia which 
claims that this agency its job is to promote and protect the public health by ensuring safety 
and quality of products and health service through registration, licensing and inspection of 
health professionals, pharmaceuticals food establishments and health institutions and 
provision of up-to-date regulatory information while promoting rational medicine use 
1.1.26  Somalia: 
Somalia: formerly known as the Somali Democratic Republic under communist rule, is a 
country located in the Horn of Africa. It is bordered by Djibouti to the northwest, Kenya to 
the southwest, the Gulf of Aden with Yemen to the north, the Indian Ocean to the east, and 
Ethiopia to the west. With the longest coastline on the continent, its terrain consists mainly of 
plateaus, plains and highlands (See Fig 1. 9). For 1994, the CIA estimated the GDP at $3.3 
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billion.  In 2001, it was estimated to be $4.1 billion. By 2009, the CIA estimated that the GDP 
had grown to $5.731 billion, with a projected real growth rate of 2.6%. (Somalia; World Fact 
book. Central Intelligence Agency. 2009-05-14). Somalia does not have regulatory agency at 
all.  
1.1.27   Kenya: 
Kenya is a country in East Africa. Lying along the Indian Ocean to its southeast and at the 
equator, Kenya is bordered by Somalia to the northeast, Ethiopia to the north, Sudan to the 
northwest, Uganda to the west and Tanzania to the south. Lake Victoria is to the southwest 
and is shared between Kenya, Uganda and Tanzania. Kenya has numerous wildlife reserves, 
containing thousands of animal species (See Figure 1.9).  
 
The Pharmacy and Poisons Board is the Drug Regulatory Authority established under the 
Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya. The Board regulates the 
Practice of Pharmacy and the Manufacture and Trade in drugs and poisons. Their aims is to 
implement the appropriate regulatory measures to achieve the highest standards of safety, 
efficacy and quality for all drugs, chemical substances and medical devices, locally 
manufactured, imported, exported, distributed, sold, or used, to ensure the protection of the 
consumer as envisaged by the laws regulating drugs in force in Kenya.  (Ministry health web 
site) 
1.1.28  Uganda: 
Uganda is a landlocked country in East Africa. Uganda bordered on the east by Kenya, on the 
north by Sudan, on the west by the Democratic Republic of Congo, on the southwest by 
Rwanda, and on the south by Tanzania (See Figure 1.9). The southern part of the country 
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includes a substantial portion of Lake Victoria, which is also bordered by Kenya and 
Tanzania. 
In Uganda, the National Medical Stores and National Public Health Laboratories, regulatory 
functions handled by professional councils, National Drug Authority (NDA) and other 
regulatory bodies and one of its functions is the implementation of the Policy. 
1.1.29  Tanzania: 
Tanzania is a country in central East Africa bordered by Kenya and Uganda to the north, 
Rwanda, Burundi and the Democratic Republic of the Congo to the west, and Zambia, 
Malawi and Mozambique to the south. The country's eastern borders lie on the Indian Ocean 
(See Figure 1.9). 
 
1.1.30  Overview background information for drug regulation of these 13 
Countries:  
The regulation of medicine has evolved over the last five decades in response to serious 
adverse events in relation to medicinal products. The early regulatory standards were mainly 
related to ensuring the quality of pharmaceutical products and subsequent advances in the 
early 1960s led to the developing of new standard for assessing the efficacy and safety of new 
medicines (Hill and Johnson, 2004) 
 
Currently pharmaceutical companies are required to obtain a marketing licence prior to the 
sale of new medicine in a particular market or country. This licence, issued by the governing 
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regulatory authority, follows a review process designed to ensure that only safe and effective 
drugs reach the market and the patient. 
 
Currently approximately 20% of countries have fully operational medicine regulation 
whereas 50% have regulation of varying capacity and 30% have either none or very limited 
drug regulation. Many developing countries are incapable of ensuring safety, efficacy and 
quality of the pharmaceutical product available in their markets and this due to the resource 
constrained in terms of staffing, standard system and training  
1.1.31  UAE: 
In 1974 the first law relating to the sale of medicine and pharmaceutical practice was passed, 
superseded by the second and current law in 1983 (HAAD, 2013). 
1.1.32  Bahrain: 
In 1978 a Registration Committee was established to regulate medical practice and service in 
pharmaceutical area (Anon, 2012) 
1.1.33  Qatar: 
The pharmaceutical area has been controlled by the Ministry of health since 1971 and 
Pharmacy and Drug Control Department at the Supreme Council of Health is the department 
who regulates the Medicine in Qatar (WHO 2006) 
 
1.1.34  Kenya: 
In Kenya, there are legal provisions establishing the powers and responsibilities of the 
Medicines Regulatory Authority (MRA), which is the Pharmacy and Poisons Board (PPB). 
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The PPB operates as a department of the Ministry of Health, but there are initiatives to 
establish it as a semi-autonomous agency under the Ministry of health. The MRA is involved 
in harmonization/collaboration initiatives, which include the African Medicines Regulatory 
Harmonization and the Harmonization of Medicines Registration in the EAC. An assessment 
of the medicines regulatory system was conducted in 2006.  
1.1.35  Tanzania: 
Tanzania Food and Drugs Authority (TFDA) is a regulatory body under the Ministry of 
Health and Social Welfare which is responsible for regulating the quality and safety of food, 
drugs, cosmetics and medical devices. 
 
It is established under Tanzania Food, Drugs and Cosmetics Act No. 1 of 2003, after 
repealing the Pharmaceutical and Poisons Act No. 9 of 1978 (which established the Pharmacy 
Board) and Food {Control of Quality} Act No. 10 of 1978 (which established the National 
Food Control Commission). TFDA, a semi-autonomous body under the Ministry of Health 
and Social Welfare, became operational on 1st July 2003 (TFDA web 
site: http://www.tfda.or.tz). 
 
1.1.36  Uganda: 
The National Drug Authority (NDA) a regulatory body under the Ministry of Health and 
Social Welfare which is responsible for regulating the quality and safety of food, drugs, 
cosmetics and medical devices. 
 
 NDA mandated with the responsibility of ensuring that the population accesses medicines 
that are of good quality, safe and efficacious, wishes to inform the general public that it has 
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received information from World Health.  NDA was established on 1986.  (NDA Web site 
http://www.nda.or.ug).  
 
1.1.37  Ethiopia:  
Reformation in the Ethiopian Food, Medicine and Health care Administration and control 
authority was establishes on 2009.The Ministry of Health is  
The Ministry of Health is responsible for the accessibility of quality health service to all 
citizens throughout the country. Although, a number of special programs have been 
operational, in the last few years, the Primary Health Care quality still requires due attention. 
However, various challenges, assumptions and bureaucratic hurdles have been hampering the 
progress in quality health care delivery system. Because of this the health care service was 
haphazardly regulated inefficiently. 
 In recognition to the health sector reform in Ethiopia, the regulation of all health care 
elements are clearly delineated from the provider and purchaser, and is redesigned to provide 
the public a dramatic result with respect to low cost, short time, high quality, and large 
amount of service. Accordingly, health and health related services and products quality 
regulation core process is redesigned in the purpose of protecting the public from any 
emerging health risks (Food, Medicine and Health Care Administration and Control 
Authority Ethiopia website FMHACA ) accessed on 10/10/2012. 
 
1.1.38   Somalia: 
Somalia does not have any regulatory agency, they do have a ministry health 
The three zonal Ministries of Health (Ministry of Health of the Transitional Federal 
Government, Ministry of Health and Labor of Somaliland, and the Ministry of Health of 
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Puntland) operate with varying and overall limited levels of influence over domestic 
operations.  Somalia is critical for the pharmaceutical trade because its duty-free conditions 
have made it a major import channel for the Horn of Africa (Kenya and Ethiopia). There are 
linkages between the pharmaceutical market in Ethiopia and Somalia, but little is known 
about the routes which are taken or the amount of goods that cross the border. Drug supply 
routes are the least investigated segment of the health system in Somalia although a study did 
find that most medicines in the central Bakaarha market in Mogadishu came from Pakistan 
and India (Capobianco and Naidu 2010). 
1.2 AIMS AND OBJECTIVES OF THE STUDY 
1.2.1 Aims: 
The principal aim of this study was to investigate the performance of health care 
professionals at the practice level concerning the safety and quality of medicinal products in 
developing countries focusing on six countries in the East African region and seven countries 
located in the Middle East.  
1.2.2 Objectives: 
 To perform some groundwork towards providing a fundamental insight into the extent 
of drug counterfeiting in these developing countries particularly where data gathering 
has traditionally been both sparse and challenging. 
 
 To design and evaluate a suitable questionnaires 
     
 To conduct a questionnaire and survey concerning counterfeit medicines in the 13 
developing countries.    
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 To evaluate how developing countries and the authorities in these regions are 
developing strategies to combat the counterfeit drug problem.   
  
 To establish the activities undertaken to improve safety of medicines in developing 
countries.          
  
 To compare the safety and use of medicines in developing countries with those of 
developed countries.          
      
 To address the problem of the counterfeit medicine in developing countries and 
advocate possible solutions as to how to contend with counterfeit medicines. 
     
 To compare and contrast the data with that in the existing literature. 
1.2.3 Hypothesis test: 
  To investigate the correlation between the GDP per country/capita against level of 
counterfeit medicine.  
 To investigate the correlation between the counterfeit medicine and education level. 
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2 CHAPTER TWO 
 
 
 
 
 
 
 
 
2.1 STUDY RATIONALE AND METHODOLOGICAL 
FRAMEWORK. 
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2.1.1 Study Rational  
The general introduction to this thesis (chapter one) highlighted the focus of earlier research 
studies on quality measures regarding the safety medicines and how they tend to be restricted 
to developed countries such as the USA and Japan in addition to the EU. However, there is a 
lack of data concerning the quality and safety of medicines and counterfeit medicines in 
emerging markets such as those of middle-eastern countries and east Africa. 
 
Given the importance of the safety of medicines, and problems of counterfeit drugs in 
developing countries, it was proposed that data relating to this topic should be collected and 
analysed from the Middle East and east Africa. 
 
The overall rationale was to: 
 
 Provide an insight into the extent of drug counterfeiting in middle-eastern countries  
 Evaluate how the authorities in middle-eastern countries combat counterfeiting. 
 Determine the activities undertaken to improve medicines safety 
 Compare the safety of medicine in developing countries such as the middle-east and 
east Africa with those of developed countries  
 
In respect of the above rationale, there is a gap in research in developing countries regarding 
a valid and reliable instrument to collect comprehensive data on quality performance at the 
practice level concerning the safety and use of medicines and counterfeit drugs. In view of 
the above shortcoming, this chapter is intended to review and lead up to an appropriate 
methodological framework for the proposed study 
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2.1.2 Study design: 
The selection of a study design is one of the most important decisions that need to be made in 
order to answer any research question. According to Yin (2003), the purpose of any potential 
academic research may be exploratory, descriptive or explanatory and the following expands 
on these categories: 
2.1.3 Explanatory studies: 
The meaning of the word “explanation” is to render complicated concepts understandable by 
showing how their component parts fit together according to some rules (Miles and 
Huberman, 1994). Explanatory research is used for studying the relationship between causes 
and effects as well as factors which together cause certain phenomena to be identified (Yin, 
2003). 
2.1.4 Descriptive studies: 
Descriptive studies are suitable when a problem is clearly structured but the intention is to 
simplify the matter to make it more understandable rather than identifying the cause of the 
symptoms. This is performed by reducing the complicated problems into their component 
parts (Miles and Huberman, 1994). 
2.1.5 Exploratory studies: 
Exploratory studies aim to gain basic knowledge within a problem area (Zarkesh, 2008). 
These studies are appropriate when it is difficult to identify the problem and when important 
characteristics are difficult to determine, they tend to start from a large pool of data that has a 
narrower focus as the research develops (Saunders et al., 2009). 
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The current research project aims to investigate the safety of medicines with regard to the 
counterfeiting in developing countries. Thus the main purpose of the work may be classed as 
exploratory even though it might also be additionally considered as descriptive research. 
When considering the sample populations from which information will be collected, namely 
healthcare workers and pharmacists, it was decided that the most appropriate technique for 
data gathering would be through the use of structured questionnaires. 
 
Cross-sectional research involves the collection of data from a whole population or a 
representative subset, at one specific point in time. There are several advantages of cross 
sectional studies such as savings in time and costs particularly since this design type has the 
potential to collect a large amount of data over a short period of time (Anon 2000). Such 
studies may be short and executed with less difficulty or costs of maintaining subject contact 
than that associated with longitudinal research, which entails repeated observations over 
extended periods.   
2.1.6 Data Collection: 
2.1.7 Data collection techniques: 
There are a number of possible data collection techniques and these include structured 
questionnaires and personal or telephone interviews (Trochim, 2006). A key difference 
between these two approaches is that in the case of structured questionnaires the respondent 
completes the questionnaire directly while interviews are completed by the reviewer based on 
the respondent’s verbal answers. 
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2.1.8 Structured questionnaires: 
A questionnaire is useful when information needs to be collected reasonably quickly from 
respondents in a non-threatening way (McNamara, 1999). It consists of a number of 
questions in a definite order. The main strengths of questionnaires are the following 
(McNamara, 1999; Passmore et al., 2002; Bourque and Fielder, 2003; Trochim, 2006): 
 
• Questionnaires are easy to distribute: 
• They are relatively inexpensive to administer  
• The same instrument may be sent to a large number of people. 
• They allow the respondent to respond at their own convenience. 
• Large amounts of data can be collected 
• They are impersonal and avoid bias which develops as a result of interaction between 
the researcher and the respondent  
• They can be completed anonymously 
• The results are easy to compare and analyse. 
 
On the other hand, there are a number of limitations associated with questionnaires. These 
include (McNamara, 1999; Passmore et al., 2002; Bourque andfielder, 2003; Trochim, 2006): 
 
• Response rates are often very low 
• The risk of not obtaining care feedback from some of the respondents 
• They can be considered impersonal 
• No clarification of items is possible 
• The questions may be difficult to develop as they must be drawn up in a way that 
avoids bias and ambiguity 
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2.1.9 Personal and telephone interview: 
These interviews are used in cases when researchers wish to obtain a full range and depth of 
information (McNamara, 1999). The method employs an interviewer who telephones or 
meets in person with respondents, spontaneously or through a scheduled appointment (Diem, 
2002). 
 
The main advantages of telephone and personnel interviews include (McNamara, 1999; Diem, 
2002; Passmore et al., 2002; Bourque and Fielder, 2003; Bowling 2005; Trochim, 2006): 
 
• Opportunity to obtain quick responses 
• The personal element and trust that can be developed through interview. 
• Clarification and explanation of items is possible 
• Few incorrectly completed questionnaires 
• High response rate   
 
In contrast, there are a number of limitations associated with interviews and these include 
(McNamara, 1999; Diem, 2002;Passmore et al., 2002; Bourque and Fielder, 2003; Bowling 
2005; Trochim, 2006). 
 
• The risk that the interviewer biases the respondent’s replies 
• Responses are not private  
• Can be costly to administer each interview 
• Time consuming if the interviews are conducted at the participants locations 
• Difficult to analyse and compare the responses. 
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Some these potential weaknesses are avoidable by careful selection, training and monitoring 
of interviewers (Bourque and Fielder, 2003; Bowling, 2005).  
Although personal or telephone interviewing may be a suitable and powerful method, a 
number of factors, such as cost, time required, and nature of the data gathered and the 
geographic dispersion of the respondents make this option less feasible. As a consequence, 
the questionnaire technique is preferred due to the confidential nature of the information 
required, as well as the high volume of data likely to be collected from different sources. 
 
2.1.10  Data collection method using the questionnaire technique: 
There are a number of methods available for collecting data using the questionnaire technique 
(McNamara, 1999; Diem, 2002), these include questionnaires that are paper based or 
electronically mailed, group administered, telephone-administered and web-based. Several 
factors should be considered when selecting the most suitable method such as the type and 
size of the population being studied, the purpose of the study, timelines, budget and resource 
(Diem, 2002). 
2.1.11  Paper or electronically delivered questionnaires: 
This method uses a printable document that is posted or mailed electronically to participants 
for them to complete at their own convenience, before returning the questionnaire. 
This method can be advantageous because it (Diem, 2002: Bourque and Field, 2003 and 
Trochim, 2006): 
• is highly cost –effective 
• requires minimum resource 
• allows privacy of responses 
• reduces bias 
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However, there are a number of challenges that need to be addressed if this method is used. 
These include (Diem, 2002; Bourque and Field, 2003; Bowling, 2005): 
 
• The difficulty in obtaining accurate mailing lists 
• The time required to receive the responses 
• The extra time involved in following up non-respondents 
• The possibility of obtaining a low response rate 
• The risk of encountering problems with collected data due to the limited flexibility 
permitted through the questionnaire. 
2.1.12  Group-administered questionnaires: 
This method brings together a group of respondents who are asked to respond to a structured 
sequence of questions. Each person is expected to complete the questionnaire without 
consulting with other persons in the group, but the researcher is available to provide 
introductory instructions, answer questions and monitor the extent to which the 
questionnaires are completed (Diem, 2002; Bourque and Field, 2003; Trochim, 2006). The 
strengths of this approach are that the response rates are high invariably since respondents 
may request clarification from the researcher, and the qualities of responses tend to be of a 
higher standard. The limitations include (McNamara, 1999; Bourque and Fielder, 2003) 
 
• The required information can be gathered quickly  
• Data can be collected over a large geographic area 
• There is some personal contact between the interviewer and the respondent  
• It allows for flexibility with the respondent 
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• Follow-up questions can be asked by the interviewer 
 
Limitations of this method include (Diem, 2002; Bourque and Field, 2003; Trochim, 2006): 
• The intrusion of a call might not be liked by some respondents  
• The need to establish the credibility of the caller 
• The questionnaires have to be relatively short 
• Restricted time for respondents to compile the answers 
• The interviewer can bias the participant’s responses 
• Greater auditory demands which may be burdensome to some respondents 
• The willingness to disclose sensitive information is low 
2.1.13   Telephone-administered questionnaires: 
Calling the participants by telephone, typically spontaneously, or by scheduling an 
appointment can be used to collect data. It may be possible to use an automated system where 
users reply via a touch-tone telephone to a computer-based interview system. A rapid 
response is possible using this approach and it can be inexpensive if calling locally. Some of 
the problems encountered with this method include access limitation from answer machines, 
reliance on correct numbers and instantaneous credibility of the caller being established in 
order to complete the call. 
 
Time zones differences and language can also be a barrier (Diem, 2002; Trochim, 2006). In 
addition, the time differences between different countries can be one of the problems, which 
may lead to it being inconvenient to answer questions from the researcher’s point of view. 
This type of method was not selected by the researcher and was not used this study.  
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2.1.14  Web-based questionnaires: 
This method involves posting a questionnaire on a website and respondents replying remotely 
(Diem, 2002). The advantages of this method include: quick responses are possible, it can be 
inexpensive if the correct software and tools are available; postage is reduced or eliminated; 
and it is easy for respondents to reply. The limitations of this method are that the respondents 
must have internet access, require basic computer literacy and reminders are still needed 
(Diem, 2002 and Bowling 2005). 
 
Taking into consideration the above factors, paper questionnaires were the preferred option 
due to the fact that many subjects in developing countries do not have computer access. In the 
execution of the study, either the author or an agent administered the questionnaires (See 
Figure 2.1).  
 
2.1.15  The study Method: 
The methodology used in this study employed a questionnaire survey for information 
gathering (See Figure 3.1). The questionnaires were delivered to the respondents either by 
post, personally or via e-mail. Pharmacists returned their questionnaire forms directly on the 
same day or by e-mail. The data were analysed with regard to the types of questions. 
Nine countries in the Middle East were chosen to conduct the pilot questionnaires as the most 
appropriate source for evaluating the performance of healthcare professionals on the safety of 
medicine in developing countries.  
Pilot questionnaires were developed and tested within the Middle Eastern countries for the 
following reasons:  
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• The author was already working with one of the most prestigious Saudi hospitals 
(King Faisal Hospital and Research Centre) as a Clinical Research associate (CRA) 
and this necessitated business visits to the Middle East twice per month.   
• The cost of field trips was covered by the employer. 
• Accessibility: there was easy access to all cities and villages in the KSA (Kingdom of 
Saudi Arabia) as well as the rest of the Middle Eastern countries apart from Iran and 
Iraq. 
• Political /Government issues: Middle Eastern countries tended to be less corrupt and 
more politically stable than those in East Africa and it was perceived as much safer to 
conduct the pilot study in the Middle East. 
 
Probability sampling methods and simple/multistage random sampling was carried out: a 
sample was drawn randomly from a list of individuals in a population.  
 
Regarding the multistage random sampling: initially, a sampling set of geographic areas was 
taken then, a subset of regions within those areas was sampled and so on. Pharmacies and 
clinics were randomly visited and questionnaires were administered to the respondents. At 
this time, respondents were informed that the questionnaires were for research purposes only. 
Ten to fifteen pharmacies were visited randomly per day during data gathering visits.  
Questionnaires that were administered in Iraq, Iran and Oman were sent by e-mail due to time 
constraints and accessibility issues. Questionnaires that were administered in Yemen, Saudi 
Arabia, Emirates, Egypt, Jordan and Qatar were administered personally.  Respondents were 
presented either with hard or electronic copies of the questionnaires. 
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Participants were encouraged to reply honestly, openly and without fear. Interviewers 
explained to respondents that there would be no future repercussions based on their responses 
and that all information would be handled maintaining utmost confidentiality in accordance 
with the stated research purpose.  
2.1.16  Background information for the agents collecting the Data: 
 The first agent was Mr. Abdi-Rizak Ali who was a graduate of Salford University in 
Manchester and studied media and communication and was employed by Horn Relief (NGO). 
He travelled regularly between Kenya, Djibouti, Ethiopia and Somalia and was based in 
Somalia. He was appointed and asked to help in data collection in Somalia, Djibouti, Kenya 
and Ethiopia. 
 
The second agent was Hassan Ahmed who was based in Saudi Arabia. Mr. Hassan was 
employed as a Medical device sales person. Hassan travelled regularly within Saudi Arabia 
and could reach all the small cities as well as villages; he also used travel for business to 
UAE and Egypt, Hassan and I covered all the Middle East countries. 
 
The third agent was Mohamed Ali Warsame who was based in Uganda. Mohamed was a 
pharmacy student and he wanted to be part of this project in order to gain experience for his 
third year thesis. I appointed and asked him to help me in Uganda.  
 
Lastly, the fourth agent was Farah Yunus who was based in Tanzania and had a background 
in Biological Science and I appointed him to help me in Tanzania. 
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2.1.17  Training the agent received:  
All the agents were provided with training, before they started collecting the data and to 
avoid bias. They were instructed not to pose leading questions during the interview.  
• General information about the project (e.g., the study's background and goals,) was 
discussed with all the agents.  
• How to introduce the survey to respondents 
• Agents were familiarised with the questionnaire before administration in the study in 
and were well informed about the project objectives. 
During data collection, there were monthly teleconferences to discuss the progress of the 
data collection. 
2.1.18   Questionnaire development: 
A questionnaire was developed based on the one tested and evaluated previously in a pilot 
study. This was worked up through a series of consultations with health care workers and the 
project supervisors.  
• The first step was to identify the two leading hypotheses about the source of the 
problem. 
• The second was to distinguish between “What would I like to know” versus “What do 
I need to know.” 
The Third step was to identify the logistical needs of field questionnaires and then start 
implementation early in the process.   
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Figure 2.1: Method of administration and collection of questionnaires 
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2.1.19  Information source:  
The developing countries chosen for the study were the following countries: Bahrain, 
Djiboute, Ethiopia, Egypt, Kenya, Qatar, Saudi Arabia, Somalia, Tanzania, UAE, Uganda 
and Yemen 
 
 
Thirteen countries were selected, either because of ease of access entry of these countries as 
determinant.  
• Easy to mobiles a team of workers who will administer the questionnaires.  
• Middle East countries were easy and safe to travel between cities.  
• Easy African countries were less safe to travel between cities but the logistics were 
cheaper than compare to Middle East countries.  
 
2.1.20  Study Instrument 
A literature search using published databases was instigated to find any existing 
questionnaire(s) with established psychometric properties to assess performance at the 
practice level concerning the safety and use of medicines and counterfeit drugs in developing 
countries.  The intention was to use any accessible instrument and modify it for the objectives 
of the study. However, no relevant questionnaire emerged from the literature search, so the 
decision was made to develop a bespoke questionnaire specifically for the study purpose.  
 
Between 2009 and 2011, the safety of medicines survey was administered to all healthcare 
workers in 13 countries (Middle East and East Africa). The survey covers level of counterfeit 
medicine and quality and safety of medicine sold in these countries. 
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2.1.21  Psychometric evaluation of the study instruments: 
There are a number of fundamental principles that need consideration when developing 
measurement instruments. In the study, seven psychometric principles will be assessed: 
applicability, acceptability, practicability, confidentiality, validity, reliability and 
sensitivity. 
 
2.1.22 (i)  Applicability and (ii) acceptability 
Applicability of the study instrument ensures the appropriateness of its content for the 
purpose of the research being conducted. Furthermore, applicability describes the suitability 
of an instrument for its intended use in terms of wording, clarity and simplicity of language 
(Higginson and Carr, 2001). Another critical aspect is the acceptability of the study 
instrument by the study participants and whether they are willing to respond to the questions. 
It also considers the time required from the participants to complete the questionnaires and 
whether the questions are clear, concise and easy to understand (Valovich et al, 2008). 
2.1.23 (iii) Confidentiality and anonymity of study participants 
Anonymity and confidentiality of participants are central to ethical practice in social research. 
Where possible, participants in this study will be assured that every effort will be made to 
ensure that the data provided by them cannot be traced back to them in reports or publications 
(Crow and Wiles, 2008).  
 
There are two possible issues that such practices raise. One is that it is occasionally difficult 
for researchers to know how far to take anonymisation in order for the participant not to be 
identifiable (given that research findings may be presented to a variety of audiences). 
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Secondly, research participants hold differing views about the desirability of anonymisation, 
presenting researchers with difficult choices between respecting the preferences of those 
participants who wish to be identifiable and those was preferring to remain anonymous 
(Crow and Wiles, 2008). 
 
2.1.24 (iv) Practicality 
The practicality of the instrument must also be considered when assessing its appropriateness 
for the purpose of the study. Practicality issues include the participant’s comfort, cost and 
mode of administration of the study instruments (e.g. interview or self administered), 
convenience and ease of understanding of the questions (Ware et al., 1981). Indicators of the 
participants’ lack of comfort include low response rate, high refusal rate, missing responses 
and administration time (Ware et al., 1981). 
 
2.1.25 (v) Validity 
Kaiser and Smith (2001) define validity as, the most fundamental consideration in developing 
and evaluating a test. The concept refers to the degree to which evidence and theory support 
the interpretations of test scores entailed by proposed uses of tests.  
 
Essentially, the concept of validity is whether or not an indicator/instrument measures what it 
claims it does and when investigating sensitive issues, this can be a complex matter. There 
are varieties of methods by which validity can be assessed. The three types of validity most 
commonly used are content-, criterion- and construct-validity. 
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2.1.26  Content Validity: 
This assesses the extent to which questions in a survey serve to encompass the important 
facets of the notion the indicator is supposed to represent in a balanced way. The weighting 
of the results are also reviewed with the set of indicators (Anon, 2001). 
 
2.1.27  Criterion Validity: 
This assesses how an observed indicator compares with other measures or outcomes (the 
criteria) already held to be valid. The aim is to correlate a new indicator with reference to a 
previously well-established indicator (gold standard) (Anon, 2001). In piloting the 
questionnaires before using the final version in the main study, participants assess the 
practicality and applicability of questions and this helps to ensure that they are clear, feasible 
and unambiguous. 
 
2.1.28  Construct validity: 
This is the most rigorous approach to establishing validity (Guyatt et al, 1993) and 
necessitates the assembly of empirical evidence to support the inference that a particular 
instrument measures what it is supposed to measure. 
 
Construct validity involves comparisons between measures and examines the logical relations 
that should exist between a measure and the characteristics of the system being studied 
(Guyatt et al. 1993). Sub-types of construct validity include convergent validity (positive 
correlation with a related measure) and discriminant validity (a low correlation coefficient is 
obtained when the measures are the unrelated constructs (Saw, 2001).   
 
  
 Page 
65   
2.1.29  (vi) Reliability 
Assessing the reliability of the instrument is essential in determining its ability to measure 
something in a consistent and reproducible manner. In other words, reliability is concerned 
with how consistently an instrument measures the concept of interest (Pinar, 2002). It 
therefore assesses whether the instrument produces results that are reproducible and 
internally consistent (Valovich et al 2008). 
 
2.1.30 (vii) Sensitivity 
Sensitivity is related to the instrument’s ability to detect and measure change when it has 
occurred (Higginson and Carr 2001). Differences among groups (approval times, milestones, 
quality measures, strategic parameters, years of study and the authorities) are checked to test 
the instrument’s ability to detect differences if they really exist (Dimoliatis et al., 2010). 
 
The questionnaires will be developed based on established psychometric principles to collect 
data from the participating health care workers in the chosen developing countries. Pilot 
testing is a critical step to increase the confidence about the clarity, feasibility and suitability 
of the questions for the particular country. Following the pilot study, changes will be made to 
the questionnaires to incorporate the feedback obtained and the lessons learned, once the 
appropriateness, convenience, relevance and clarity of the questionnaires are ensured from 
the pilot study. Questionnaires will then be distributed to the rest of the countries for 
completion.  
There were no standard questionnaires available to use and therefore the researcher designed 
and developed new questionnaires. One has to have quantitative information to test specific 
hypotheses that have previously been generated and in this case, there is none available to use. 
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2.1.31  Study Plan: 
A comprehensive review and critical analysis of the literature reported in chapter one 
demonstrated a significant problem concerning counterfeit medicines in developing countries. 
So in order to discover the source(s) of the problem and improve safety aspects of medicines 
in these developing countries. Therefore, the following study plan was developed to capture 
data on the safety of the medicines in these countries. The data were then subjected to a 
substantial scrutiny to fulfill the objectives of the study. 
 
The Thesis consists of three main chapters that investigate the major areas of the safety 
medicines with respect to drug counterfeiting in developing countries (Middle East and East 
Africa) 
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Figure 2.2: The Delphi Approach to be used in this study: 
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3 CHAPTER THREE 
 
 
 
 
 
 
 
3.1 PILOT STUDY TO VALIDATE THE QUESTIONNAIRE 
FOR EVALUATING A STUDY OF THE SAFETY OF 
MEDICINES WITH RESPECT TO DRUG 
COUNTERFEITING IN DEVELOPING COUNTRIES 
ESPCIALLY THE MIDDLE EAST: 
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3.1.1 Introduction:  
 
Pilot studies offer a good opportunity to assess the feasibility of large full-scale studies and 
are almost an essential prerequisite. Conducting a pilot prior to the main study can enhance 
the likelihood of success within the main study and potentially improve the quality of the 
main study. They should be well designed with clear feasibility objectives, logical analytical 
plans, and explicit criteria for determining feasibility.  
 
In this Chapter therefore, questionnaires were tested in a pilot study performed in Saudi 
Arabia, Emirates, Bahrain, Iraq, Yemen, Jordan, Egypt, Iran and Qatar. The aim was to detect 
any flaws in questioning and correct these prior to the main survey. The piloting was intended 
to facilitate the conversion of open-ended- to closed questions by determining the range of 
possible answers.  There was also a chance to perform a trial analysis on the pilot sample and 
having performed the pilot survey, amendments could then be made in order to maximize the 
response rate and minimise the potential error rate on answers.  
 
3.1.2 Reasons for Conducting Pilot Studies: 
Van Teijlingen e et al have provided an overview of the reasons for performing a pilot study. 
In general, the rationale for such a preliminary study can be grouped under several broad 
classifications (Van Teijlingen et al., 2001).  
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Resources: This deals with assessing time and budget problems that may occur during the 
main study. The idea is to collect pilot data on such things as the length of time to mail or fill 
out all the survey forms. 
 
• Management: This covers potential human and data optimisation problems such as 
personnel and data management issues at participating centres. 
 
• Scientific: This discusses the assessment of treatment safety, determination of dose levels 
and response as well as estimation of treatment effect and its variance. 
3.1.3 Aim of the Pilot study: 
• The aim of this Pilot study was to detect any flaws in questioning and correct these 
prior to the main survey. 
•  To gather information prior to a larger study, in order to improve its quality and 
efficiency. 
• To identify the information needed for the logistics of the main study and identify 
possible sources of error. 
3.1.4 Method: 
See Section 2.1.15 more details. 
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Figure 3.1 shows stages in the Development of Pilot Questionnaires. 
 
 
 
3.1.5 Materials: 
The instructional materials used in the survey consisted of: 
• Questionnaires, 
• Clipboard pen,  
• Paper clips, 
• Staplers 
• Pen and pencils 
• Maps for each area 
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• Laptop computer.  
• Umbrellas 
• Letters of introduction 
• Hard copies of the questionnaires. 
• Envelopes to store completed field questionnaires 
Hard copies were employed to administer the questionnaire personally to participants. In 
those countries where travel was not feasible, a laptop computer was used to send e-mails. 
The information needed for the logistics of the pilot study as shown above and also possible 
sources of errors i.e. incomplete list, non-response bias, response bias and wording as well as 
error solution was discussed. 
Strategy 
•  To ensure the sample was representative of the population under study 
• To follow-up on leads of “where to find” sample 
3.1.6 Results: 
 
A total of 100 pharmacy owners and healthcare workers including private clinics were 
interviewed per country. The majority of the respondents that answered questionnaires were 
within the age range 34-45. The overall ratio of male to female participants was unequal in 
that it was heavily skewed by almost a four fold factor towards males (figure 4.1). Thus, out 
of those pharmacy owners or staff who participated in the pilot study, 74% were male 
whereas only 22% were female. This disparity was largely attributable to the culture and 
religion in the Middle East whereby the vast majority of the women were housewives and it 
was not customary to find them in the workplace. No responses were received from Iraq or 
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Iran due to people being reluctant to answer questionnaires and also the lack of an 
interviewer or agent.  
 
 
 
Figure 3.2: Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners: gender of the pharmacist or pharmacy owners.  
 
Although the study participants were derived from a variety of backgrounds or professions 
which included doctors, nurses, pharmacists, pharmacy assistants, pharmacy technicians or 
ancillary nurses (See figure 3.2), a mean of the majority were pharmacists (50%), pharmacy 
technicians (12.5%) or pharmacy assistants (16%). Bearing in mind that Iraq and Iran have 
not responded throughout the pilot survey and zero (0) respondents were received.  
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Figure 3.3: Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners: “What is your level of education?” 
 
Graph 3.4 shows that majority of the responds were employer as compare to rest of the 
respondents, the lowest responds were others.  Some of the others were relatives of the 
pharmacy owners and a few of them were voluntary workers including students from 
different colleges and universities. A mean of preponderance of the respondents consisted of 
employers (approx. 37%) see (figure 3.3) and only 4.7% were children or the offspring of 
employers. Less than 3% were excluded from the study either because of insufficient time 
available to complete the questionnaires or the questionnaires remained unattempted. 
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Figure 3.4:  Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners: “What is your status?” 
 
Regarding data concerning drug regulation, amongst those countries surveyed, a mean of 
42% of the respondents stated that they had received some information relating to drug 
regulation compared to 32% who had received none (figure 3.5). This is a relatively high 
proportion of responses indicating a non-reception of regulatory information and may be 
ascribed to the low level of regulatory inspection as shown in Figure 3.6. 
 
 In essence, a mean value of 30% of respondents had undergone no inspection within the 
previous 5-year period and in the case of Yemen, only 5% stated that they had been inspected 
whilst 95% reported no inspection.  
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In terms of competency and expertise, over 25 - 30% of respondents indicated that their 
knowledge of drug dispensing was very good or excellent compared to 12% who described 
their knowledge of dispensing as fair to good (see figure 3.7). 
 
 
Figure 3.5:  Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners: “Have you received any information related to drug regulation 
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Figure 3.6:  Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners: “Have you been inspected by regulatory agency within the last 5 
years” 
 
When the responders were asked; if they have been inspected by regulatory agency for the 
last five years, the majority of the respondents said they had one or two inspection last five 
years, Yemen were exception where 98 respondents said that they have not had any 
inspection and this is due to a lack of inspectors available and weak enforcement of 
intellectual property regulations.The World Health Organisation (WHO) estimates that only 
one in six countries have fully drug regulatory agency (WHO 2006).  
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Figure 3.7:  Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners: would you say that your knowledge of drug dispensing is? 
 
The broad majority of participants in those Middle Eastern countries surveyed bought their 
medicines from approved pharmacy outlets, the percentage proportions ranging from 25% in 
Egypt up to 46% in Bahrain. The exception to this finding was the case of Yemen where only 
8% of individuals bought medicines in registered pharmacies, 30% purchased them in 
unapproved pharmacies, 29% in supermarkets and 30% in hospitals (Figure 3.9). However, 
this is not a reliable indication of whether registered pharmacies had been supplied with or 
encountered counterfeit medicines. Few countries in the Middle East suffer poverty to the 
degree of Yemen, so it might be speculated that one solution to the problem of counterfeit 
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medicine sales in such countries is product price reduction to the consumer instigated by 
pharmaceutical companies. 
 
 
 
Figure 3.8: Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners (analysed by country): “Where do most patients buy their 
medicines?” 
 
The problem of counterfeit medicines is universal whether it is in big cities, villages or rural 
areas. However, the perception of counterfeit incidence in this survey did vary between the 
locations. The majority of the respondents indicated that villages and rural areas were the 
localities to find counterfeit medicines most frequently (Figure 3.8).  It is tempting to suggest 
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that poverty and subsequent lack of education contributed towards this result but there is no 
direct evidence to substantiate this supposition from the survey.    
 
 
Figure 3.9: Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners (analysed by country): “Where are fake medicines most likely to be 
sold?” 
 
More than half of the respondents admitted that it was easy to buy medicine from Middle 
East Countries (see Figure 3.10).  In the same context, the rank order of countries reporting 
that it was fairly/very easy to buy medicines was: Yemen (78%) > Egypt (53%) > 
Bahrain/Saudi Arabia (34%) > Qatar (33%) > Emirates (30%) > Jordan (16%) (Refer to 
Figure 3.10). 
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Figure 3.10: Responses to the question asked of 100 healthcare workers per country and 
pharmacy owners (analysed by country): “How easy is it to buy medicines in your 
country?” 
 
To better understand the data in this survey and to establish the size and extent of the problem 
of counterfeit medicines, is difficult for several reasons: 
• The problem of poor drug quality caused by adulteration, poor manufacturing or 
decomposition has always been present in developing countries (Caudron et al 2008) 
• Over the last 20 years, direct counterfeiting of prescription drugs has increasingly 
been added to that list (Wertheimer et al., 2003) 
• Whether this represents a true increase in counterfeiting or is simply new attention 
being paid to a problem that has always existed is difficult to determine from the 
limited published research (Newton et al., 2006) 
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Nevertheless, the survey has shown that 78% see figure 3.9 the counterfeiting drug cases 
affect poorer countries; for example Yemen is poorer than either Qatar or the Emirates and 
some respondents indicated that, this is really a public health issue, principally because 
counterfeit medicine is very difficult to identify. 
 
Patent medicine stores are owned by the holders of patent and proprietary medicine vendors 
licenses. Ordinarily the patent medicines should be sold in their original packs. Over the 
Counter (OTC) drugs are the only drugs authorised to be sold by the vendors but they 
generally sell all types of drugs as determined by their financial capability. Considering the 
knowledge base of these vendors, whose minimum academic requirement to obtain a license 
is the first school-leaving certificate, they are not in a good position to differentiate between 
fake and genuine product. 
 
Community pharmacies are statutorily registered with the Pharmacists Council of their 
country. With such pharmacies, there should not be any serious problem of the sale of fake 
drugs. Unfortunately however, there are many unregistered “pharmacies” special Yemen 
flourishing. In addition, in such premises drugs are purchased from doubtful sources with its 
attendant danger to the health of the public. 
 
Poor patients are at risk from using expired and fake medicines in Yemen according to one of 
the responders in Yemen.  He added that almost all counterfeit drugs – which are 
considerably cheaper than drugs manufactured in the west – are smuggled into the country, 
mostly from India and China.  
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According to one anonymous health worker, most of these cheaper imitation drugs have not 
been tested in laboratories and even if they were genuine, they had often exceeded their 
expiry dates. Additionally, they seldom met international standards for proper storage. 
 
One of the respondents complained that counterfeit drugs were killing their business. He said 
“This is really a serious problem for us as an emerging medicine supplier. We cannot 
compete with smuggled and counterfeit medicines that are sold at low prices. It is also 
affecting the importers of medicines.” The respondent added that part of the problem was the 
absence of any legal provision with regards to prescribing or dealing with counterfeit 
medicines. 
3.1.7 Discussion: 
In this pilot study, the recruitment rate was adequate, and the individual response rate for 
each country was comparable, the range being between (100%; 100/100) Bahrain – (90%; 
90/100). Qatar was the exception along with Iran and Iraq from whom a zero response was 
received. A response rate of nearly 100 of the pharmacists returning questionnaires out of the 
100 per country initially targeted might raise the question of potential bias because 
questionnaires were shorter and quick to complete. Response rates tended to be higher for the 
questionnaires administered personally rather than by e-mail and values for this parameter 
ranged from 72% down to 20% between these modes of delivery. 
This research pilot survey has provided some useful data that will assist in the initiation of the 
main studies. Two countries, namely Iran and Iraq did not return their questionnaires. 
Therefore, these two countries were eliminated from the main study. 
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While the questionnaires highlighted the ease of purchase of medicines without a prescription 
from some pharmacy outlets, they may have also reflected the possible imperfections in 
registering a large number of drugs in these countries. Thus, the registration number of a 
regulatory body may be easily faked; bureaucracy, internal policies and the inability of some 
small and medium enterprises to meet the cost of registration may additionally delay or even 
deny certification of some companies and their products. Furthermore, it is unclear from the 
pilot study to what extent regulatory bodies monitored drugs and companies after initial 
certification.  
 
 Although the sample sizes are too small to make broad conclusions and/or generalisations 
about counterfeit drugs in Middle Eastern countries, they do provide at least one reasonable 
scenario of the cities sampled. The failure of effective regulation could be the result of 
deliberate counterfeiting, or substandard production, transport or storage. The researcher 
discussed these results with several local counterfeit drug investigators. The conclusions of 
these discussions were as follows: the wide variation in lower medicine safety rates among 
pharmacies suggests that most pharmacists were buying good quality drugs and storing them 
properly. However, some pharmacists were buying, either wittingly or unwittingly, 
substandard drugs, expired drugs that had had their packaging possibly re-stamped with new 
expiry dates, or they were incapable or unwilling to store drugs correctly. 
 
Additionally, there were too few drug inspectors in these Middle Eastern Countries especially 
Yemen, while the number of licensed manufacturing and selling premises increases 
exponentially. Pharmacists are not required to register with professional bodies or state 
boards and do not need to maintain continuing education after their initial qualification. 
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Furthermore, there is a strong general culture of self-prescription in the Middle East, which is 
enabled by pharmacists willing to sell drugs without a prescription. 
Middle East governments should make efforts to harmonise regulatory requirements across 
states and consolidate regulatory functions, as recommended by the WHO (WHO 2006 a). 
They should also increase penalties for those involved in the sale of substandard products as 
recommended by their governments. In addition, they should also consider requiring that all 
drug manufacturers receive licenses from central government, even while allowing states 
with sufficient regulatory capacity to continue licensing sales establishments. 
 
There was concern that the authorities might be defensive about working with external 
independent researchers and would be slow to give permission (or perhaps refuse permission) 
to collaborate in the research. Some investigators also suggested that their authorities might 
be part of the problem – for example, one of the investigators expressed that authorities often 
advised pharmacies of visits prior to the arrival of inspectors, which might bias collected 
samples. In addition, there have been reports that the authorities are currently conducting 
extensive drug quality surveys and therefore small scale independent surveys from outsiders 
are discouraged. 
 
This pilot study will be followed by a larger study to explore the extent of the availability of 
substandard and counterfeit drugs in the market. The pilot study calls for an investigation of 
pharmacies located in different parts of the country - rural, semi-urban, peri-urban - where the 
problem may be more rampant due to less stringent drug quality enforcement.  
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Finally, there were two parameters that worked well within this pilot study and these were the 
design of the questionnaires and face to face interview. 
The questionnaires were too short and modifications were made. Hence, it was expanded in 
order to include more questions addressing the problem of the counterfeit medicines.  
 
There was no background introduction and no identification the person or organization doing 
the survey in the pilot study. Consequently, an introduction, study purpose and an indication 
of the individual performing the study was added to the first page of the main study 
questionnaire. The underlying strategy was to train interviewers and build in quality checks 
when the main study commenced.  
 
Hence, it is important to ensure an overall high response rate, for example by offering 
incentives to participate or send reminders to non-responders (Silman and McFarlane, 2002). 
Therefore, it was decided to offer incentives to participators especially in Yemen and Egypt. 
And this approach worked well and encouraged more respondents to return or complete the 
questionnaires.  
 
In the case of disease-curing drugs, consumers may be aware that products are available and 
they are obviously highly motivated to get these products. Where governments have placed 
artificial price controls or import duties on these drugs counterfeiters may step in to supply 
the demand, offering far less effective or even dangerous products at affordable prices. 
According to Morris and Stevens 2007combined total duties and taxes on retail medicines in 
11 developing countries in 2003 ranged from 24%. Many high-tariff countries have a serious 
problem with counterfeit medicines and the authors state, “it is unlikely that this is entirely 
coincidental 
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3.1.8 Summary of Chapter 3: 
 
•  A pilot study was conducted in order to detect any flaws in the design and wording of 
the questions and improve these prior to the main survey 
• To determine preliminary testing of the hypotheses that lead to testing more precise 
hypotheses in the main study.  
• To determine ideas, approaches, and items that may not have been foreseen before 
conducting the pilot study. Such ideas and items tend to increase the chances of 
getting clearer findings in the main study. 
• To determine a thorough check of the planned statistical and analytical procedures, 
providing a chance to evaluate the usefulness for the data. 
• To reduce the number of unanticipated problems and to have an opportunity to 
redesign parts of the study in order to overcome difficulties that the pilot study 
unveiled. 
• To save time (specially travelling) and finances in the long term. 
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4 CHAPTER FOUR: 
 
 
 
 
 
 
 
 
4.1 A STUDY ON SAFETY OF MEDICINES WITH REGARD 
TO DRUG COUNTERFEITING IN MIDDLE EASTERN 
COUNTRIES: (BAHRAIN, EGYPT, EMIRATES, QATAR, 
SAUDI ARABIA, OMAN AND YEMEN) 
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4.1.1 Introduction: 
 
Medicine counterfeiting in seven Middle Eastern countries was studied in order to obtain 
some form of indirect evaluation of potential outcome hazard. The reasons underlying study 
country choice were as follows: 
  
• Valid data availability regarding counterfeit drugs was either sparse or non-existent in 
each of the countries  
• There was an anecdotal impression that there are high levels of counterfeit medicines 
available throughout the Middle East and North East Africa. 
• Statistics from the World Health Organisation suggest that drug counterfeiting may 
attain a level approaching thirty five % of all drugs in the Middle East compared to 
<1% in the US A and Western Europe.  
 
Points to be considered throughout the chapter included:  
• The reasons why counterfeit medicines exist and the extent of the problem  
• Counterfeit drug production (which drugs are counterfeited where?) and the channels 
of distribution 
• Consequences of counterfeit medicines  
• The possibility of a correlation between national illiteracy rate and severity of  
medicine counterfeiting  
• The relationship between rank order of gross domestic product (GDP) for a country 
versus its regulatory ranking. 
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4.1.2 AIMS AND OBJECTIVES OF THE STUDY: 
4.1.3 Aim:  
The overall aim of this chapter is to present a concise, authenticated and up-to-date snapshot 
of the problem of counterfeit drugs in developing countries with a focus on the Middle East 
(Yemen, Saudi Arabia, Emirates, Qatar, Bahrain, Oman and Egypt).  
4.1.4 Objectives: 
• To  estimate the level of medicine counterfeiting present in these countries  
• To obtain an indirect assessment of potential outcome hazard in these countries which 
might ensue from counterfeiting 
• To investigate any possible link between counterfeit medicines and degree of national 
education. 
• To examine any potential correlation between the regulatory ranking and GDP 
ranking.  
 
4.1.5 Methodological Framework: 
4.1.6 Methods: 
(i) Questionnaire distribution to seven Middle East countries 
4.1.7 Study participants: 
 
The study involved pharmacists in hospitals, private clinics and owners or managers of stores 
such as supermarkets who provided or sold medicines in each individual country.  
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4.1.8 Data Collection: 
During the period 2009 to 2010, 4 persons were appointed as agency researchers in order to 
administer questionnaires to the study participants (See information in Chapter two – 
methodology). 
 
They administered informal questionnaires to two hundred fifty healthcare personnel 
(including doctors, pharmacists and other health care workers) as well as outlet 
owners/managers in each of the seven study countries (total n= 1750). Participants were 
informed that they were being asked to complete the questionnaire in order to obtain 
information and data concerning the level of medicine counterfeiting present in their 
respective country and that the results would only be used for research purposes. 
 
Pharmacies, health care clinics or other outlets were selected in areas that the field 
researchers considered representative of each village, town or city. Each city was divided into 
10 area and villages were divided into two areas.  
They approached the personnel and requested that they complete questionnaires straightaway 
or they offered to retrieve the questionnaires several days later.  Twenty-five percent (25%) 
(437/1750) of those who completed the questionnaires responded immediately and 14% 
(250/1750) requested that the researchers return in order to retrieve the completed forms. 
Researchers assisted 18% (315/1750) of the respondents by guiding them through the 
questionnaire form. This was done if the respondent indicated that they had questions or did 
not understand what was being asked. The overall response was 63.3%. 
Thirty six percent (636/1750) of healthcare personnel refused to complete the questionnaires 
indicating either that they did not feel safe or comfortable or that they would need prior 
clearance from their superior i.e. their supervisor or the outlet owner. Following completion, 
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the agent collected the questionnaires then they were submitted to initial screening and 
sorting. 
 
Questionnaires were then scanned and sent by e-mail to the thesis author. In the case of those 
questionnaires that were administered by mail or electronically, the participants were re-
contacted on several occasions where necessary by the agents and there was a direct 
correlation between the number of follow-up contacts and the response rate. Finally, 
questionnaires were sorted by country and groups and they were then analysed by country 
and subgroups. 
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Figure 4.1 
Map of the Middle East countries studied and showing the distribution of collection 
sites with 1250 of pharmacies and 500 ploy clinic that participated. Countries coloured 
green and orange were those sampled in the first phase of collection and the rest were 
sampled in a second phase. Countries in purple (Iran), grey (Iraq) and light red 
(Jordan) were not sampled due to travel difficulties and the absence of a local research 
agent.  
 
(ii) Analysis of possible factors such as national gross domestic product (GDP), degree of 
regulatory control and level of education on the occurrence of drug counterfeiting in Middle 
East countries. 
 
In the second part of this chapter, data was extracted from the literature regarding national 
GDP, the degree of regulatory control as assessed by the Pearson Product Moment 
Correlation model and the general level of education in each Middle East country was then 
ranked. This was then analysed with respect to the rank order of drug counterfeiting level as 
assessed by the Pearson Product Moment Correlation model. 
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4.1.9 Results and analysis: 
 
(i) Results from the questionnaire 
 
It is noteworthy that from the information obtained via questionnaires, approximately two 
thirds (63.3%; 1115/1750) (see table 4.1) of the respondents returned the questionnaires.  
Individual response rate for each countries was comparable the range between (57%; 
143/250) Qatar – (73%; 184/250) Yemen and there was little variation between the countries. 
79% (880/1115) of the respondents were men and only 21.0% (235/1115) of whom were 
women and this is due to cultural and religious factors. More men are in employment than 
women in Middle Eastern countries and the majority of the respondents (37.1%) were Arab 
so this finding was somewhat expected. 13.9% of respondents were of Asian origin whereas 
2.1% were Caucasian and 7.5% were black/Africans (see table 4.1). More men were 
employed fulltime than women and again this was expected as it is due to cultural and 
religion practise since it is not customary for women to take up employment. (Source: 
Adopted from World Bank 2011). 
 
Table 4.1 Characteristics of the study population. 
 Women Men Total 
 n % n % n % 
(Age )       
18- 24 years   46 4.1 98 8.9 144 13 
25- 34 years   55 5 137 12.2 192 17.2 
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35- 44 years   90 8.1 246 22 336 30.1 
45- 54 years   34 3 145 13.1 179 16.1 
55- 64 years   10 0.9 240 21.5 250 22.4 
65- 74 years   0 0 14 1.3 14 1.3 
85 over          0 0 0 0 0 0 
 Total  235 21 880 79 1115 100 
       
 (Race)       
White 10 0.9 29 2.6 39 3.5 
Arab 81 7.2 570 50.6 651 58.4 
Asian 34 3 211 19 245 22 
Black/African 23 1.3 109 6.2 132 11.8 
others 37 3.3 11 1 48 4.3 
Total 185 19.4 930 80.6 1115 100 
(Employment )       
 Women Men Total 
 n % n % n % 
Full time  117 10.5 620 55.6 737 66,1 
Part time 54 4.8 324 29 378 33.8 
Total 171 15.4 944 84.6 1115 100 
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Figure 4.2 Status of respondents in the survey 
 
Apparently 28 % of the respondents were licensees compared to 13% of whom were 
pharmacy or clinic owners (see Fig 4.2). Actually 26% were employed workers,  19% were 
children or offspring of the clinic or the pharmacy owners and this is predictable because in 
local culture,  a high proportion of children look after their family business.  
 
Finally 8 % of respodents were spouses of the clinic or the pharmacy wheres as an additional 
8% were other such relative of the owners and co-owners .  
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Figure 4.3 Education levels of respondents in the survey  
 
Although 45.4% of respondents were pharmacists, 20% were pharmacy assistants and 9% 
were pharmacy technicians resulting in a total of 74.4% of pharmacy-related participants and 
this indicated the highest proportion of such staff in the supply of pharmaceuticals. Hence 6% 
of the respondents were medical doctors, especially in Yemen where many practitioners also 
own pharmacies  and some of the doctors who were working as pharmacists were not 
registered to practise in the Gulf Country Cooperation (GCC) (figure 4.3). Furthermore, 7.2% 
of respondents were ancillary nurses who were working in pharmacy and they were found 
mainly in the rural areas and villages.  
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Yemen has the highest rate of illiteracy (46%) of those countries studied according to the 
United Nations, whereas Qatar has the lowest illiteracy rate (11%) which is closely followed 
by the UAE (11.3%). Approximately 17.1% of the Saudi population is illiterate as are 28% of 
Egyptians. Out of the two remaining countries, 18% of the Oman population and 13% of the 
Bahrain population are illiterate. 
(Sources: United Nations, 2009 World Almanac, the Economist) 
 
 
 
 Figure 4.4 The numbers of patients seen daily at clinics or by pharmacies who usually 
bought medicines or requested treatment. 
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The commonest range of patient numbers seen daily at clinics or by pharmacists (6-30 
patients daily) was reported by the majority of respondents. However, at the busier end of the 
scale, (11%) respondents reported that >30 patients daily came to buy medicines at their 
pharmacy or clinic. (Figure 4.4). 
 
 
 
Figure 4.5 Questionnaire responses regarding proportions of patients with knowledge of 
appriopriate drugs to buy.  
 
The majority of the respondents (38%) stated that patients asked the pharmacist for advice 
regarding what medication to buy compared to 27% who indicated that patients already knew 
or had used the drug before i.e. a repeat precription. Therefore, 18% of respondents thought 
that patients were influenced by advertisements  and only 17% indicated that other factors 
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influenced their use e.g. the doctor prescribed the medicine to patients. The majority of 
respondents reported that patients trusted the pharmacist and always sought advice (Figure 
5.5). 
 
Counterfeit medicines represent a significant threat to the whole healthcare system, 
contributing towards a risk of a deterioration in patient  health or even death and affecting the 
public (end user) image of physicians, pharmacists, nurses and private and government 
institutions (WHO 2010). 
 
 
 
 Figure 4.6 Questionnaire responses regarding whether patients report to the  
pharmacist or doctor that a drug purchased was not effective  
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Surprisingly, 17% of respondents replied that patients do not complain or report if a drug is 
not effective compared to 5% who stated that patients reported and requested another brand 
of medicine. Hence, 24 % of respondents replied that patients bought the same drugs again 
compared to 5% who said that patients changed the brand name of drugs bought on the first 
occasion or selected another type of medicine. This latter option corresponded with the 
percentage of patients who reported drug inefficacy. 
 
Thus, 6 % of the respondents reported that patients bought different drugs on their subsequent 
visit to the pharmacy or clinic whereas 8% replied that patients bought the same drug on their 
next visit. In the majority of instances, patients only report when a pain persists  or a 
morbidity is worsened and some of them may experience a placebo effect.  
 
 
Figure 4.7 Questionnaire responses regarding possible reasons reported why drugs were 
not effective in patients.  
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To start with 46% of the respondents stated that patients did not use their medicines as 
prescribed. This would be a compliance issue e.g. they did not take the drug everyday or did 
not finish the course of treatment. 
On the other hand, 21% of respondents reported that patients were misdiagnosed and 
consequently given the wrong type of medicine.  Moreover, 24% of respondents stated that 
drugs taken by the patient were probably sub-standard or fake and this is an alarming figure.  
Eight per cent of respondents said that medicines were expired and therefore were not 
effective by asking their patients.  
 
Physicians and nurses tend to have a low index of suspicion that a fake drug may be the cause 
of therapeutic failure and they are more likely to attribute poor clinical outcomes to human 
variation. Similarly, patients, their physicians, and their families may not know that they have 
been harmed by a fake drug and worst case scenario is that a patient might even die without 
even knowing that they had a treatable illness. 
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Figure 4.8 Questionnaire responses regarding Respondents view on whether patients 
obtain their drugs from unapproved or approved outlets.  
Therefore, 75% of respondents stated that patients do not obtain their drugs from approved 
outlets which poses the question whether they even realise or are aware of the risk involved 
in buying medicines from unapproved or unregistered places. 
 
In general, more products are available without a prescription in the Middle East region than 
in the western world. Along with these “relaxed” regulations comes a greater responsibility 
for community pharmacists to function in a “triage” role to ensure safe and effective 
medication use and to ensure patients seek medical attention when appropriate (Kheir et al. 
2008). The extent to which pharmacists are meeting these responsibilities is unknown and 
beyond the scope of this thesis in the Middle East setting. 
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Figure 4.9 showing responses to three combined questions  Q16 -where is the cheapest 
patient buy their medication Q17 - most patient buy their medicine and Q22 where is 
fake medicine is distributed to.   
 
Evidently, 17%  of respondents indicated that patients bought their medicines at public 
hospitals and this is largely due to the fact that they were supplied on a subsidised basis. 24% 
of respondents stipulated that patients bought medicines at approved pharmacy stores 
whereas 19.1% of respondents reported that patients obtained their medicines at unapproved 
outlets such as a local store or corner shop (figure 4.9). 
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Manifestly, 8% of the respondents expressed the view that patients bought their medicines at 
Drug store and 19.4% of respondents indicated that they thought that patients bought their 
medicines from supermarkets. This last statistic may reflect a convenience of medicine 
purchase whilst shopping.  
 
 
 
Figure 4.10 Responses to the questions “Do patients complain that the cost of medicines 
are high”, “Do patients prefer to buy cheap medicines over brand names” and “Do you 
know of a manufacturer that produces and sells fake medicines?”  
 
Purposefully, 89.3% of respondents reported that patients always complained about the high 
cost of medicines compared to 10.7% of respondents who said patients did not complaint. 
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68.4% of responses indicated that patients bought cheaper or generic medicines in preference 
to brand names whilst 31.6% of responses specified purchases of brand names and this might 
be attributed to the high per capita income of these countries (Cockburn et al., 2005).  
 
Although, 94.3% of respondents did not know of manufacturers that produced and sold fake 
medicines compared to 5.7% who responded affirmitively to this question and this might be 
ascribed to a political reason or a fear of government (Cockburn et al., 2005). 
 
 
 
Figure 4.11 Questionnaire responses regarding the most likely location of counterfeit 
medicine sales. 
 
The majority of respondents indicated that patients did not only buy drugs based on 
prescription. Hence, the health care personnel reported that most patients bought their drugs 
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from well-established pharmacies or clinics which were required to be appropriately licensed 
to obtain patent and proprietary pharmacy licence to operate or approved supermarket stores.  
 
In rural areas and villages, approximately one-third (26%) of the respondents also testified 
that patients bought medicines from unapproved pharmacies or stores. The most common 
types of medicine to be substandard or counterfeit were those sold in big cities (32%) see 
figure 4.11. 
 
Interestingly, one-fifth of respondents (19%) indicated that fake medicines were sold in 
villages whereas only 8% claimed that fake medicines were sold in rural areas. A further 8% 
of respondents indicated that other places were where counterfeit medicines were sold and 
such places specified included service stations and kiosks. 
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Figure 4.12 showing questionnaire responses regarding the types of medicines most 
prevalently counterfeited in Middle Eastern countries.  
 
Surprisingly, the majority of respondents reported that recreational drugs (sexual medicines 
e.g. Viagra) were not only in high demand but most frequently counterfeited.  The second 
most faked medicines were expensive drugs regardless of the disease they were intended to 
treat. Furthermore, other drugs that were used to treat common diseases such as malaria and 
infections were least likely to be counterfeited and this is ascribable to their pervasiveness in 
the region. 
 
Reliable data on these issues are scarce in order make comparisons with the current findings. 
Given that the situation is likely to vary widely from country to country, it is difficult to 
extrapolate from these figures to a reliable global estimate. 
 
In many parts of the Middle East countries, there is a high demand for medicines, which 
cannot always be met by official healthcare systems. In addition, where resources are limited, 
consumers will look to secure low-cost alternatives to genuine products. Both of these factors 
tend to promote black-market sales and a ready outlet for counterfeit medicines (WH0 2003).  
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Figure 4.13   Questions whether respondents knew or had been trained to identify 
counterfeit medicines or whether they had ever come to possess fake medicines.  
 
 Hence, 79.6 % of respondents reported that they had no training to identify fake medicines 
whereas 20.4% of respondents said they had training and attending seminars. On other hand, 
62% of respondents answered that they had not come into possession of fake medicine 
indirectly or directly, compared to 38% of respondents who responded that they come across 
medicines counterfeits and the majority of these respondents were from Yemen and Egypt. 
 
The public have a key role to play. There is an educational need, to encourage patients to 
choose reputable suppliers of drugs and to be aware of the risks of counterfeit medicines. In 
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this instance, the majority of the respondents replied that, it was not always easy, and some 
counterfeit drugs mimicked legitimate drugs so well that, without running a laboratory test, it 
is very difficult to tell the difference. However, we were informed by the trainers to look for 
signs of counterfeit drugs that should raise suspicion. These signs included unanticipated side 
effects and changes in packaging, labeling, color, taste, and pill shape. 
Q29 
 
Figure 4.14: Responses to the question regarding the seriousness of medicine 
counterfeiting 
 
The majority of respodents claimed that there was a mild counterfeit medicine problem in 
their country compared to a few respodents who reported that the problem was severe (figure 
4.14).  
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Given its clandestine nature, and a lack of effective reporting logistics, it was difficult to 
obtain a clear estimate of the scale of the counterfeit medicine problem in the Middle East 
Countries. Nevertheless, the evidence suggested that it is a significant problem and is not 
receiving the attention it deserves.  
 
Counterfeit medicines are a much greater problem in less well developed countries. However, 
it is difficult to extrapolate from these figures to a reliable global estimate. Suggestions that 
10–30 per cent of all medicines across all developing countries are counterfeit might 
therefore be plausible but difficult to verify. 
 
 
Figure 4.15: Questionnaire responses by health care workers as to what measures would 
be most appropriate to check the incidence of medicine counterfeiting 
 
Surprisingly, 22% of respondents answered either that the death penalty was the best method 
of stopping the counterfeiters, or that it was the most appropriate punishment  and this may 
have been attributed to cultural and religious reasons. Only 13% respondents perceived 
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withdrawal of the licence as appropriate.  Clearly, 15 % of those questioned indicated that 
closure of their outlets would be the most appropriate method to deal with counterfeiters 
while 10% of respondents indicated that seizure of consignments would stop re-offending.  
 
Although, 28% of the respondents indicated that a severe jail sentence was the best method to 
stop culprits.  Interestingly, 12% of the respondents said that a heavy fine would abolish or 
reduce medicine counterfeiting. In this context, India plans to introduce the death penalty for 
the sale and manufacture of fake and counterfeit medicines that cause grievous harm. The 
move follows widespread concern that existing regulations pose little deterrence to 
unscrupulous drug vendors (Mudur et al., 2003). 
 
The vigilance of healthcare professionals is paramount and often, in most primary care 
settings, the pharmacist is the most readily accessed healthcare provider. As such, this 
individual needs to be able to pick up signs and symptoms from patients and other people 
with whom interaction occurs in the pharmacy and at the bedside 
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Figure 4.16: Questionnaire responses of healthcare workers regarding the best way to 
tackle the problem of Medicine counterfeiting 
 
Remarkably, 40% of respondents believed that mass education on fake medicines were 
needed to reduce counterfeiting, whereas 3% of respondents believed that reduction of Value 
added Tax (VAT) on essential medicines was the best way to reduce or tackle the problem of 
counterfeiting and it was notable that Middle Eastern countries do not charge VAT at all.   
 
Extraordinarily, 15% of respondents indicated that introduction of stiffer penalties for 
offenders might be the best solution although 30% suggested that prosecution of unregistered 
pharmacist was the best answer. Nevertheless, the majority of respondents agreed that 
measures of some sort were required to stop or reduce counterfeiting (figure 4.16). 
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Figure 4.17:  Questionnaire responses to the question asked of 1115 healthcare workers 
regarding perception of problems with the health care system in the 7 Middle East 
Countries: 
 
Although, 22 % of responses indicated that a lack of health insurance for most citizens was 
problematic with the healthcare system in their country and this may well have been due to 
the culture and the islamic religion which do not allow insurance. In addition, 8% of 
respondents reported lack of healthcare infrastructre as a problem, and this may suggest that 
the majority of the Middle Eastern countries had a good infrastructre .  
 
Eventhough, 30% of respondents believed that corruption was prevalent in their health care 
system and that bribery was rife whilst 12% thought that counterfeit medicines were a 
problem and only 7% claimed that a shortage of medical personnel was at the root of their 
difficulties.  
 
However, 8% of respondents held the view that shortage of hospitals was problematic and 
this particularly applied to Yemen while 13% thought quackery was a hindrance in their 
health care system.  
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Table: 4.2 Scorecard developed to measure the quality of medicine in Middle East. 
✓= quality present 
X = quality lacking 
                                                  7 Middle East Countries  
  Bahrain Egypt Oman Qatar Saudi Arabia  Yemen  UAE 
Effective Regulatory 
agency (man power) X ✓ ✓ ✓ ✓ X ✓ 
Effective Border control 
of counterfeit medicine ✓ X ✓ ✓ ✓ X ✓ 
Healthcare Personnel 
Awareness ✓ X ✓ ✓ ✓ X ✓ 
Patient Awareness X X X ✓ X X X 
Drug quality testing  ✓ ✓ ✓ ✓ ✓ X ✓ 
High degree counterfeit 
problems X X X ✓ X X ✓ 
Lack of adequate civil 
liability X X X ✓ ✓ X ✓ 
Weak or Absent rule of 
law X X X X X X X 
Price Control ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Taxes and tariffs ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Total number of quality 
measures   
( 0ut of 10) 5 4 6 9 7 2 8 
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(ii)      Analysis of possible factors such as national gross domestic product (GDP), 
degree of regulatory control and level of education on the occurrence of drug 
counterfeiting in middle eastern countries 
 
 
Source: (World Fact Book) 
 
Figure 4.18: GDP per capita and the rank of 7 Middle East countries. 
  
 According to the world bank, Qatar is ranked number one in the middle east in the ranking of 
GDP per capita and Yemen is ranked last (i.e. 7th of those countries studied) (See figure 
4.18). However, even though countries such as Qatar, UAE and Saudi Arabia are rich, they 
are still classified as “developing” according to the world bank. In this context, the economic 
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impact of drug counterfeiting on legitimate companies is enormous and they must have an 
influence on governments, their policies, and society at large. 
 
 
Correlation 0.943 
Determination 0.890 
T-Test 6.390 
p-value 0.001 
 
 
Figure 4.19: Correlation between GDP rank against regulatory rank for the 7 Middle 
East countries 
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Statistical analysis using the Pearson Product Moment Correlation model showed that there is 
a significant correlation between the GDP ranking and regulatory ranking as shown above (P 
<0.001). 
 
The plot suggests that the richer countries tend to spend more money on regulatory affairs 
than poorer countries. The structures of the individual Middle East regulatory authorities 
were explored through with key regulatory authorities in the region. Five authorities were 
under the autonomy of the ministry of health and they were financed by their governments. 
Saudi Arabia and Yemen had independent stand-alone authorities.  These regulatory 
authorities had a variety of other responsibilities depending on the size and resources 
available for each authority. 
 
The increased urbanisation and elevation of per capita income in Middle East countries has 
probably led citizens to have unhealthy diets and aggravated lifestyle-related diseases such as 
diabetes and cardiovascular ailments. This has increased the market for drugs such as insulin, 
statins and antihypertensives. Although patents for medicines ultimately expire, increasing 
lifestyle-related diseases would maintain revenue of the prescription medicines market in the 
long-term and encourage prospects for generic medicine manufacturers in the near future 
 (Capital, 2010). 
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Figure 4.20: Level of education in the seven Middle East countries studied. 
Sources: United Nations, 2009 World Almanac, the Economist 
 
As a result of government investment in education, the average educational attainment of the 
labor force in general in the Middle East has increased. 
 
However, due to the rising number of young students, especially in rural areas, countries such 
as Yemen and Egypt face a serious obstacle towards achieving universal basic education. 
In Egypt, guaranteeing education for those aged below 15 is an enormous challenge since 
more than a third of the population is between 6 and 14 particularly in rural areas. In the 
mountainous areas of Yemen, despite substantial efforts to build new schools or repair 
existing ones, classes may have to be held outdoors. 
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Figure 4.21: The suspected level of drug counterfeit ranking for the 7 Middle East 
countries in the study (n.b. the lower the number of ranking, the higher the counterfeit 
drugs present in that country).  
 
Attempting to measure the effects of drug counterfeiting is extremely difficult and 
discovering and measuring output is a real challenge.  As can be seen from the graph shown 
above, more counterfeit medicines were found in Yemen and it was ranked least (1) 
compared to Qatar which was ranked number 7; there is no agreement on factors that should 
be considered when calculating the scale of counterfeiting (Chaudhry, Zimmerman, 2009).  
While there are strict laws against counterfeiting in the UAE, the scourge of fake medicines is 
all too common. It was in the early 1990s that the UAE first implemented anti-counterfeiting 
laws. Before 1990s, one could see any variety of pirated goods openly displayed - from 
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Lacoste shirts, Rolex watches and Prada handbags and medicines up to a vast array of audio 
and videotapes. The majority of the Yemeni respondents indicated that they felt there are 
insufficient regulations in their country.  
 
 
 
Figure 4.22:  The rank level of drug counterfeiting plotted against the rank level of 
education in 7 Middle East Countries: 
 
Statistical analysis using the Pearson Product Moment Correlation model showed that there 
are also significant correlation between the level of counterfeit medicines and education level 
as shown above (P < 0.79). Therefore, the higher the level of education in a particular country, 
then less medicine counterfeiting was present. 
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Health care providers and pharmacist need to educate patients and the general public on 
counterfeit medicines and the appropriate and efficient reporting systems available for 
suspected cases. 
 
4.1.10  Discussion: 
 
This study, according to the authors’ knowledge, is the very first to demonstrate the extent of 
the vast threat of the presence of the illegal counterfeit drugs trade in the Middle East. Thus, 
it has not been feasible to compare the current results with the findings of others as such 
studies simply do not exist and any verification of such studies has been a fruitless exercise.  
  
The findings of this study suggest that there are disparities between healthcare workers and 
lay persons in their appreciation of the counterfeit medicines phenomenon. 
 
 Firstly, the findings revealed a lower awareness amongst healthcare professionals than 
among lay persons about the dangers of purchasing illegal medicines or dietary supplements 
outside pharmacies i.e. through illegal channels. The fact is that lay persons, nurses and 
physicians are claiming that, more awareness is needed.   
 
Therefore, it also suggests that there may be unreasonable use of drugs in Middle East 
countries. Pharmacists reported that some patients purchased medicines without a valid 
prescription and obtained them from unregistered channels. Nearly 90% of healthcare 
workers (i.e. pharmacists, Nurses and other health care workers) acknowledged writing 
prescriptions for patients even though the law in these countries only permits prescribing by 
qualified doctors. 
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Given that unregistered channels – such as roadside hawkers or commercial vehicles were 
cited by respondents as the most likely source of poor quality medicine, it is reasonable to 
conclude that a proportion of patients are exposed to these substandard medicines. The law in 
these countries requires that every pharmacy have a qualified pharmacist, registered with the 
government healthcare agency to oversee day to day operation. One example is Yemen where, 
despite national regulations which demand legal prescriptions for drugs, people tend to buy 
from illegal but cheaper street vendors where, according to WHO sources, one in five drugs 
is counterfeit. 
 
The number of respondents indicating that they would not do anything when they discovered 
a counterfeit medicine is a concern because most of the citizens access drugs through their 
neighborhood chemist  particularly when they are poorly educated . 
 
The fact that respondents who indicated that they would not report a counterfeit incident to 
their respective regulatory agency or to the police may be attributed to the perception that 
corruption is widespread in the country. Thus, in such cases, reporting an incident could 
jeopardise their personal safety or economic wellbeing and this applied especially to a 
country like Yemen.    
 
The UAE was the third largest importer of counterfeit medicines after India and Syria. They 
were shipped from China via Hong Kong to Dubai and then distributed all over the world, 
especially to developing countries. Therefore, Dubai (UAE) is a major gateway for 
counterfeit medicines.  
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Counterfeit medicine initially went into a free zone warehouse at Dubai airport owned by a 
fictitious company, and were later moved to the Jebel Ali free zone. The UAE government is 
therefore considering increasing inspections and raids and a federal pharmaceutical law 
would be introduced to tighten penalties and introduce jail terms and larger fines. The belief 
is that the law should deter pharmacies from knowingly stocking counterfeit drugs thus 
stopping importers from targeting the UAE market.The UAE will also set up a committee to 
investigate the nature of the trade in the Middle East, and has banned re-exporting of 
medicines without Ministry approval, in order to prevent the country being used as a staging 
post for counterfeits. 
 
According to a member of the parliamentary health committee, about 70 percent of the drugs 
available in Yemen are contraband and “there is no quality control checking (United nation 
report 2006). Some health experts claim that smuggled medicines enter the country mainly 
from the Horn of Africa, particularly Djibouti, from where they are brought by sea to the 
Yemeni coast. “Trading in counterfeit drugs is a lucrative business worldwide (United Nation 
report, 2006). Unfortunately, a proportion of pharmacies in Yemen do not buy medicines 
from the original manufacturers and in one instance, a respondent reported some years ago 
that they discovered a bottle filled with water in place of a medicine which is potentially 
dangerous.  
Yemen spends approximately US $117m per annum on medicines, according to the country’s 
Supreme Drugs Authority (United nation report, 2006). Most of this money is spent on 
importing medicines from a total of 50 countries via 400 importers, since local 
pharmaceutical plants only produce 17 percent of Yemen’s requirements. 
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The Middle East market in general has witnessed an increasing demand for drugs such as 
Viagra which are employed in the treatment of erectile dysfunction which affects about 150 
million people around the world and they are not limited to adults only, but to varying age 
groups. Men, women, and young people across all socio-economic divisions look to these 
drugs to create an enhanced sexual experience. About 250 sexual stimulant medications are 
produced by seven local factories, which has stabilised the medical situation in Yemen.  
These drugs should be taken according to the prescription. As much as it is useful for certain 
situations, these are a great danger especially to people who suffer from heart disease and 
diabetes (United Nation report 2006). Hence it has been noted that the type of Viagra 
registered with the supreme body of medicines that contains the substance sildenafil, which is 
expensive, but the rest of the drugs are cheap, ranging from only Yemen riyal (YR) 100-200 
as a collection of vitamins, minerals and chemical components that help build the body’s 
cells (United Nation report 2006). 
Overall, the Middle East market is flooded with legal and illegal, effective and ineffective 
drugs as well as smuggled and locally crafted sexual stimulants. Some local producers make 
excellent products, but it is difficult for consumers to know which drugs are beneficial and 
which could harm their health. Many people have little or no knowledge about their disease 
state, so pharmacists should be able to advise them or suggest consultation with a clinician. 
 
While proven drugs such as Viagra are imported from India and Switzerland, they are often 
too expensive for the Middle Eastern population especially in Yemen and Egypt. 
Consequently, the majority resort to the drugs produced by factories in their own country. 
These drugs are not of lower quality than the imported drugs according to some local 
pharmacists who have claimed “there is a difference in the mechanics of how these drugs 
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work.” While the drugs were originally crafted to help older men or those with illnesses to 
retain sexual prowess, many young men have enthusiastically embraced them. In addition to 
the pharmaceuticals sold in Yemen there are stimulants derived mostly from Yemeni honey.  
 
Yemeni honey contains natural substances that many people believe can help them maintain 
an erection. Thus, materials derived from this honey are often referred to as “Yemeni 
Viagra.” The smuggling and counterfeiting of such erotic stimulants throughout the Arab 
world is a major threat to the health of the people. These drugs do not undergo adequate 
testing, and may be at best ineffective and at worst, lethal.  
 
Moreover, the view of many clinicians is that in order to protect the health of citizens, it is the 
responsibility of government officials to address the problem of smuggling and counterfeiting 
of medicines. 
 
Ministries of Health must ensure somehow that only individuals issued with a doctor’s 
prescription can receive these drugs, and that the drugs are authentic. Resolving this issue 
will require the cooperation of all workers in the health sector including, pharmacists, drug 
store operatives and hospitals. Furthermore, educating the public on the awareness of the 
dangers of these drugs will also help in this respect to settle this issue. 
 
In Yemen, there is a specific local problem, which does generalise to other parts of the 
Middle East. This is exemplified by Khat (the leaves of catha edulis) which is a stimulant 
when chewed. Many men feel an increased sexual desire when they chew Khat (The leaves of 
Catha Edulis), however, this bitter leaf can also prevent an erection and it is likely that in 
rural regions even this herb is traded under false pretenses. 
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On a more formally prescribed drug, a study performed in some Arab countries in the Middle 
East (Kyriacos et al., 2008) examined the quality of amoxicillin formulations the aim being to 
investigate the quality of locally produced and imported amoxicillin products in the Lebanese, 
Jordanian, Egyptian and Saudi markets. The authors found that a substantial proportion of the 
amoxicillin was outside USP limits especially Jordan and Egypt and as such, it was 
considered unsafe (See Figure 4.23). 
 
 
Figure 4.23 Quality of amoxicillin formulations in some Arab countries 
Source: (Kyriacos,. et al 2008) 
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4.1.11 Conclusions: 
 
The higher-income countries in the Middle East as can be seen from my findings have 
stringent regulations and more rigorous legal control than those countries that are not 
fortunate enough to be rich. Such rich countries represent greater rewards to the counterfeiter. 
One reason why drug counterfeiting has thrived in the Middle East is that authorities have 
been unprepared for the sheer scale and sophistication of counterfeiting and had neither the 
appropriate law enforcement framework nor the legislation to tackle them.  
 
Smuggling of drugs remains a widespread and dangerous problem. Figures from the World 
Health Organization show that it can reach 35% of all drugs in the Middle East, compared to 
less than 1% in the U.S and Western Europe. One confiscated shipment by the Syrian ring to 
Egypt contained counterfeit copies of one brand of a leukemia drug with a street value of 
over $4 million -- equivalent to 50% of the annual sales of the brand (WHO, 2006a). 
Counterfeiters now also target the most lucrative markets, copying high-value, high turnover, 
high-demand drugs where huge profits are possible. 
 
As stated earlier, counterfeit drugs are a threatening and dangerous problem in the Middle 
East. In most of the Middle East countries, about half of the total drugs produced are 
counterfeit drugs. Poor public health conditions and high prices of drugs have provided a 
chance for the industries producing counterfeit drugs and selling them at cheap prices. As a 
result, in some Middle East countries, the governments and pharmaceutical industries have 
begun to expend more effort in combating the problem. Some pharmaceutical companies 
including GlaxoSmithKline, considering introduced holograms on their product packaging in 
order to differentiate them from counterfeit or substandard fakes. Technology however is not 
  
 Page 
129   
a “magic bullet” that will stop the counterfeiting problem on its own. It needs to be combined 
with other measures including tough legislation and regulations against counterfeiting, 
rigorous enforcement, stiffer penalties, and diligent surveillance on the part of the authorities 
(GSK, 2011) 
 
To conclude, in order to crack down on the number of counterfeit drugs and irrational drug 
use in the Middle East, healthcare workers and patient awareness must be increased. Patients 
especially must be better educated on the potential dangers of self prescription. Pharmacists 
must be also reinforced and made even more aware of the importance of buying and 
distributing only high quality drugs that have not exceeded their expiry date or been 
counterfeited.  
 
One initial step in the process is overcoming inadequacies within the drug supply system, by 
improving parts of the supply chain, including local production, storage, distribution and 
retail outlets. In addition, higher investment in the logistics and operation of medicines 
regulatory agencies which are often taken for granted in rich nations.  
 
A second step is to overcome inadequate legal powers, or instigate better enforcement of 
those powers, to protect patients from the criminality or negligence, with actions ranging 
from improving the regulatory environment to helping police, customs and intelligence 
agency investigations.  
 
India, China, Pakistan, Far East Asia, Brazil, Mexico and Chile are the main countries that 
produce counterfeited drugs, one particular example is the occurrence of fake Viagra which is 
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often sold in Middle East Countries in forged packages with forged Pfizer trademark and 
seals (United Nation Report 2006)  
 
Pharmaceutical companies should be more open about the drugs that are counterfeited; 
notwithstanding the negative implications that such disclosures often carry. Health 
professionals should note any failure of a drug to bring about effective treatment, and 
encourage their members to use only trusted sources of supply. Consumers must also be 
educated about the scope and dangers of counterfeiting. Whereas, again, these 
recommendations are directed toward individual nations battling counterfeiters within their 
borders, there are at least two steps that should be taken at the international level. These 
include: 
• The creation of an international database of all known sources of counterfeits, 
whether substantiated or not. This database would become a reference point for all 
countries whether importing from or exporting drugs to the specified country. 
• Pharmaceutical companies need to open the lines of communication with all relevant 
parties and should divulge all counterfeiting information to agencies such as 
INTERPOL, or to the national police force of the country that they suspect has 
counterfeits of their drug.  
Without the cooperation of the pharmaceutical companies, it will be very tough to confront 
offenders. A certain degree of immunity from publicity needs to be given to the companies. 
Consumer education will no doubt become more important as companies agree to disclose 
more sensitive information. 
 
The problem of drug counterfeiting is likely to increase in the future as healthcare costs 
continue to escalate around the globe and trends of globalisation and deregulation continue to 
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open new markets (WHO 2010). As new markets emerge, demand for pharmaceuticals is 
likely to increase and with it, the supply of substandard or counterfeit drugs. Furthermore, 
increased globalisation will require improvements in communications between governments 
and, thus, between drug regulatory authorities. With new lines of communication, buttressed 
by stricter penalties for counterfeit drug traffickers, along with technological improvements 
to track drugs along the distribution chain, counterfeiters may be kept at bay.  
 
Although it is unlikely that counterfeiting will ever cease to be a thorn in the side of 
governments, drug regulatory authorities, licit pharmaceutical manufacturers and the patients 
at the end of the chain, improved communication and extended collaboration among all of the 
relevant parties across national boundaries provides the best opportunity for curtailing the 
seemingly exponential potential of the counterfeit trade in the future. 
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4.1.12   Summary of Chapter 4: 
 
•  In this chapter the awareness of the extent of the counterfeit medicine problem in the 
Middle East was identified. 
• The illegal trade and manufacture of medicines is a global problem, 
disproportionately affecting low- and middle-income Middle East countries were 
highlighted in this Chapter. 
 
• Countries in the Middle East with weak regulatory oversight and law enforcement 
attract illegal manufacturers, while countries with strict law enforcement prevent them 
were highlighted in this Chapter. 
• Awareness of the threats that might be caused by counterfeit medicine. 
• Awareness of the scale of counterfeit medicines and dietary supplements sold outside 
pharmacies. 
 
• Further research is needed to determine the consequences of counterfeit drugs and 
identifying health risks in Middle East. 
 
• Additional research is recommended to create standardised research instruments that 
may help to identify specific interventions that may best enhance the safety of patients 
and further substantiate best practices. 
• These findings suggest that healthcare professionals need to become better educated 
about counterfeit medicines and be trained in skills to readily identify counterfeit 
medicines. 
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5 CHAPTER FIVE: 
 
 
 
 
 
5.1 A STUDY ON SAFETY OF MEDICINES WITH REGARD 
TO DRUG COUNTERFEITING IN SIX EAST AFRICAN 
COUNTRIES: (DJIBOUTI, ETHIOPIA, KENYA, 
SOMALIA, TANZANIA AND UGANDA) 
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5.1.1 Introduction: 
 
Counterfeit and substandard drugs are a serious and growing problem around the world – 
especially in East African Countries.  There are many reasons for this phenomenon, including 
illegal imitation, inappropriate packaging, poor manufacturing processes, and improper 
conditions during transportation and storage. At the point of supply or purchase, such drugs 
share the common feature that they are not what they purport to be, so for simplicity we class 
them all as ‘fakes or counterfeits’ in this study. 
 
The scale of the problem remains unclear. The World Health Organisation (WHO) estimates 
that counterfeit drugs constitute up to 25 per cent of the total medicine supply in less 
developed countries (LDCs) (Harris et al 2009). In Africa and South East Asia, more detailed 
sampling has revealed that between 30 and 60 per cent of medicines were substandard 
(WHO, ‘Counterfeit medicines’, Fact sheet No. 275). The largest producers and suppliers of 
counterfeit medicines were India and China and fake drugs existed in most therapeutic 
classes and posed direct threats to patients. 
 
 Counterfeit medicines fail to provide effective treatment. Largely because fake drugs often 
contain insufficient bioavailable active ingredient. Thus, a patient who believes he is 
addressing his disease is in fact remaining untreated or exposed to sub-therapeutic doses. The 
disease thus progresses, often leading to death, especially in children and the elderly. 
 
 However, it has been estimated that approximately 700,000 deaths from malaria and 
tuberculosis are attributable to counterfeit drugs in East African countries, adulteration with 
toxic chemicals, often leading to death or injury. There have been numerous deaths due to 
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consumption of cough syrup contaminated with anti-freeze, including 84 children in Nigeria 
in 2008 (Kelesidis et al. 2007). 
 
In 2008 contaminated Heparin from China killed 62 people in the US (FDA 2008).  
If for example an anti-infective drug contains some active ingredient, but too little to kill the 
invading organism, it can lead to the emergence of drug resistance. This is a serious problem 
with tuberculosis where extremely drug resistant strains have now been found in 49 countries 
(Keshavjee and Farmer, 2012). In addition, malaria, parasites in much of Africa and Asia are 
now resistant to most drugs, except those based on artemisinin and there are even worrying 
signs of emerging resistance to these drugs too. Resistance is also a serious problem for HIV 
medications and how much counterfeiting contributes towards this is an unknown factor 
(Keshavjee and Farmer, 2012) 
 
East African countries have been unwilling to accept that they have a problem with 
counterfeit medicines. There is little respect for trademarks or copyright, and this encourages 
pirating activities (including counterfeiting of medicines). They do not have the infrastructure 
or resources necessary for effective detection and consequently, the process of enforcement is 
invariably weak. 
  
Definitions of counterfeiting set a very high burden of proof, making it difficult to collect 
enough evidence for successful prosecutions. Additionally, in East African countries, 
regulatory and legal systems are inadequate or too slow to respond (Castell and Brickwood, 
2009)  
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Legitimate drug manufacturers know which distributors to whom they supply stock. However, 
farther down the supply chain, drugs may be traded repeatedly, making it difficult to follow 
the movement of products so the supply ‘chain’ more closely resembles a network. Efforts to 
deal with counterfeit medicines may be hampered by corruption inside these East African 
Countries either  at high-level, when the trade in medicines is associated with politically 
powerful individuals, or at a more local level, when corrupt staff with regulatory or 
enforcement roles compromise enforcement programs (Morris and Stevens  2006).  
 
In many poor countries, like those in East Africa, fake drugs often displace or crowd out real 
drugs, especially in street markets where vendors have no reputation to protect. The solution 
must, therefore, be to enable patients to distinguish between what is real and what is not. 
Another measure is to enable manufacturers to protect the identity and quality of the drugs 
they produce through the supply chain all the way to the ultimate consumer. This chapter and 
study is concerned with examining potential solutions and recommendations to limit the 
amount of counterfeit medicines sold in areas like East Africa. 
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5.1.2 AIM AND OBJECTIVE OF THE STUDY: 
5.1.3 Aim:  
The aim of this work was to perform a study on the safety of medicines in relation to drug 
counterfeiting from the perspective of clinicians, pharmacists, and other healthcare workers 
and owners of drug outlets in East African countries: (Djibouti, Ethiopia, Kenya, Somalia, 
Tanzania and Uganda) 
5.1.4 Objectives: 
• To determine at least partially, the level of drug counterfeiting present in these countries  
• To assess the perception on the safety of medicines in relation to counterfeiting 
• To understand any possible link between medicine counterfeiting and the level of 
education. 
• To understand any possible link between the regulatory ranking and GDP ranking in 
each country.  
 
5.1.5 Methodological Framework: 
5.1.6 Study design: 
This section outlines the methodology and the selection of a study design is one of the most 
important sections in a thesis in order to answer the research questions. According to Yin 
(2003), the purpose of any academic research can be exploratory, descriptive or explanatory. 
In this study, it was initially exploratory using questionnaires administered to healthcare 
workers including pharmacists and clinicians as in the previous chapter firstly regarding 
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counterfeit medicines and then a correlative analysis was performed on the relationships 
between GDP, regulatory ranking and educational levels. 
5.1.7 Data Collection: 
 Data collection was performed between 2009 and 2011 in order to reach all regions 
including some rural areas in each of the study countries.  A number of individuals were 
recruited to be agency researchers and to help in the administration of questionnaires (see 
more details in chapter 2). Pharmacies, other drug outlets and other health care workers were 
randomly selected in townships by the field researchers who considered them to be 
representative of each state.    
 
They approached concerned personnel, with the request that they complete the questionnaires 
and if they could not complete them immediately, the researchers offered to retrieve the 
questionnaires several days later.  Forty-four per cent (660/1500) of those who completed the 
questionnaires responded immediately and 21% (315 of 1500) requested that the researchers 
return to pick them up. 
 
In the case of 10% (150 of 1500) of the questionnaires, researchers assisted respondents by 
guiding them through the form. This was done when the respondents indicated that they had 
queries or that they did not understand what was asked. 26% (435of 1500) of healthcare 
personnel refused to fill out the questionnaires with some saying that they did not feel safe or 
comfortable or would first need clearance from their superiors.  
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5.1.8 Results and Analysis: 
The results from the questionnaires and correlative analysis of potential medicine counterfeit 
influencing factors are presented in the following order: 
 
(i) Questionnaire distribution to six East African countries 
 
i. Characteristics of the study population 
ii. About their patients, medicine costs and fake medicines. 
iii. Types of fake medicines and the medicines most likely to be faked 
iv. Possible measures to stop or reduce the occurrence of sub-standard counterfeit 
medicines. 
(ii) Analysis of possible factors such as national gross domestic product (GDP), degree of 
regulatory control and level of education on the occurrence of drug counterfeiting in East 
African countries. 
i. Correlative ranking of GDP and education versus level of medicine counterfeiting 
 
A breakdown of the total characteristics of the study population for all 6 East African 
countries is shown in Table 5.1 below. 
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Table 5.1 Characteristics of the study population. 
 Women Men Total 
 n % n % N % 
(Age )       
18- 24 years   52 4.8 45 4.3 97 9.1 
25- 34 years   78 7.3 137 12.8 215 20.1 
35- 44 years   85 8 274 25.7 359 33.7 
45- 54 years   108 10.1 123 11.5 231 21.6 
55- 64 years   7 0.65 105 9.9 112 10.5 
65- 74 years   0 0 51 4.7 51 4.7 
85 over          0 0 0 0 0 0 
 Total  330 31 735 69 1065 100 
       
 (Race)       
White 0 0 0  0  
Arab 23 2.2 176 16.5 199 18.7 
Asian 106 10 111 10.4 217 20.4 
Black/African 78 7.3 508 47.7 586 55 
others 23 2.2 40 3.7 63 5.9 
Total 230 21.6 835 78.4 1065 100 
(Employment )       
 Women Men Total 
 n % n % N % 
Full time  119 11.2 302 28.3 421 39.5 
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Part time 98 9.2 546 51.3 644 60.5 
Total 217 20.4 848 79.6 1065 100 
 
It is significant that from the information obtained through questionnaires overall that more 
than two thirds of the respondents (71% 1065/1500) (see table 5.1) returned the 
questionnaires and 69% respondents were men compare to 31% respondents who were 
women. Individual response rate for each countries was comparable the range between (66%; 
164/250) Tanzania – (77%; 192/250) Somalia and there was little variation between the 
countries.  
 
 This gender difference is largely due to culture and religion. More men are in employment 
than women in East African countries.  The majority of the respondents (55%) were black 
African and this was expected. One fifth (20.4%) of respondents were Asian whereas 18.5% 
were Arab and 5.9% were of other ethnic origins (see table 5.1).  
 
More men were employed fulltime than women and again, this was expected as it was due to 
cultural and religious practice and the fact that more males than females received school 
education. The status of each respondent in the East African countries is shown in figure 5.1 
below: 
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Figure 5.1 shows overall status of questionnaire respondents in the East African 
countries studied. 
The majority of the respondents (35%) were owners of the pharmacies or clinics, whereas 
15% of the respondents were licensees. On the other hand, 13% of the respondents were 
children and 7% were spouses see fig 5.1.  On the other hand, 26% of the respondents were 
workers compared to 4% who were of other categories, i.e. volunteers and co-owners. 
 
In the context of the above data, a study conducted in Laos on the knowledge and perception 
of medicines quality among sellers and consumers concluded that sellers lacked adequate 
scientific knowledge. The study tested knowledge of medicine quality using four criteria: 
correct labelling, testing, registration of medicines, and knowledge of active ingredients noted 
on the label. Of 59 sellers interviewed, only one had full and adequate knowledge of what 
constituted a high-quality medicine.  51% of urban sellers, 53% of rural sellers, and 39% of 
remote sellers could identify at least two of the four criteria for a quality medicine 
(Syhakhang et al., 2004) 
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Figure 5.2 Education level (professional qualification status) of respondents to the 
questionnaire. 
Surprisingly, 27.4% of the respondents were medical doctors, the majority of whom worked 
in clinics which sold medicines see figure 5.2. In contrast, 13% of respondents were 
pharmacists whereas 29.1% were pharmacy assistants. Only 6.5% of respondents were 
pharmacy technicians, suggesting that the pharmacy technician role is not prevalent in East 
African countries (see figure 2). 
 
On the other hand, 2.8% of respondents were qualified nurses compared to 8.7% who were 
ancillary nurses. Lastly, 5.5% of respondents were from other education categories, like 
engineers, dentists and former farmers/nomads. Regrettably, in this region of Africa still, 
there are many pharmacies working without pharmacy qualification. This study is significant 
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because the people rights to health includes the right access to a reliable standard of health 
care and assure the medicines received are not only genuine but also safe, effective, of good 
quality and affordable (Erhun et al., 2001) 
 
Figure 5.3 Responses to question asked of 872 healthcare workers in 6 East African 
countries regarding the number of patients they saw weekly.   
 
Hence, 41.2 of the respondents (i.e. the majority) indicated that more than 30 patients visited 
their clinic or pharmacy to have treatment or buy their medicines weekly whereas 24.4% of 
those who responded specified that 6-10 patients per week came to their clinic or pharmacy 
to obtain medicines.  Respondents that were from big cities tended to see more than 30 
patients per week as a consequence of the high catchment population, see figure 5.3.   
 
  
 Page 
145   
 Respondents to the questionnaire indicated that due to the rapidly rising cost of healthcare 
and the prices of medicines, there was growing concern in this region of Africa where 
patients had to pay for healthcare commodities such as medicines. Hence, those patients 
visiting clinics were limited by these factors and a proportion of the remainder sought help 
from traditional healers. 
 
Figure 5.4; Responses to question asked of 750 health care workers in 6 East African 
countries “how do patient know the appropriate medicine to buy.”  
 
The majority of the respondents (58%) to the questionnaire replied that patients sought advice 
from the pharmacist/healthcare professional about the appropriate medicine to buy, see figure 
5.4. This was in contrast to 30% of respondents who reported that patients had used the 
medication previously and they were aware of what they wished to select. Only 5% of 
respondents indicated that patients responded to an advertisement, and this may suggest that 
patients trusted their local pharmacist to provide suitable advice on the selection of a 
medicine.  
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While it is impossible to evaluate the extent to which patients are exposed to counterfeit 
medicines, it is therefore also challenging to establish how many of those adverse events 
reported are linked to counterfeit drugs. Patients in this region of the world do not tend to 
question that the drugs they receive from a pharmacist or healthcare specialist are legitimate 
or that they will cure disease and alleviate symptoms rather than causing serious harm or 
even death. 
 
 
Figure 5.5 showing responses to questions asked of healthcare workers “has the patient 
ever reported that drugs bought were not effective and did the patient buy the same 
drugs or a different drug.” 
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 Although, 13.3% of respondents indicated that patients reported that the medicine they were 
using was not effective and did not help their condition at all whereas 86.7% of respondents 
specified that patients did not report to them if the medicine they were using was not effective, 
see figure 5.5. 
 
The other two questions were linked to the first question which was that if patients reported 
to their local clinic or pharmacy that the medications they bought was not effective (or in 
other words not improving their condition). Thus, 82% of respondents reported that patients 
bought the same medicine every time they visited their clinic or pharmacy compared to 
45.3% of respondents who replied that patients bought a different medicine. 
Consequently, the survey found that patients generally did not report to their local pharmacy 
or clinic if the medicines were not effective or did not help them.  
 
 
Figure 5.6; Responses to the question asked of 1500 healthcare workers in 6 East 
African countries “What are some likely reasons that drugs were not working”. 
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Surprisingly, 37% of respondents claimed that medicines sold and used to treat patients were 
sub-standard, whereas 14% of respondents said that patients did not use their drugs as 
prescribed, see figure 5.6. According to the WHO, an estimated 25% of medicines consumed 
in developing countries were believed to be counterfeit. In some African countries, the figure 
is thought to be as high as 50%. Therefore the current findings are not too dissimilar from 
those of the WHO. 
Whereas, 23% of respondents revealed that many drugs were beyond their expiry date and 
this may have explained their non-effectiveness. In many parts of Africa, medicines are sold 
in coffee shops, kiosks, corner shops and also by vegetable sellers which may explain why 
26% of respondents thought patients were misdiagnosed, and continued receiving the wrong 
medication. 
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Figure 5.7; Responses the question asked of 1500 healthcare workers in 6 East African 
Countries “do patients buy their drugs from unapproved places.” 
 
The majority of respondents (70%) were in accord with the available literature and specified 
that most patients bought their medicines from unapproved outlets such as kiosks, coffee 
shops or corner shops, see figure 5.7.  
 
On the other hand, 24% of responses indicated that patients bought their medication from 
approved outlets such as pharmacies or government hospitals. These tended to be patients 
who were compliant with government laws and therefore preferred to buy their medications 
from approved outlets. Trade in these products is more prevalent in countries with weak drug 
regulation control and enforcement, scarcity and/or erratic supply of basic medicines, 
unregulated markets and unaffordable prices. However, as counterfeiting methods become 
more sophisticated, counterfeits are increasingly present in better-controlled markets (WHO 
2003).  
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Figure 5.8 showing responses to the question asked of 1500 healthcare workers in 6 East 
African countries “Where is the cheapest place that most patients buy their medicines 
and where are fake medicines distributed.” 
 
While, 10.1% per cent of respondents said that unapproved pharmacy stores were where 
patients obtained their medicines and this was attributable to the cheaper prices, whereas 24% 
of respondents indicated that patients procured their medicines in public or government 
hospitals, the principal reason being that poor patients either were given free or subsidized 
medicines at these sources, see figure 5.8. Seventeen point four per cent of respondents said 
patients got their medicines at other outlets, like kiosks, coffee shops, internet shops, local 
corner shops, at vegetable markets or on the buses. 
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The majority of the respondents did not want to comment on where fake medicines were 
distributed and this was due to fears concerning the government. The main reason for 
counterfeiting medical products is that huge sums of money can be made because of the low 
manufacturing costs. However, in many countries, legislation or enforcement is inadequate 
and counterfeiters face extremely low risks of being punished.   
 
This makes counterfeiting attractive for criminals. The expansion of trade and deregulation 
offers greater opportunities to introduce fake products into official channels (Chan et al., 
2008) 
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Figure 5.9 showing responses to the questions asked of 1500 healthcare workers in 6 
East African countries; “Do patients complain that the cost of medicines are high”; “Do 
patients prefer to buy cheap medicines over brand names” and “Do you know of 
manufacturers that produce and sell fake medicines?” 
 
 While, 93.2% of responses indicated that patients complained that the cost of medicine was 
too high compared to only 6.8% of respondents who said patients did not complain and even 
some of the patients haggled to reduce the cost of their medicines, see figure 5.9. 
 
This study showed that, 76% of respondents claimed that patients preferred to buy cheap 
medicines or a generic medicine rather than a brand name. Thus again, the survey 
emphasized just how expensive medicines can be in poor African countries. While, 63.2 % of 
respondents indicated that they were aware that some manufacturers sold substandard 
medicines. On other hand, they were conscious of overseas producers selling fake medicines 
though 36.8% of them reported that they did not know of any manufacturers in their own 
country in this respect. The majority of the respondents indicated that they were of the 
opinion that China and India were the two leading countries from which sub-standard 
medicines were sourced. 
 
Prescription medications have become a powerful tool in the medical arsenal against disease 
and promotion of health and quality of life. Yet the success of prescription drugs and their 
extensive use has attracted unsavoury characters interested in exploiting vulnerable patients 
and the market for medicines. Some countries, such as Tanzania for example, rely on the 
International Dispensary Association’s quality assurance for testing their essential medicines 
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and since 2006 the Association has tested batches of medicines made overseas (Mackintosh 
et al., 2011). 
 
It is not unusual for people in developing countries to pay, on average, proportionately more 
for medicines through out-of-pocket expenditure than consumers in the developed world, 
including those individuals who pay insurance premiums regardless of their health status. It 
just so happens, that one third of the global population lacks reliable access to essential drugs 
(WHO, 2004) and this sector directly overlaps with those in developing countries. 
Governments should have a role to play beyond enforcing the rule of law and many East 
African government interventions in the pharmaceutical market have restricted supplies of 
quality medicines, driving up prices and simply leading to gaps in the market.  
 
This situation has then been exploited by purveyors of fake medicines. Governments could 
substantially reduce these problems by removing impediments to the supply of quality 
medicines, such as taxes, tariffs, price controls and arbitrary regulations (Harris, 2009). 
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Figure 5.10 showing responses to question asked of 1500 healthcare workers in 6 East 
African countries “Where are fake medicines most likely to be sold.” 
 
Across those East African countries studied, villages were the most likely places where 
counterfeit medicines were likely to be found. Thus, 28% of respondents indicated that the 
village setting was a safe haven where sub-standard or fake medicines were sold compared to 
only 10% of respondents who thought that big cities were the locations where such 
counterfeits were to be encountered, see figure 5.10.  
 
Some respondents feared that harmful counterfeit medicines could impel rural communities 
in Africa to re-adopt traditional medicines in order to address their needs and it was 
somewhat telling that 19% of respondents answered that it was rural areas where most 
counterfeit medicines were traded. Only 8% of respondents indicated that other unusual 
places such as buses, on the streets, vegetable markets and laundry shops were credible places 
for counterfeit medicine sales. 
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Figure 5.11 showing responses to the question (Q25) asked of 1500 healthcare workers 
in 6 East African countries: 
 
Africa is fraught with challenges as was apparent from this survey question.  There is a 
substantial lack of previous data from which to judge the types of medicine most frequently 
counterfeited and few objective studies have been conducted in the continent (Caudron, J.M. 
et al., 2008). Moreover, from the graph shown above (Fig 5.11), the majority of respondents, 
ranging from to generally reported that drugs used in widespread disease areas i.e malaria and 
infectious diseases, were most commonly faked. The quality of antimalarial drugs is 
particularly important in this context since it affects the ability to effectively manage one of 
the most prevalent diseases in East Africa (Amin et al., 2005).  
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Hence, it has been reported that sub-standard and counterfeit antimalarial drugs are present in 
the markets of developing countries and a small sample study of this drug group across 
Africa in 2008 found that over 30 per cent of these drugs originating from Asia failed quality 
checks. However, locally-produced drugs fared even worse, with nearly half being discovered 
as substandard (Bate et al., 2008). On the other hand, the number of counterfeited recreational 
drugs such as Viagra in this region of Africa, are on the increase and according to the current 
survey, respondents specified this type of drug as the second most faked group of medicines 
encountered in their country. Moreover, expensive drugs and those that are uncommon, 
regardless of the disease area of treatment, are also faked but not too the same extent as more 
the common drugs.  
 
Counterfeit medicines in East African countries were originally focused upon life-saving 
medicines including those for infectious diseases, antimalarials and cardiovascular drugs. 
However, it might be hypothesised from the survey that there may be an increasing trend 
towards ‘lifestyle’ medicines such as those for erectile dysfunction as mentioned above and 
there were even reports of agents for weight loss. 
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Figure 5.12. Responses to questions asked of 1500 healthcare workers in 6 East African 
countries: “Do you know or have you been trained how to identify fake medicines?” and 
“Have you ever come into possession of fake medicines?”  If their answer was “yes” to 
the second question, respondents were asked “What have they done about it.” 
 
The results showed that, 90.5% of respondents signified that they had not been trained or did 
not know how to identify fake medicines compared to only 9.5% who claimed that they had 
been on a training course or were self-trained and knew how to identify counterfeit medicines, 
see figure 5.12. 
 
East African governments need to increase public awareness about identifying counterfeit 
medicines but this will only be productive if the counterfeits are poor and easily detectable. In 
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such cases, patients should have sufficient information concerning the existence of 
counterfeits, be given advice on how best to avoid them and what they should do if they are 
suspicious about the authenticity of a medicine or medical device.  
Unfortunately, many counterfeits are extremely good copies designed to deceive the patient 
and visual examination alone is unlikely to identify the fake. Consequently, it is sometimes 
only laboratory analysis that is capable of establishing whether a medicine is authentic or 
counterfeit.   
 
The results also showed that 60% of respondents signified that they had come into possession 
of fake medicines as opposed to 40% of individuals who said they had not come into 
possession of fake medicine or even if they had, they were not aware of it.  
 
The majority of the respondents suggested in the comment section of the questionnaire, that 
governments should establish or launch a 24 hour hotline to enable the public (assuming they 
had communications access), healthcare professionals, those engaged in the supply chain and 
industry to report directly, and where necessary, confidentially to a regulatory agency. The 
reporting of any suspicions concerning counterfeit medicines or medical devices could be 
accomplished via telephone or through a Ministry of Health website. Another suggestion 
from the respondents was that, governments needed to instigate a national conference held 
yearly to raise awareness of the domestic efforts to tackle these issues. 
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Figure 5.13: Responses to the question regarding the seriousness of medicine 
counterfeiting 
 
The majority of respodents claimed that there was a severe counterfeit medicine problem in 
their country compared to a few respodents who reported that the problem was mild (figure 
5.13).  
 
However, the evidence suggested that it is a significant problem and is not receiving the 
attention it deserves. Counterfeit medicines are a much greater problem in less well 
developed countries. However, it is difficult to extrapolate from these figures to a reliable 
global estimate. Suggestions that 10–30 per cent of all medicines across all developing 
countries are counterfeit might therefore be plausible but difficult to verify. 
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Figure 5.14.  Responses to the question asked of 1500 healthcare workers in 6 East 
African countries “What measures are in place to check the incidence of fake medicines 
in your country. 
 
Arising from the results presented in figure 5.14, it can be seen that 510 out of 1065 
respondents replied that closure of certain selling outlets would reduce the number of illegal 
transactions with fake medicines whereas 67 out of 1060 respondents indicated that 
withdrawal of a trade license would stop further illegal trade. Out of 1065 respondents, 102 
were of the opinion that a death sentence would definitely reduce medicine counterfeiting, the 
rationale being that a fake medicine has the potential to kill a patient so the punishment 
should be the death sentence. On the other hand, 102 of the respondents also indicated that 
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seizure of consignments would stop the offenders repeating the crime, whereas 121 subjects 
said that a heavy fine would be as equally effective as other penalties. Only 47 respondents 
thought that freezing offenders assets and bank accounts would stop reoffending compared to 
116 who thought that a severe jail sentence would deter the would be counterfeit seller.  
 
Overall, respondents strongly believed that rigorous measures were needed in order to curtail 
or completely stop the growth of sales and manufacturing of counterfeit medicines. 
 
 
 
Figure 5.15 showing responses to questions asked 980 healthcare workers in 6 East 
African countries; “How best to tackle the problem of fake medicines in East African 
Countries.” 
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The research presented that, 33% of respondents thought that mass education about 
counterfeit medicines was the best way to combat this problem. The public have a key role to 
play and there is an educational need, to encourage patients to choose reputable suppliers of 
drugs and to be aware of the risks of counterfeit medicines. 
 
The largest proportion (44%) of respondents signified that the introduction of stiffer penalties 
for offenders was the best way to tackle the growth of fake medicines. Successful 
enforcement calls for collaboration between different agencies, such as customs officials, law 
enforcement agencies and drug regulatory bodies. Often, these bodies have not previously 
worked together or are inadequately resourced. The success of INTERPOL’s training 
programmes in East Africa suggests a model by which joint working can be accomplished 
(WHO, 2010). On a smaller scale, 6% of respondents indicated that a reduction of VAT on 
essential medicines and prosecution of unregistered pharmacies or stores was a good way to 
reduce the trade in counterfeit medicines. 
 
Legal systems in East African countries are often not equipped to deal with the extremely 
serious consequences of counterfeit medicines and penalties for counterfeiters are too light to 
act as deterrents. Stronger legislation would help empower those who have to deal with 
purveyors of counterfeits and counterfeiters in the course of their work; namely, the police, 
customs officials and the judiciary. 
 
(ii) Analysis of possible factors such as national gross domestic product (GDP), degree of 
regulatory control and level of education on the occurrence of drug counterfeiting in East 
African countries. 
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Arising from the analysis and the graph shown in Fig 5.15 below, Kenya is ranked number 
one in the GDP ranking of East African countries, whereas Somalia is ranked number 6 due 
to a combination of problems, such as a lack of central government and a long running civil 
war. 
 
 
 
Figure 5.16 GDP per Capita ranking of 6 East African Countries.  
Source: (World FactBook: https://www.cia.gov/library/publications/the-world-
factbook/rankorder/2004rank.html ) 
The criteria for ranking of the six East African countries with respect to regulatory control 
was performed using several parameters which are shown by the scorecard in Table 5.2 
below. 
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Table 5.2 Showing the scorecard used to rank the quality of the regulatory control in 6 
East African countries: 
 
✓:  this quality is present                  X: this quality is not present or lacking 
 
 
  
                                                                                              6 East African Countries  
  Djibouti Ethiopia Kenya Tanzania Somalia  Uganda 
Effective Border control of counterfeit 
medicine ( Man Power) X X 
 
✓ 
 
X X X 
Healthcare Personnel Awareness 
(Education level)  X X ✓ ✓ X ✓ 
Patient Awareness (Education level) X X ✓ ✓ X ✓ 
Drug quality testing  ✓ X ✓ ✓ X ✓ 
Man Power to police the fake 
Medicine X X X X X X 
Lack of adequate civil liability X X X X X X 
Weak or Absent rule of law X X X X X X 
Price Control ✓ ✓ ✓ ✓ ✓ ✓ 
Taxes and tariffs ✓ ✓ ✓  ✓ X X 
Effective Regulatory agency X X X X X X 
Total number of quality measures  (10  
0ut of 10) 3 2 6 5 1 4 
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Figure 5.17:  Regulatory control ranking of 6 East African countries based on the 
scorecard shown above 
 
East African economies have large informal sectors, which are not integrated with the formal 
economy or large business.  Research has suggested that promised investments in the region's 
overwhelmingly poor rural infrastructure is lacking, with the significant exception of agro-
industrial firms embracing out-grower schemes or those that otherwise contribute to the 
coordination of smallholder production and trade. (Booth et al., 2007) 
  
East Africa is a solid economic bloc with a combined population of over 120 million and it is 
estimated that at least 50% of the populace regularly use medicines. Traders are solely 
interested in profit, but this is a human rights issue because the possible consequences of the 
counterfeit business are really immense. Take, for example, a person with severe malaria if 
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s/he cannot access the genuine drug, then it may be a life threatening situation. Hence, the 
priority should be to boost weak drug regulatory systems, and provide the resources to help 
them to routinely track down and test the quality and safety of drugs before they reach 
patients.  
 
 
Figure 5.18 showing correlation between regulatory control and GDP ranking in 6 East 
African Countries 
 
Statistical analysis using the Pearson Product Moment Correlation model showed that there 
was a significant correlation (P <0.001) between the GDP and regulatory control rankings 
(derived from the scorecard shown in Table 5.1) as shown above. 
 
Developing countries are particularly vulnerable, in part because regulatory officials often 
lack the capacity (See figure 5.3) or political will to curb the distribution of fake goods. 
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Additionally, because legitimate drugs can be expensive, poor consumers also fuel demand 
by knowingly or unwittingly turning to cheaper counterfeit varieties. 
 
 
 
Figure 5.19 showing Illiteracy rates in 6 East African Countries (CIA World Book, 
2012). 
 
Illiteracy and access to knowledge are two of the key problems that inhibit socio-economic 
development in developing countries. Rural people lack the vital information they need to 
improve their lives, and because most are illiterate, they cannot benefit from many 
educational methods. Furthermore, lack of electricity and poor roads isolate these regions and 
further complicate development efforts rural schools aim to teach literacy skills but 
insufficient funding makes this very challenging. Furthermore, children rely solely on these 
schools to gain literacy skills because most have illiterate parents. 
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More than two out of every three pupils who have finished two years of primary school in 
East Africa fail to pass basic tests in English or numeracy, according to a new report. The 
survey by (Agwunobi et al., 2009) conducted for a civil society group that monitors 
educational achievement, reported that despite significant gains in enrolment, pupils did not 
learn core skills expected at their age and grade level. In part, the difference between 
Tanzania and the other countries is likely to be driven by the much smaller share of pupils 
attending private schools, even among the non-poor, suggesting they must be particularly 
selective, claimed the report. In Kenya, the pass rate in private schools was 83%, compared 
with 75% in government schools, while in Uganda the gap was 53% to 36%. 
 
 
Figure 5.20:  Level of counterfeit ranking against level of education in 6 East African 
countries. 
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Statistical analysis using the Pearson Product Moment Correlation model showed that there 
was a significant correlation between the level of counterfeit medicines and education level 
as shown above (P <0.89) Thus, a positive rank correlation between education level and 
counterfeiting exists across those East African countries studied though it should be noted 
with caution that correlation does not establish causation. On average, governments in these 
developing countries spend approximately 3% of gross national product (GNP) on education 
(Knight and Sabot, 1990) and spending on combatting counterfeit medicines is largely an 
unknown quantity. 
 
5.1.9 Discussion: 
 
Poor countries, such as those in East Africa, tend to have highly inefficient, slow and 
expensive legal systems to enforce the control of medicine counterfeiting and so it even more 
challenging for patients to be assured of the quality of the medicines with which they are 
supplied. 
 
The major sources of fake medicines are most likely to be from India and China. One set of 
figures from the European Commission showed that 75 per cent of drugs being imported 
from 22,000 small drug producers in India were counterfeit and supplied through informal 
channels (Bate, 2008). The Associated Chamber of Commerce and Industry of India 
estimated that this market was growing by 20-25 per cent per annum and in order to have 
some appreciation of the scale of this problem, India’s global pharmaceutical exports totaled 
$10.3 billion in 2010 (Nair, 2012). A large proportion of these fake medicines are life-saving 
drugs but surprisingly recreational drugs are catching up and in the future they may be the 
most common type of counterfeit drug found in East Africa. Nigeria is an example of a 
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country in West Africa that has been very successful in combating the problem, whereas 
Kenya and Tanzania are East African countries that are only at the elementary stages of 
dealing with it (Ahmed and Dillard, 2011). 
 
Pharmacists and other health care workers have reported that some patients acknowledge 
purchasing medicines without valid prescriptions and through unregistered channels.  Given 
that unregistered outlets – such as roadside hawkers or commercial buses were cited by 
respondents as the most likely source of poor quality medicines, it is reasonable to conclude 
that some patients at least may be exposed to these substandard medicines via these routes. 
Indeed, a preponderance (approximately 70%) of healthcare workers (i.e. pharmacists and 
nurses and even non-educated healthcare workers) conceded to actually writing prescriptions 
for patients even though the law in these countries only permits qualified doctors to prescribe 
drugs and that every pharmacy should have a qualified and registered pharmacist to oversee 
day to day operations.  
 
Outlets authorized only to sell over-the-counter medicines often illegally stock prescription 
medicines. For example, in Tanzania, stocking of prescription medicines without a permit is 
the norm. Additionally, while medicines sold in shops should be packaged and labelled, they 
are sometimes sold loose as individual tablets. Loose tablets of painkillers and antimalarial 
medicines were found in 29 and 22 drug stores respectively, often packaged in homemade 
envelopes labeled with a hand-written note (Goodman et al., 2007) 
 
The number of healthcare workers who indicated that they would not take any action when 
they discovered a counterfeit medicine is worrying because most citizens access drugs 
through their neighborhood chemist,  particularly when they are poorly educated. The number 
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of respondents who indicated that they would not report a counterfeit incident to the 
respected regulatory agency or police may be ascribed to the perception that corruption is 
widespread in the country, or that reporting the incident could jeopardize their personal safety 
or economic wellbeing and this was particularly the case in Somalia and Ethiopia.    
 
There are certain factors about medicines in this African region which should be noted. For a 
predominant proportion of patients, medicines are too expensive thus forcing individuals to 
search for cheaper alternatives. For some, they are inconvenient prompting the quest for 
doctor-free alternatives. Counterfeit drugs of every description have an impact on nations of 
every population and income level. No drug appears to be invulnerable and no country is 
immune (WHO, 2013).  
 
While data are limited, there is little doubt that counterfeit drugs are an increasing problem 
globally, with hundreds of thousands of people dying annually as a result. East African 
countries and all developing countries represent a lucrative market for counterfeiters of 
medicines and medical devices. Weak economies, increasing prices, a large market, (as the 
current survey found) and also increased internet connectivity, inconsistent regulatory 
oversight and a complex supply chain all conspire to encourage those engaged in the 
manufacture and supply of counterfeit medicines and devices (Akunyili, 2011).  
 
Even with reforms, developing countries, especially those examined in this study (East 
Africa), face significant logistical and social challenges in cracking down on counterfeit 
production. The existing situation has been facilitated by the lack of coordinated anti-
counterfeiting initiatives by various national and multinational regulatory agencies and 
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professional organizations. Health professionals must take an active role in evaluating and 
implementing both revised and new responsibilities that further protect patient safety  
 
The problem of counterfeit medicines in the world’s pharmaceutical drug supply is growing 
and will not disappear in the foreseeable future. However, as discussed in the last two 
chapters, there are measures and tactics that can facilitate efforts of the pharmaceutical 
industries and governments to combat this serious problem. 
 
Given the lack of previous hard data on the proportion of fakes and the patchiness of precise 
information on the incidence of disease in East Africa, any attempt to estimate the impact of 
fake medicines is inevitably as much art as science. Nevertheless, the scale of the problem is 
such that estimates serve a useful purpose of calling attention to the issue and as long as they 
are approached with caution, then approximations have some value. The likely impact of 
counterfeit medicines on mortality in East Africa is overwhelming especially in a country like 
Somalia where there are governmental problems and a long running civil war. In addition to 
mortality, fake medicines also have an impact on morbidity though assessing such an impact 
is equally difficult. 
 
If private companies are able to implement solutions to the problem of identity preservation 
and quality assurance, such as those described above, they would then have strong incentives 
not only to advertise their products but also to educate the public about the nature of the 
problem. In addition, there may be a role for third party groups, such as health advocacy 
NGOs. Such groups have done important work educating the public in Sub-Saharan Africa 
about the problem of HIV-AIDS. In view of the scale of the problem of fake medicines, it 
seems plausible that such groups could be persuaded to get involved in proactive education 
campaigns describing the nature of the problem and the need to ensure that medicines are 
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supplied from reputable sources and are, so far as can be ascertained, what they say they are 
(WHO, 2010). 
 
Counterfeit drugs on the market may well amplify any humanitarian disaster and the poorest 
countries are most likely to suffer from a lack of legitimate medication in such a crisis 
especially since access to services is severely restricted.  The producers focus on profit while 
exploiting the limited availability of health services to the poor. 
 
Reports of counterfeit pharmaceuticals in Africa indicate that there are a wide variety of 
detrimental effects. In addition to poor public health, these include lost revenues to firms that 
might otherwise be used to develop newer and better products, lost taxes to governments 
responsible for public health, additional costs firms and governments incur to protect supply 
chains from counterfeit products. This results in disincentives to foreign investment, and 
consequent loss of jobs and economic opportunities. 
 
WHO launched a taskforce in late 2006 to fight a thriving multimillion dollar illegal trade in 
counterfeit drugs, vaccines and other medical products and this was called the International 
Medical Products Anti-Counterfeiting Taskforce (IMPACT) its aim being to put a stop to the 
deadly trade in fake drugs. However, some NGO’s and countries like India, Brazil do not 
agree with the work offered by IMPACT. Its areas of focus are: 
•              Legislative and regulatory infrastructure 
•              Regulatory implementation 
•              Enforcement 
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•              Technology 
•              Communication 
There is need to strengthen the theme that there should be some world treaty organization to 
counteract with the global health care threat of counterfeit medicines (WHO, 2006a). 
 
In an ideal developing world, everyone would obtain their pharmaceuticals from reliable 
pharmacies, which would in turn be sourced from reputable distributors, who would use 
dependable logistics companies, and so on back to the manufacturer. Meanwhile, at each 
point in the chain, the pharmaceuticals would be stored and handled according to standards 
established by the manufacturer and their identity through the chain secured using 
technologies such as those described above. 
 
Unfortunately, we do not live in an ideal world and at least for the time being, many patients 
are likely to continue to source their medicines from non-qualified street hawkers. These 
sellers have usually purchased the medicines from distributors that move them from place to 
place in small vehicles at ambient temperatures approaching 40C for extended periods of time. 
Furthermore, these distributors invariably purchase their medicines from wholesalers, many 
of whom store medicines for months in warehouses lacking air conditioning and who often 
take consignments from intermediaries of dubious repute. Hot and humid climates in these 
countries pose serious problems, with at least some medicines showing decreased 
concentrations of the active ingredient upon testing (Hogerzeil et al., 1992) 
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Some respondents who took part of this study recommended that medicine counterfeiting 
should be legislated as a specific crime against humanity. Currently, a crime against 
humanity is known as ‘extermination’ which is defined in international law as ‘the intentional 
infliction of conditions of life, inter alia the deprivation of access to food and medicine, 
calculated to bring about the destruction of part of a population’. No instance of medicine 
counterfeiting has ever exterminated a population, but even so, it is highly notable that within 
the definition, denying access to a medicine can be considered as a component method of 
attacking a civilian population, and may be at the root of a crime against humanity. Hence, 
denying access to a medicine is exactly what counterfeiters do when they supply a fake 
medicine lacking the therapeutic qualities of a real medicine. 
 
In summary, while there is no crime against humanity specifically for medicine 
counterfeiting, current legal doctrine defines it as possibility. However, in reality, to crack 
down on the number of counterfeit drugs and irrational drug use in East African countries, the 
awareness of healthcare workers and patients must be increased and patients in particular, 
must be educated on the potential dangers of self-prescription. Some pharmacists and outlet 
managers should also be re-educated and be made more aware of the importance of buying 
and distributing only high quality drugs that have not passed their expiry date or are 
discernible counterfeits.   
 
The problem of counterfeit drugs should be discussed overtly by concerned professionals and 
a good example of this was given by a meeting held in Nairobi, Kenya, in 1985. However, 
since that time, the counterfeit market has rapidly expanded, largely as a result of the 
widespread use of internet marketing which is increasingly accessible especially in larger 
cities. Counterfeit drug rackets are most common in regions where the regulatory and 
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policing infrastructure for drug control are at their weakest. Thus, one of the key 
battlegrounds in the fight against organized counterfeit crime is Africa as a whole, where 
drugs are counterfeited on a huge scale (Newton et al., 2010).  
 
Evidence from this study is exceptionally alarming because it discloses to some extent, the 
size of the medicines counterfeiting challenge in East Africa, the magnitude of which needs 
to be fully appreciated by healthcare professionals. Therefore, the preventive role of 
healthcare professionals has to increase and continue to develop for the benefit and safety of 
patients. This research survey may possibly lay some groundwork for further studies on the 
prevalence of counterfeit drugs in East Africa and neighbouring countries. By assessing the 
scale of this phenomenon in East Africa, an effective collaboration in detecting and 
preventing counterfeit medicines is needed. Sharing responsibility by setting up an anti-
counterfeit network to include governments, international institutions, pharmaceutical 
companies and other interested bodies, would be helpful in decreasing the phenomenon of 
counterfeit medicines in this region (WHO, 2006a). This was identified as a major issue for 
the future by nurses and physicians in the current study.  
 
Additional data gathering and analysis revealed significant rank correlations between GDP, 
regulatory control and levels of education across countries in the region respectively versus 
counterfeiting. These correlations were interesting and though their outcomes were not 
surprising it should be emphasised that they did not establish causation 
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5.1.10  Summary of Chapter 5: 
 
• This Chapter reviews the extent of the counterfeit drug trade in East Africa and what 
aspects of it were particularly unique. 
 
•  The Survey found that the majority of the faked medicines were drugs intended to 
treat diseases, which were common to the area, like malaria and infections. 
 
• The survey also indicated that, the counterfeit problem was more pronounced in 
countries where the manufacture, importation, distribution, supply and sale of drugs 
were less regulated and enforcement was weak. 
 
• According to the report the prices of the medicine are too high and patient complain 
and find to buy medicine unapproved stores. 
 
•  This survey also found that citizen of these countries would like to see stiffer 
penalties to be introduced such as death, prison and closure of their outlets and stores 
for those violating the drug laws. 
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6 CHAPTER SIX: 
 
 
 
 
 
 
 
 
 
 
6.1 GENERAL DISCUSSION 
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The main objective of the questionnaire surveys conducted in this thesis was to provide an 
overview of the safety of medicines in developing countries with respect to the problem of 
counterfeiting.  The data collected from the (1065) respondents in East African and (1115) 
Middle Eastern countries (total n: 2180) confirmed that, medicine counterfeiting is a 
substantial problem. Systematic records regarding the global incidence of counterfeit 
medicines were not abundant in the literature; consequently, a re-examination of individual 
reports on medicine quality with respect to counterfeiting was timely.  The current literature 
evaluation presents some additional information on counterfeiting in East African and the 
Middle East countries. While it is anticipated that drug quality is often compromised in 
developing countries, the current research does pinpoint the level of perception and some of 
the likely causes of the problem. Although it is a possibility that the research protocol and the 
questionnaires circulated in this study may be a valuable starting point for others mounting 
subsequent work in this field. 
 
Hence, it is important to bear in mind that there is increasing awareness of escalating 
medicines counterfeiting in industrialised countries as the current study found (see figures 
4.12 and 5.13) in addition to those in the developing world and the legal supply chains within 
these nations receive increased pressure every year. This study showed that the Middle 
Eastern respondents recounted only  a mild counterfeit medicine problem in their country 
compared to East African respondents who reported that the problem was severe (see figures 
4.14 and 5.13).   
 
The majority of the respondents were owners of pharmacies or clinics and the rest of those 
surveyed were mainly employers or relatives of the owners. In the context of the current 
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study, the knowledge and perception of medicines quality among suppliers and consumers 
revealed that sellers often lacked adequate scientific knowledge. Thus, still the findings 
highlighted the fact that, in this area of Africa and the Middle East, there are many 
pharmacies working without an appropriately qualified pharmacist in charge. This outcome is 
significant because people’s rights to health include the right of access to a reliable standard 
of health care and an assurance that medicines they receive are not only genuine but also safe, 
effective, of good quality and affordable. 
 
Healthcare workers indicated that due to the rapidly rising cost of healthcare and the price of 
medicines, there was mounting concern in East African and Middle Eastern countries since 
patients invariably had to pay for healthcare commodities such as medicines. Hence, those 
patients visiting clinics were limited mainly by the numbers of the patients seeking help from 
traditional healers and herbalists.  
 
Although it is challenging to evaluate the extent to which patients are exposed to counterfeit 
medicines, it is an even greater test to establish how many of the adverse events reported are 
linked to counterfeit drugs. Patients in East Africa and the Middle East do not tend to 
question whether the drugs they receive from a pharmacist or healthcare specialist are 
legitimate or that they will cure disease and alleviate symptoms rather than causing serious 
harm or even death. Therefore, the survey found that patients generally did not report to their 
local pharmacy or clinic if the medicines were not effective or that they did not help them. 
 
The view of those surveyed indicated that in East Africa, at least 70% of the drugs distributed 
were thought to be counterfeit and in the Middle East, more than 60% of medicines issued 
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were considered fake. These figures are alarming to say the least and should raise concern 
among the authorities of the countries in question. 
 
Whereas substandard medicines have been with us since they were first compounded, they 
are an inevitable consequence of inadequate pharmaceutical industry regulation and 
inspection in much of the developing world. For example, substandard antimalarials were 
identified in Yemen, Cameroon, Nigeria, Kenya, Senegal, Uganda and Tanzania (Abdo-
Rabbo et al., 2005)  
 
The present survey found that from a total of 2180 respondents in 7 Middle Eastern and 6 
East African countries there was an overall opinion that at least sixty per cent of patients had 
been supplied with counterfeit drugs. This was in comparison with 5% of patients who had 
received a counterfeit prescription while only 1% believed that they had been exposed to a 
counterfeit drug according to a previous marketing survey of more than 5000 consumers 
across five European countries including the UK. (Jackson et al., 2010)  
The present study reflected the view that most classes of therapeutic drug were counterfeited. 
When examining the differences in the prevalence of fake medicines between regions within 
these developing countries, it should not be forgotten that, there is an uneven distribution of 
governmental control (i.e. policing) in urban compared to rural areas as suggested by the 
current findings.  
 
 An alarming trend for industrialised countries is the fact that they appeared to be more 
heavily targeted by drug counterfeiters. The numbers of seized goods as well as the 
counterfeit cases in different well developed countries have undergone a fast rise leading to 
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the assumption that the magnitude of counterfeiting on their markets has risen considerably 
(FDA, 2011).  
Furthermore, the gap between developed and less developed states concerning the prevalence 
of counterfeit drugs within their markets remains relatively large. The former have taken 
clear measures to maintain the incidence as low as possible inside their borders.  The WHO 
has been playing a clear role in aiding countries in their anti-counterfeit efforts, and the 
World Trade Organization also helps to regulate international drug trade. All these are 
strengths that can be utilised in combating the global problem (WHO, 2010).  
 
This Study also provides more specific data on medicine safety with regard to counterfeiting 
in East African countries and the Middle East.  Although it is evident from those interviewed 
that East African countries were affected more than the Middle East and this is due to the 
different rank of socio-economic factors as seen in the survey. Hence it is very difficult to 
make a sound judgment about counterfeit medicines in developing countries but within this 
context, it is recommended that priority to be given to heavier policing of counterfeiting.  
 
The range and geographical diversity of these countries were comparable and there was little 
variation between them in terms of the number respondents. The majority of respondents in 
both East African and the Middle Eastern countries were in agreement with the available 
literature which specified that most patients bought their medicines from unapproved outlets 
such as kiosks, coffee shops or corner shops (see figures 4.8 and 5.7). 
 
The challenges of addressing how to combat drug counterfeiting in East African and the 
Middle Eastern countries were not comparable.  Twenty-two per cent of Middle Eastern 
respondents expressed the opinion that the death sentence for offenders would reduce 
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medicine counterfeiting whereas 48% of East African respondents were in favour of closure 
of offender’s outlets (see figures 4.15 and 5.13). The study also identified major differences 
between the two continents regarding the best way to combat this problem. Thus, 11% of 
respondents in East African countries believed that reducing VAT on essential medicines 
compared to only 3% of respondents in Middle East countries would contend with the 
problem. However both East African and the Middle Eastern respondents agreed that one 
unequivocal measure to tackle and reduce the real threat was through mass education (see 
figures 4.16 and 5.14). 
 
The results also indicated that drugs counterfeited and supplied in villages received little 
attention compared with those counterfeited and distributed in the big cities in both East 
African Countries and the Middle East (see figures 4.11and 5.10) and this is not surprising 
since monitoring and potential control in outlying regions is much more likely to be 
negligent. 
 
Additionally, and as predicted, the  survey findings  also showed that respondents felt that 
prescribing and dispensing as opposed to uncontrolled purchase, were the  two most 
important safety aspects of access to medicines in the majority of East African and the 
Middle Eastern countries . In the light of these survey results, it is recommended that 
strengthening medicine regulatory authority control, promotion of national awareness of the 
problem and obtaining a rigorous resolution to fight counterfeiting are perhaps the crucial 
primary tasks.  
 
However, the most common deficiency of information the study identified was a lack of 
pharmaceutical communication in developing countries. Consequently,  pharmaceutical 
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companies need to open the lines of communication with their sources of information to keep 
track of underground counterfeiting operations and should disclose all information to 
agencies such as Interpol or to the national police force of any country in which companies 
suspect counterfeit versions of their products are being sold. Without the pharmaceutical 
companies’ cooperation, it will be very difficult to confront offenders and penalise them 
(Gupta et al., 2012).  
 
The graphs in chapters 4 and 5 regarding the plots of GDP against education and 
counterfeiting clearly demonstrate that GDP per capita is positively correlated with level of 
education and any presence of counterfeiting in these developing countries. Countries with an 
abundance of natural resources tend to do better than countries with less resource wealth.  
 
Somalia has the lowest GDP per capita of all those countries sampled and it is one of the 
nations with the highest levels of medicines counterfeiting. The current study demonstrated 
that GDP influences not only education but other resources such as healthcare expenditure. 
While the correlation between GDP and counterfeiting is strong, education and regulatory 
control can be equally powerful though the causality link remains unsettled. 
 
In oil rich countries like the Gulf States, the labour income growth of those with tertiary 
education exceeds GDP growth, largely as a consequence of a strong shift towards higher 
skills and the impact of the global economic crisis on overall economic activity in these 
countries. Lynn and Vanhanen (2012) have convincingly established that national IQs 
correlate positively with GDP, education, and many other social and economic factors. Once 
more however, the direction of causality still remains debatable. 
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6.1.1 Solutions and Recommendations: 
There is no standard solution applicable to all countries to eliminate medicine counterfeiting. 
Each country has to develop a strategy based its own circumstances  taking into account the 
available infrastructure as well as human and other resources. This should be part of the 
overall national drug quality assurance system. 
 
Harmonised efforts to eradicate trade in counterfeited medicines will be severely hampered 
by corruption especially in East Africa. Governments must initiate a commitment to protect 
their citizens by rooting out officials or business leaders involved in the manufacture or trade 
of counterfeit medicines. In addition, agencies must ensure that their enforcement activities 
are not compromised by corrupt officers (Castell and Brickwood 2009).  
The importance of raising public awareness about acquiring medication only from known 
sources (pharmacies) and also the exposure and reporting of names of individuals and 
companies involved in trading fake drugs must be stressed. As an example of this, the Saudi 
Food and Drug Association has requested all drug companies to report any counterfeited 
drugs and provide SFDA with samples along with the necessary documentation (SFDA, 
2011). 
 
Governments should contest such national problems as counterfeiting as part of their 
responsibilities. It should be recommended that all African countries establish a central drug 
administration which would regulate the licensing of all drugs in lieu of the current licensing 
system whereby state drug regulatory agencies allow the manufacture of drugs which are not 
approved. Stiffer penalties such as death, 10 years minimum prison sentence and higher fines 
should be recommended for those violating the drug laws (Ramchandran, 2003). 
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Accepting that counterfeit drugs are a global and persistent problem, prompts the concept that 
it can only be combated by international collaboration. During 2006, in the WHO 
international conference on (Combating counterfeit drugs: Building effective international 
collaboration’) held in Rome, it was declared that the WHO should lead the establishment of 
an International Medical Products Anti-counterfeiting Taskforce (IMPACT) of governments, 
non-governmental and international institutions aimed at encouraging and coordinating anti-
counterfeiting initiatives. 
 
In February 2004, the U.S. FDA issued a report entitled ‘Combating Counterfeit Drugs: A 
Report of the Food and Drug Administration (FDA, 2004). This report identified six critical 
measures to combat fake drugs. This included securing the actual drug product and its 
packaging, securing the movement of the product through the drug distribution chain, 
enhancing regulatory oversight and enforcement, increasing penalties for counterfeiters, 
heightening vigilance and awareness of counterfeit drugs and increasing international 
collaboration (FDA, 2004). The U.S. FDA also recommended the use of Radio Frequency 
Identification (RFID) tags started on 2007 and it was suggested that the drug supply chain in 
the U.S. would be RFID-secure following its introduction (FDA, 2004). 
 
Legal frameworks are under revision to boost anti-counterfeiting measures in many countries 
including European Member States, India and the United States. In Britain, there are 
proposals for the introduction of a charge of corporate killing’ for companies who have 
contributed to the deaths of customers and this could also apply to drug companies if they did 
not take reasonable steps to warn the public of a fake product . Some countries such as 
Vietnam, the United Arab Emirates, Oman, Bahrain, Kuwait and Qatar even have provisions 
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of death sentence as punishment for counterfeit drugs related offences (Anonymous, Lancet, 
2003). 
 
Many research-based companies are working through the Pharmaceutical Security Institute 
(PSI), a counterfeit intelligence forum that conducts worldwide investigations. Information 
on illegal activity obtained by PSI is provided to governments and international agencies, 
which are responsible for proceeding against counterfeiters (PS1 Web site).  
The International Pharmaceutical Federation (IPF) and International Federation of 
Pharmaceuticals Manufacturer Association (IFPMA) are actively involved as observers of 
WHO activities aiming to establish guidelines and rules for policies against substandard 
medicines (WHO, 2010).  
 
 The German Pharma Health Fund (GPHF) has developed basic training methods for about 
35 commonly used essential medicines in their finished dosage forms. International agencies 
like Interpol, the World Customs Organization (WCO), the World Intellectual Property 
Organization (WIPO) and the International Chamber of Commerce (ICC) have contributed 
significantly in addressing the problem. More and more pharmaceutical companies have 
adopted sophisticated techniques like holograms, watermarks and tamper proof packaging to 
safeguard their products (Parry, 2005).  
 
An international coalition is working for consumer awareness and also to educate the end 
users to differentiate between genuine and fake versions of drugs. The overall goal of WHO 
support has been to promote the regular availability and accessibility of affordable essential 
medicines of good quality. WHO provides support to countries to strengthen pharmaceutical 
legislation, Good Manufacturing Practice (GMP), national drug regulatory capacity and 
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performance, to promote information exchange among drug regulatory authorities and to 
strengthen drug procurement (WHO, 2002). Update references needed. 
 
The Malaysian ministry of health has also introduced such holograms on their pharmaceutical 
products as a security measure. These holograms are tagged and registered with a security 
device known as Meditag. Each Meditag has a unique serial number and can be scanned with 
a special device to verify its authenticity. However, these holograms are not too dependable 
as it is possible to copy them. Hence, they are not adequate in stopping counterfeiting (Perry, 
2005). Another technique mentioned previously is radio frequency identification or RFID 
which contains a chip with an antenna affixed to the drug packaging.  
 
The exact location of the drug can then be detected using radio waves. This technology is not 
cheap, but is said to be one of the most effective techniques developed so far to uproot and 
stop counterfeiting. Some pharmaceutical companies such as Purdue Pharma and Pfizer have 
already employed RFID technology to trace their respective products, OxyContin and Viagra 
(Parry, 2005). 
6.1.2 Mass Education and Raising Awareness: 
If private companies are able to implement solutions to the problem of identity preservation 
and quality assurance, such as those described above, they would then have strong incentives 
not only to advertise their products but also to educate the public about the nature of the 
problem.  
 
In addition, there may be a role for third party groups, such as health advocacy NGOs. Such 
groups have done important work educating the public in Sub-Saharan Africa about the 
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problem of HIV-AIDS. Given the scale of the problem of fake medicines, it seems plausible 
that such groups could be persuaded to get involved in proactive educational campaigns 
describing the nature of the problem and the need to ensure that medicines are from reputable 
sources and are genuine. A qualitative study of Sudanese policy makers and pharmacists 
suggested that awareness of counterfeit is lowest among the poor and people living in remote 
areas (Alfadl et al., 2013)  
 
Other private companies might also be encouraged to join such campaigns. Manufacturers of 
retail goods, for example, are acutely aware of the problems created by fakes, so they might 
be willing to support a general campaign educating the public about the importance of buying 
the authentic medicine. (Harris et al., 2009). 
6.1.3 Limitation of the Study: 
There were limitations in the current study, which could be classed into three categories: the 
lack of localized funding in rural regions for manpower restricting data acquisition, travel 
difficulties and security issues.  
 
One of the main limitations regarding safety of medicines in developing countries is the lack 
of funding and manpower, which in this study, restricted the availability of data particularly 
in the more rural regions. Therefore, it may also have skewed the findings towards the urban 
areas and it would have been advantageous to obtain data from every urban rural area in East 
Africa and Middle East countries that was surveyed.  However, the impact was probably 
minimal due to the complete data set that was available and easily obtained from other cities 
and rural areas.  
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In order for questionnaires to be practical, a good response rate invariably necessitates it 
being of reasonable length. This tended to moderate the possibility of evaluating certain 
components in greater depth. On the other hand, this study covered the majority of relevant 
topics and is one of the first studies to identify the perceived severity of medicine 
counterfeiting in the developing countries of East Africa (especially Somalia). 
 
In Somalia and Ethiopia above all, travel between cities, and even within cities, was very 
difficult and hazardous because of civil wars involving the Somali Transitional Federal 
Government, the Eritrean-Ethiopian conflict and inherent ongoing inter-tribal clashes.  This 
limited free movement within these two countries, though it was a definite positive aspect 
that local agents could be enlisted to administer the questionnaires. 
 
The level of government corruption was also part of the study limitation and this made it 
additionally challenging to collect data in a timely manner from government hospital 
pharmacists expecting to receive bribes.  Many health care workers were concerned for their 
safety and were reluctant to answer the questionnaires. However, it was made perfectly clear 
to respondents at the outset that the questionnaires were confidential and intended for 
research purposes only.  
 
6.1.4   Future Work: 
 
Given that the topic of safety of medicines with respect to counterfeiting in developing 
countries is likely to remain a key issue for the foreseeable future, it would be advantageous 
and beneficial for prospective studies to use similar study instruments or adapted versions for 
future work.  Although it might not be feasible to curb counterfeit medicines completely, it 
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should be possible with the right will and appropriate measures, to lower the rate of 
counterfeiting in developing countries considerably. 
 
However, it is clear that the aim and objectives of this study have been achieved and the 
findings have demonstrated the potential for combating counterfeit medicines both in the 
Middle East and East Africa. This may also contribute to other similar initiatives in other 
regions of the world such as Latin America and Far East Asia where counterfeiting is a 
problem. 
 
As mentioned earlier, more research is needed to quantify the effects of trade in counterfeit 
medicines, to support advocacy and to inform policy making. Without good data, it is also 
hard to plan education or intervention campaigns or to know what works. There is certainly a 
need for testing and validation of devices for assessing drug quality in the field. Health 
systems research may also help to identify ways in which prevention, monitoring and 
enforcement can be integrated into healthcare delivery (Hyder et al, 2008). 
 
The studies where analysis of GDP against drug counterfeiting along with education and 
regulatory control are useful as a prompt to those countries where any upgrading of GDP 
occurs since a proportion of the subsequent wealth benefit could be invested in the 
controlling measures. 
6.1.5   Conclusions: 
Therefore, I would like to conclude   that, counterfeiting of medicines is of international 
concern. There is therefore, a need to implement intercountry, sub-regional and regional 
cooperation to combat counterfeiting of medicines. Counterfeit drugs have a long history. As 
early as 400 B.C., there have been warnings of their existence (WHO 1999) and Dioscorides, 
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a Greek physician, pharmacologist and botanist who lived from 40–90 AD, wrote in his 
‘Materia Medica’ about the detection of counterfeit drugs (WHO, 1999). The threat of 
counterfeit medicines therefore is hardly a new one and has persisted through the ages. The 
‘modern’ issue of counterfeit medicines emerged in the 1980s when more and more member 
states of the WHO reported the incidence of medicine counterfeiting. Hence it was first 
brought to greater attention in developing countries through an international conference on 
the rational use of drugs in Nairobi 1985 (WHO, 2003).  
 
Both branded and generic drugs are likely to be subject to counterfeiting, however, a patented 
high-priced medication is more likely to be faked in either an industrialised or developing 
country (Harris et al., 2009). The difference between these types of country will depend very 
much on the level of drug regulation control and enforcement as well as the prices in the legal 
supply chain.   
  
In most industrialised countries like the USA, Japan or members of the EU, the extent of drug 
counterfeiting is below 1% of the share of the total medicines market value. An exemption is 
the former Soviet Union where up to 20% of the market may consist of counterfeit drugs 
(WHO, 2010). In contrast, in extensive parts of Africa, the Middle East and Asia, between 
10-30% of available medicines are fakes and this figure could be even higher (WHO, 2010). 
 
The data presented in this thesis suggests that 71% of medicines available in East African 
countries, especially in Somalia, are counterfeit and this largely due to a lack of regulatory 
control. Both in developed countries and those that are developing (especially the Middle 
East) it is often lifestyle medicines such as slimming agents and anabolic drugs that are faked.  
The best known symbol of counterfeit medicines is of course, the widely known drug for 
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erectile dysfunction ‘Viagra®’. In developing countries, however, it is often more crucial 
medicines that are faked. Examples include antibiotics and drugs against very prevalent 
diseases such as malaria, HIV/AIDS or tuberculosis (Kelesidis et al., 2007). 
 
Therefore it may be concluded that the problem in developing countries is with all 
substandard medicines and not just counterfeits. What is needed first and foremost is for each 
country to have a medicines regulatory framework which: 
 
Prohibits distribution of any medicine unless it is first licensed in that country. 
Only issues licenses to a particular person or company who will be held  
     responsible for the quality of that particular product. 
Restricts the importation/distribution of a medicine to the individual or  
     company who holds the license. 
 
 Hence, the aim of this project was primarily to increase awareness in developing countries 
(especially East Africa) in terms of the perception of the growing market in counterfeit 
medicines and the public health risks associated with this illegal practice. Moreover, the 
current findings are only a starting point and larger studies regarding medicine counterfeiting 
in different developing countries are needed alongside strategies to combat the problem.  
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8 Appendix 01 
 
 
 
PILOT QUESTIONNAIRES FOR A STUDY ON SAFETY OF 
MEDICINES WITH REGARD TO DRUG COUNTERFEITING IN 
DEVELOPING COUNTRIES (SPECIALLY – MIDDLE COUNTRIES) 
 
 
Data Collection form for Safety of medicines with to drug 
counterfeiting in developing countries: 
State: 
Country: 
City: 
Village:                   
Name of Pharmacy or Clinic:      
Date of Interview:  
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Q1 Sex Male                            Female  
Q2 – What is your age Group:  18-24                                              
24-35                                              
35- 45                                             
46-54                                             
55-64                                              
65+                                                 
 
Q3 - What is your race? White                                              
Arab                                                
Asian                                               
Black African                                 
Other                                                
 Specify________________ 
Q4- Employment status?   
Full Time Work                             
Part time  Work                             
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Other:_____________ 
 
Q5 - What is your Status: Licensee                                         
Owner                                            
Spouse                                            
Child                                             
Other                                               
 Specify________________ 
Q6- What is your level Education  Pharmacist                                      
Assistant Pharmacist                       
Pharmacy technician                       
Medical Doctor                               
Nurse                                               
Ancillary Nurse                              
Other                                               
Other                                               
Specify________________ 
Q7 - Years of Work Experience?  
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Q8- Have you received Any 
Training in drug dispensing 
Yes                                     No  
If yes Please where and when did 
you receive it  
 
Q9 – have you received any 
information related to drug 
regulation 
Yes                                    No   
If yes who gave it to you:   
Q10 - Please specify those 
regulation you know about   
FDA                                                 
EMEA                                             
Your Own Country regulatory         
WHO                                               
Other                                               
Q11 -Have you been inspected in 
the last five years? 
Yes                                      No  
If yes Please specify who inspected 
you and when: 
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Q12-In general would you say your 
knowledge of drug dispensing is? 
Excellent                                         
Very Good                                      
Fair                                                  
Poor                                                
 
Q13: Where do most patients buy 
their medicines? 
Patient medicine store                    
Approved Pharmacy stores            
Un-approved Pharmacy stores       
Super  Market                                 
Public Hospitals                              
Other                                               
 
Specify:_______________________ 
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Q14- Where are fake medicines 
most likely to be sold? 
Big Cities                                      
Villages                                         
Rural area                                      
Urban area                                     
Others                                            
Specify:______________________ 
Q15– How easy is it to buy 
medicines in your country? 
Very easy                                       
Fairly easy                                      
Not very easy                                  
Not at all easy                                
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9 Appendix: 02 
 
 
Doctors, Health care Workers and Pharmacist Survey: 
This questionnaire has been designed to better understand the safety of 
medicines with regard to drug counterfeiting in the development countries. 
Your responses to these questionnaires will be made confidential and 
mainly for research purpose. 
 
Data Collection form for Safety of medicines with to drug 
counterfeiting in developing countries: 
State: 
Country: 
City: 
Village:                   
Name of Pharmacy or Clinic:      
Date of Interview:  
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About Yourself ( Q1 – Q7) 
Q1- What is your gender? Male   Female  
Q2- how old are you?  
18- 24 years       
25- 34 years        
35- 44 years        
45- 54 years        
55- 64 years        
65- 74 years        
85 over               
 
 
Q3 - What is your race? White                    
Arab                      
Asian                     
Black African       
Other                       
 Specify________________ 
Q4- Employment status?  Full Time Work     
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Part time  Work    
Other:_____________ 
 
Q5- What is your Status? 1- Licensee      
2- Owner          
3- Spouse         
4- Child          
5- Worker           
6- Other             
Specify________________ 
Q6- What is your level of 
Education  
1- Pharmacist                         
2- Assistant Pharmacist        
3- Pharmacy technician        
4- Medical Doctor                 
5- Nurse                                 
6- Ancillary Nurse                
7- Other                                   
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Specify________________ 
Q7 – Years of work Experience:  
Q8- Have you received Any 
Training in drug dispensing 
Yes    No  
If yes Please where and when did 
you receive it  
 
About Your Customer or Patient (Q8 – 18) 
 
Q9- How Many patients do you 
see or buy your medicines per 
day? 
1 – 5 patient         
6 – 10 patient       
11- 20 patient       
21 – 30 patient      
Above 30 patient   
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Q10 – How do patients know the 
appropriate drug to buy? 
Used the drug before            
Ask the Pharmacist               
Respond to advertisement     
Other                                     
 Specify: _____________________ 
Q11 –Has any patient ever 
reported to you that the drug 
He/She bought was not effective? 
Yes    No  
Q12 – Did the patient buy the 
same drug again  
Yes    No  
Q13 -Did the patient buy a 
different drug again 
Yes    No  
Q14 – What are some likely 
reasons that drugs were not 
working? 
Drugs were expired                                        
Drugs were sub-standard or fake                    
Patient was misdiagnosed                               
Patient did not use the drug as prescribed      
 
Q15 – Do the patients buy drugs 
from unapproved places:  
Yes    No  
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If yes:  what is the reason? 
( check all that apply) 
Drugs are Cheaper                 
Convenient for the patient     
It is the only place to buy       
Other                                      
 
Specify: _________________________ 
Q16: Where do most patients buy 
their medicines? 
Drug store                                     
Approved Pharmacy stores           
Un-approved Pharmacy stores      
Super  Market                                
Public Hospitals                            
Other                                             
 
Specify:_______________________ 
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Q17- Where is cheapest place to 
buy medicines? 
Drug store                                       
Approved Pharmacy stores             
Un-approved Pharmacy stores        
Super  Market                                 
Public Hospitals                              
Other                                               
 
Specify:_______________________ 
 
Q18 – Do patients complain that 
the cost of medicines are high? 
Yes    No  
Q19- Do patient prefer to buy 
cheap medicines over brand 
names? 
Yes    No  
About the Fake Medicines (Q19 – Q33) 
Q20- Do you know of a 
manufacturer that produces and 
sells fake medicines? 
Yes    No  
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Q21- If yes: Where is it located? Within your Country                     
Outside of the country                   
Other                                              
Specify:_____________________ 
Q22 – Where are fake medicines 
distributed? 
Drug store                                      
Approved Pharmacy stores            
Un-approved Pharmacy stores       
Super  Market                                 
Public Hospitals                              
Other                                               
 
Specify:_______________________ 
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Q23- Where are fake medicines 
most likely to be sold? 
Big Cities                                   
Villages                                      
Rural area                                   
Urban area                                  
Others                                         
Specify:______________________ 
Q24 –Where are patients most 
likely to buy fake medicines? 
Patient medicine store                 
Approved Pharmacy stores          
Un-approved Pharmacy stores     
Super  Market                               
Public Hospitals                            
Other                                             
 
Specify:_______________________ 
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Q25 – What type of medicines are 
most commonly faked? 
Drugs Common disease: i.e. Malaria, infections etc    
Drugs that are expensive regardless of the disease       
Drugs that are in high demand i.e. Viagra                     
Drugs that are not common                                            
Other                                                                              
 
Specify:_______________________ 
 
Q26 – Do you know or have you 
been trained how to identify fake 
medicines? 
Yes    No  
Q27 – Have you ever come into 
possession of fake medicines? 
Yes    No  
  
 Page 
238   
Q28 – If you have answered Q 26 
yes. What have you done with the 
fake medicine? 
Reported to superior officer                                        
Alerted police                                                 
Reported to Authority (regulatory agency)    
Destroyed the medicine                                 
Did nothing                                                    
 
Q29 - How serious is the problem 
of fake medicines in health care 
delivery? 
Not problem                                                                 
Mild problem                                                  
Moderate problem                                           
Severe Problem                                              
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Q30- What is the reason for the 
growing trade in fake medicines? 
Heavy taxes/ VAT on drugs                                                
Government policies towards health delivery       
Poor economic situation                                          
Lack of health insurance for most citizens            
Other                                                                      
 
Specify:_______________________ 
 
Q31 – In your opinion, could fake 
medicines be eliminated if the 
patent rights of the original drug 
manufacturers were respected  
Yes    No  
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Q32 – What measures could be 
put in place to check the 
incidence of fake medicines? 
Seizure of consignments                                                        
Severe jail sentence                                                  
Death sentence                                                         
Closure of sale outlets                                               
Heavy Fine                                                              
Withdrawal of licenses                                            
Freezing of assets/bank accounts                               
Other                                                                         
Specify:_______________________ 
Q33 – Rank the best way to 
tackle the problem of fake 
medicines in your country?  
(1 is the best way and 5 is the 
worst) 
Reduction of VAT on essential medicine                                                                                         
Prosecution of unregistered pharmacist/store                                                                    
Mass education on fake medicine                                                                                   
Introduction of stiffer penalty for offenders                                                                     
Bann on all sales medium that help self medication                                                                    
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Q34 – Rank the following 
problems with the health care 
system in order of importance? 
(1 is the most important and 7 the 
worst) 
Lack of Infrastructure                                                                                                                       
Fake Medicine                                                                                                                   
Shortage of medical personnel                                                                                       
Lack of health insurance for most citizens                                                                       
Corruption in healthcare delivery                                                                                         
Shortage of Hospitals                                                     
Quackery                                                                                                                               
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Q35 - We want to know your 
rating of the problems of 
counterfeit medicines in your 
country. 
 
Using any number from 1 to 10 
where 0 is the worst possible 
counterfeit medicine problem and 
10 is the least possible counterfeit 
medicine problem in your 
country,  
 
 
1  Worst Counterfeit Medicine found                                   
2                                                                               
3                                                                              
4                                                                               
5                                                                               
6                                                                               
7                                                                               
8                                                                              
9                                                                                        
10   Least Counterfeit Medicine found                   
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Q36 : We want to know your rating 
of the quality of the regulatory 
control in your country:  
Using any number from 1 to 10 
where 0 is the worst and 10 is the 
best rating 
Effective Border control of 
counterfeit medicines (manpower) 
Healthcare Personnel Awareness  
(Education level). 
Patient Awareness (Education level) 
Drug quality testing 
Manpower to police fake medicines 
Lack of adequate civil liability 
Weak or Absent rule of law 
Price Control 
Taxes and tariffs 
Effective Regulatory agency 
 
 
 
 
 
 
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
 
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
 
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
1-  2- -3 -4 -5 -6 -7 -8 -9 -10  
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Q37-  General Comments/  
additional comments   
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10 Appendix 03 
 
 
COVERING LET TER 
 
Date: ______/_______/_______ 
 
Dear Sir/ Madam 
The following questionnaire is part of survey and study to better understand the safety of 
medicine in the development countries. It is recognized and narrated from WHO that the 
World Health Organization (WHO) estimates that 8% to 10% of the medicines in the global 
medicine supply chain are counterfeit, reaching as high as 25% to 60% in developing 
countries. 
 The questionnaire should only take 15 minutes to complete. Please answer all questions in 
such a way as to reflect most clearly Counterfeit medicine. Most questions will require you to 
circle your selected response. Others will require you to write down a number. Do not leave 
blanks.  
Your participation is very much appreciated and we thank you for your contribution to this 
important research. 
 
Ahmed Elmi MSc MICR Csci
  
 
